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ABSTRACT
COMBATING MALIGNANT MELANOMA WITH THE MULTIFACETED SOY-DERIVED
PEPTIDE LUNASIN
Christopher P. Shidal
April 24, 2017
Lunasin is a 44 amino acid peptide that has been shown to have cancer chemopreventative and
chemotherapeutic properties. This study investigated the potential utility of Lunasin as a chemotherapeutic
in melanomas. Studies showed that Lunasin had little activity against established melanoma cell lines
using adherent culture methods; however, Lunasin’s in vitro activity was significantly higher in nonadherent colony-forming assays and oncosphere formation. These results led to the investigation of whether
or not Lunasin has selective effects on cancer initiating cells (CIC) that are known to be present in
melanomas. It was revealed that Lunasin selectively inhibited the proliferation of high-ALDH expressing
CICs, and prevented oncosphere formation. In vitro results were extended into mouse xenograft studies
using parental cells and isolated CICs. Lunasin significantly inhibited tumor growth in both cases, with the
highest inhibition being observed in tumors initiated by CICs while achieving an excellent safety profile.
Lunasin reduced the invasive potential of CICs in vitro and in an in vivo experimental metastasis model.
Mechanistic studies revealed that Lunasin may disrupt integrin signaling by inhibiting phosphorylations of
the intracellular kinase FAK as well as altering the PI3K/AKT axis. Additionally, it was demonstrated that
histone acetylation in H3 and H4 core histone are significantly altered in CICs treated with Lunasin. While
histone acetylation is potentially involved in Lunasin’s anticancer activity, the effects seen in these studies
are mainly integrin-driven. These studies demonstrate that Lunasin has activity against putative CICs, and
that Lunasin has potential utility as a therapeutic in treating malignant melanomas.
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CHAPTER 1: INTRODUCTION
1.1 BACKGROUND AND RATIONALE FOR THIS STUDY
Lunasin as an Anticancer Agent
Consumption of high amounts of soy is prevalent in many Eastern cultures and has been linked by
epidemiological studies to lower incidence of certain types of cancer [1-3]. Several components of soy
have been attributed with its chemopreventative and chemotherapeutic properties including isoflavones [4],
protease inhibitors [5], and bioactive peptides [6]. In combination, these components may work in a
concerted effort to reduce carcinogenesis through several mechanisms of action. For example, genistein, a
well-studied soy isoflavone, has been acknowledged to assert its anticancer effects through a variety of
mechanisms including cell cycle arrest and induction of differentiation [7]. Bowman Birk Inhibitors (BBI)
present in soy isolates perform an import action in the uptake and stability of bioactive peptides [8].
Lunasin, a 44 amino acid peptide encoded by the 2S Albumin gene in soy, has been reported to have
several activities which may drive its anticancer effects; previous reports have shown that Lunasin
functions as a histone acetyltransferase inhibitor [9] as well as an integrin antagonist [10]. With these
studies in mind, using soy intake as a functional food seemingly has promising health benefits in preventing
carcinogenesis. Additionally, investigating diet as a potential anticancer agent would appear an
encouraging avenue for future therapeutic-based studies. This dissertation will specifically investigate the
utility of the soy-derived peptide Lunasin as a chemotherapeutic agent against malignant melanomas.
Lunasin is a soy-derived peptide that has demonstrated anticancer, anti-inflammatory, antioxidant,
and immunomodulatory activity [11-14]. Lunasin has been reported as a 43 amino acid fragment present in
processed 2S albumin protein [15]; however, the Davis lab recently identified a native 44 amino acid
sequence of Lunasin isolated from defatted soy flour consisting of the sequence:
SKWQHQQDSCRKQLQGVNLTPCEKHIMEKIQGRGDDDDDDDDDN [16]. This 44 amino acid
sequence was verified by subsequent studies by Serra et. al. [17]. Lunasin has been proposed to have three
distinct domains that are responsible for its therapeutic and chemopreventive activity: an RGD sequence
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involved in internalization of the peptide via integrin binding, a poly-aspartic acid tail that binds
lysine residues present in H3 and H4 histone tails, and a hypothesized chromatin binding domain [9, 18].
Limited studies have described the direct chemotherapeutic effects of Lunasin against cancer as it is
generally defined as a chemopreventive agent based on earlier studies by De Lumen and coworkers [9, 1922]. Thus, many questions remain about the number of cancer types sensitive to Lunasin, the possible
mechanisms of Lunasin’s anticancer effects, and to what extent Lunasin is involved with the tight
correlation of soy consumption with a protective effect against certain cancer types [23-25].
Lunasin has been found to inhibit transformation induced by multiple carcinogens and viral
oncogenes [9, 19, 26-28]. Moreover, studies in the Davis lab indicate Lunasin is able to inhibit
transformation of mouse fibroblast cells induced by carcinogens present in cigarette smoke including
cadmium and nicotine-derived nitrosamine ketones (unpublished data). The most discussed mechanism of
action of Lunasin is the inhibition of histone acetyltransferases (HATs) and modulation of histone
acetylation (Figure 1). The acetylation of core histones initiates the unwinding of tightly packed DNA
from the nucleosome complex allowing for transcription of target genes. HAT inhibition alters normal
acetylation patterns leading to hypoacetylation of histone tails, repressing transcription and can account for
global cellular effects including proliferation, cell cycling, and apoptosis [29-31].

Although some

evidence supports HAT inhibition as Lunasin’s primary mechanism of action, to date, there have been no
functional studies to support this hypothesis. Moreover, as new principal mechanisms of Lunasin action
are still being discovered, it is not clear in the different experimental systems that have been studied
whether histone acetylation is involved in all cases.
Studies in the Davis lab confirm a significant antiproliferative effect of Lunasin on non-small cell
lung cancer (NSCLC), an effect which is mediated by disrupting cell cycle signaling [32]. Previous studies
have suggested that Lunasin reduces cyclin-dependent kinase (CDK) levels, and may promote aspirininduced apoptosis in breast cancer models [33, 34]. Additionally, Lunasin was reported to induce apoptosis
and alter expression of matrix adhesion proteins in metastatic colon cancer [35]. Lunasin was recently
shown to suppress FAK/ERK/NF-κB signaling in human colon cancer as well as potentiate the
antiproliferative and antimetastatic effects of oxaliplatin [36].

2

Sadly, many plant-derived compounds (e.g. curcumin) are quickly metabolized or excreted resulting in
poor bioavailability; however, Lunasin is active and bioavailable in humans consuming physiologically
relevant amounts of soy [37]. In this study, volunteers were orally dosed with Lunasin (155.5 mg/day) in
50 grams (g) soy protein for 5 consecutive days. De Mejia et al. revealed Lunasin is
orally bioavailable; however, incomplete gastrointestinal (GI) absorption resulted in a low concentration
(71.0 ng/mL or approximately 14 nM) of Lunasin in plasma samples [37].

Figure 1: Proposed mechanism in which Lunasin decreases histone acetylation. The poly-aspartic acid
tail of the Lunasin peptide may inhibit binding of HATs to lysine residues on core histone H3 and H4 tails.
This effect disrupts the normal cycles of histone acetylation/deacetylation and subsequently represses
transcription of target genes. Transcriptional machinery is unable to initiate transcription when chromatin
is tightly wound around the nucleosome complex (top). Histone acetylation allows for the unwinding of
chromatin and exposes sights of transcriptional regulation (bottom).
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Prior studies suggest that Lunasin interacts with a specific subset of integrin subunits, as
supported by a 2012 study by De Mejia and coworkers [12]. Furthermore, recent studies suggest that
internalization of Lunasin is mediated by αvβ3 integrins via clathrin and caveolin-mediated endocytosis
[38]. Proximity ligation assays (PLA) verify that the specific integrin subunits αv, α5, β1 and β3 network
with the Lunasin peptide [10]. In normal cells, integrins mediate cell-cell and cell-matrix adhesions by
recognizing binding motifs (i.e. RGD) as well as cooperating with growth factor receptors to induce
proliferative and survival signaling [39, 40]. The ubiquitous activity of integrin signaling provides an
interesting target for cancer prevention and treatment because many of these pathways are deregulated in
cancer and result in uncontrolled proliferation and metastasis. More specifically, this dissertation aimed to
elucidate the effects of Lunasin on downstream pathways associated with integrin signaling and how
disrupting these pathways can therapeutically benefit melanoma patients.
Perhaps the most intriguing aspect of the Lunasin peptide is the fact that it has been shown to have
immunomodulatory properties as well as those previously mentioned. Having a therapeutic with several
mechanisms may lower the possibility of chemoresistance due to the upregulation of pathways associated
with the inhibition of oncogenic pathways caused by chemotherapeutic agents as seen in B-Raf targeted
therapies (i.e. vemurafenib). In one study, Lunasin was shown to increase antigen specific T cells when
mice were challenged with allergen, while also suppressing inflammatory cytokines through NF-ĸB
inhibition [41]. A subsequent study demonstrated that Lunasin provided a significant advantage in
dendritic cell activation and maturation and conferred an enhanced immune response to viral challenge in a
similar murine model [42]. Relevant to melanoma, Lunasin in combination with cytokines (IL-2 and IL12) synergistically enhanced NK cell-mediated cytotoxicity leading to significantly improved tumoricidal
activity both in vitro and in vivo [13]. Lunasin, when introduced into a host, induces an immune response
as indicated by the use of multiple antibodies raised in both rabbit and mouse models [16]; thus, Lunasin
could be considered an antigenic peptide. Perhaps, the introduction of an immunogenic peptide such as
Lunasin promotes the mobilization of cells involved in innate immunity (NK cells, etc.) in order to combat
tumor-associated molecules; though, this hypothesis is only speculator at this point, and subsequent studies
on the precise mechanisms of Lunasin’s immunomodulatory functions are necessary.
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Studies utilizing Lunasin have demonstrated its significant benefit in several cancer models;
however, specific mechanisms of action and their induced response in cancer cells is only beginning to
become clear. Without functional studies to investigate the precise activity of mechanisms such as integrin
antagonism or histone acetylation, it is difficult to target the exact cause of Lunasin’s anticancer activity.
This dissertation aims to explore the functional domains of the Lunasin peptide while also expanding the
knowledge of its chemotherapeutic potential in preclinical models of human melanoma with a strong
emphasis on understanding the interactions between Lunasin’s RGD domain and integrin subunits on the
extracellular matrix (ECM).

Integrins as a targeted therapy in melanoma patients
Integrins are vital to many cellular processes, and remain an important and underexplored target
for cancer therapies (Figure 2). Recent studies utilizing RGD peptides have shown targeting of integrins as
a viable treatment alternative in melanoma therapy by inhibiting tumor angiogenesis, growth, and
metastasis [43-45]. Integrins are heterodimeric membrane proteins primarily implicated in cell adhesion
and migration [46, 47]; yet, integrins have also been reported to be intimately involved in cell growth,
differentiation, and survival [48, 49]. Integrin heterodimers are composed of a single α-subunits and a
single β-subunits, of which there are 18 and 8 variations, respectively. These α- and β-subunits comprise
the 24 heterodimeric proteins known in humans [50], and make integrin signaling flexible yet highly
intricate [51]. Furthermore, integrin expression profiles in vitro can vary largely depending upon the type
of adhesion (adherent cells versus cells in suspension) [52], and can result in recruitment of very different
subsets of proteins. Proteins attracted to different adhesion structures (e.g. paxillin) can produce diverse
yet specific signaling cascades.
By categorizing NSCLC lines based on integrin expression profiles, studies have associated
explicit integrin subunits with Lunasin sensitivity [10]. Moreover, it was shown that Lunasin exerts its
anticancer effects in NSCLC by reducing activating phosphorylations of v-akt murine thymoma viral
oncogene homolog 1 (AKT), focal adhesion kinase (FAK), and interactions of β-subunits with integrinlinked kinase (ILK), thereby altering signaling pathways downstream of integrin-ligand binding [10].
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In melanoma models, the integrin αvβ3 is currently the predominant target for therapeutic
applications of integrin antagonists. Integrin αvβ3 is expressed at low levels in non-transformed epithelial
cells relative to melanoma cells [53], as αvβ3 expression has been related to metastatic potential and
dissemination of melanoma neoplasms to a metastatic phenotype [54, 55]. Crosstalk between integrins and
growth factor receptors has been well documented [56, 57]. Enhanced cancer cell survival has been
attributed to a number of interactions between integrin signaling and other pathways including increased
BCL-2 expression, PI3K-AKT activation, or NF-κB signaling [58-60]. This dissertation proposed that in
melanoma models, similar to recent findings in NSCLC [10], Lunasin binds αvβ3 integrins through its
RGD domain and inhibits proproliferative and prosurvival signaling.

Figure 2: Integrin-associated signaling pathways and the cellular effects associated with integrin
signal transduction. Integrin signaling is ubiquitous in that several intracellular kinases (and their effector
proteins) are involved in signal transduction. These transduction pathways elicit various cellular effects
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including proliferation, differentiation, and migration, to name a few. Specific kinases highlighted in this
dissertation are enclosed in red boxes.

Certain integrins have specific roles in melanoma; for instance, it has been shown that α4β1, a
homing molecule on leukocytes that binds VCAM-1, is absent on melanocytes, yet present in melanoma
cultures [61]. Consequently, α4β1 may help melanomas mimic hematopoietic cells by enabling melanoma
migration into tissues that expressing VCAM-1 [62]. Other integrins implicated in melanoma are α3β1 and
α5β1, which were elevated in metastatic melanoma tissue. Furthermore, α1β1, α2β1 and α6β1 integrin
subunits were found to be reduced in metastatic versus primary melanoma [61]. However, roles of
integrins in CICs are somewhat ambiguous. Recent studies show that integrin subunits may be a viable
marker for CICs and may be responsible for stem cell pool maintenance and differentiation mediated by
FAK [63, 64], but the specific functions of integrins in CICs when compared to non-CICs have yet to be
elucidated. CICs are proposed to be more tumorigenic based on properties such as chemoresistance,
immune evasion, and self-renewal capabilities [65, 66]. Whether integrins, through mechanical adhesion or
signal transduction mechanisms, play a central role in these cellular processes is a major focus of this
dissertation.
Cilengitide, a cyclic RGD (cRGD) peptide, has been used to treat glioblastoma and is the first
integrin inhibitor to be used in Phase III clinical trials [67]. Unfortunately, cilengitide had minimal clinical
efficacy as a single agent in treating malignant melanoma [68]. Clinicians noted a significant decrease of
αVβ3 expression in cilengitide-treated melanoma patients. Interestingly, the sole responder to cilengitide
treatment had no tumoral αVβ3 expression. Additional clinical trials utilizing integrin-targeted therapeutics
in combination with standard treatments have yielded disappointing results [69, 70]; despite promising
preclinical data [71-73]. Despite not obtaining a significant difference, the treatment arm combining
standard-of-care chemotherapy and anti-integrin targeted therapy trended toward improved overall survival
in addition to having a favorable kinetic profile [69]. Furthermore, targeting of integrin subunits explicitly
expressed on cancer cells may represent a dynamic solution to reducing off-site, adverse side effects
generally seen with traditional chemotherapy. Using integrin antagonists to suppress angiogenesis as well
as integrin-associated signaling cascades may prove useful in the future as novel therapeutic strategies that
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do not simply target the bulk of rapidly proliferating tumor cells. The multiple modes of action of Lunasin
may provide a substantial boost in antitumor efficacy over more traditional integrin-targeted therapies.

Melanoma and the presence of melanoma stem cells
Skin cancers account for nearly half of all diagnosed cancer cases in the United States and have
increased in frequency over the last thirty years [74]. Melanoma is estimated to account for 76,000 new
cancer cases in 2014 [75]. Despite being less frequent than other skin cancers, nearly 75% of skin cancer
deaths are attributed to melanoma [75]. Even more unnerving, NCI’s Surveillance, Epidemiology, and End
Results (SEER) program estimates cases of melanoma have nearly tripled in the past thirty years increasing
from 7.9 (per 100,000) in 1975 to 22.7 in 2011, while 5-year survival rates remain constant. Early
detection and diagnosis is paramount for overall survival with 5-year survival rates of 98%, 62%, and 16%
for localized, regional, and distant diseases, respectively [75]. Epidemiological studies have shown that the
single greatest risk factor for melanomagenesis is UV exposure [76]; however, heredity has been reported
to be involved in up to 12% of melanoma cases [77]. Classification of melanomas (reviewed in [78]) relies
on a staging system which incorporates tumor thickness, presence of ulcerations, mitotic rate, and the
existence of metastasis. If diagnosed at an early stage, melanoma is a highly curable disease; however,
progression from the radial to vertical growth phase indicates the ability to invade surrounding tissues and
potential for metastatic dissemination [79].
Continued research of melanoma has provided several “cracks in the armor” of metastatic
melanoma leading to the development of several targeted therapies that aim to inhibit proliferation,
metastasis, and angiogenesis of primary and secondary tumors. One such targeted therapy is vemurafenib,
which decreases melanoma cell viability and proliferation resulting in tumor regression and increasing
overall mean survival time [80, 81]. Vemurafenib targets a mutated form of the B-Raf protein found in
approximately 60% of melanomas in which a V600E substitution leads to constitutive Raf signaling within
the mitogen-activated protein kinase (MAPK) cascade [82]. In the majority of patients harboring this
mutation, mean survival time has been improved with vemurafenib; however, after initial tumor regression,
many patients experience recurrence of tumors that are vemurafenib-resistant [83-85]. Conferred
resistance to vemurafenib may occur through a number of mechanisms including, but not limited to,

8

feedback activation of epithelial growth factor receptor (EGFR), upregulation of other Raf proteins, or
upregulation of N-Ras [85-87].
One explanation for the reformation of palpable tumors with chemoresistance is the presence of
CICs within the bulk tumor population. The presence of CICs and their origin have become a topic of
debate [88-92]. According to the cancer stem cell theory, a subset of cells within the tumor population
have properties that resemble physiological stem cells including the ability to self-renew while also giving
rise to daughter cells that differentiate to reform heterogeneous tumor populations [88] (Figure 3). The
present study will show that CICs exist within established melanoma cell lines at a relatively high rate, and
that this subset of cells displays enhanced tumorigenicity and invasiveness.

Figure 3: Stochastic model compared to the cancer stem cell model. The stochastic model of
tumorigenesis argues that all individual cells within a tumor population have the intrinsic ability to form a
tumor. The cancer stem cell hypothesis states that only a subset of tumor cells have the capacity for
reforming heterogeneous tumor populations. The cancer stem cell hypothesis has recently become a topic
of debate. While several models seem to appropriately fit the cancer stem cell hypothesis, several
researchers have provided evidence suggesting some models do not follow this model.
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Discovery of melanoma cells with stem cell-like plasticity was initially found in patient tumors
overexpressing CD20 and CD133 [93, 94]. CD20 is a membrane-spanning surface molecule generally
found on B lymphocytes; per se, it is the molecular target for therapeutic monoclonal antibodies (e.g.
rituximab) for treatment of select leukemias and lymphomas. CD133 (prominin-1) is a membranespanning protein of no known function that is classified as a marker for primitive hematopoietic and neural
stem cells. These subsets of cells were found to have properties of stem cells as well as enhanced ability to
form palpable tumors in immunodeficient mice. Ensuing studies verify ATP-binding cassette sub-family B
member 5 (ABCB5), a drug transporter playing a key role in chemoresistance, and Low-Affinity Nerve
Growth Factor Receptor (LNGFR/CD271), a member of the tumor necrosis factor (TNF) receptor family
involved in survival and differentiation of neurons, as viable CIC biomarkers [66, 95]. However, scientists
are slow to embrace this concept for a number of valid reasons. One concern remains the standardization
of techniques for identifying and propagating cancer stem cells. Serial dilution and transplantation of CICs
into NOD/SCID mice has long been the gold standard for determining stem cell populations; however,
spheroid assays in addition to genetic lineage tracing provide in vitro assays for CIC classification [89].
To make matters more complicated, some evidence supports plasticity of differentiated cancer
cells in a breast cancer model [96]. By reverting to a dedifferentiated phenotype, stem-like cells arise de
novo in response to environmental cues [96]. These data support the theory of bidirectional movement
between stem and non-stem compartments, and have serious implications on the plasticity of cells in cancer
models as well as subsequent therapeutic strategies. The phenomenon of “phenotype switching” has also
been reported in melanomas [97]. The hypothesis proposed by Hoek and his coworkers suggests that cells
within a tumor may be able to undergo a change between invasive and proliferative phenotypes depending
on environmental cues and genetic alterations. Additional publications have aimed to refute the claim that
melanoma “fits” the cancer stem cell theory. Quintana et. al. recently reported that nearly 1 in every 4
melanoma cells may be able to produce a palpable tumor in vivo; however, the percentage of tumorigenic
melanoma cells was highly variable depending upon the immune status of the host animal [98]. This report
questions whether or not cancer stems cells are a rare subpopulation despite the fact that the rarity of CSCs,
according to the CSC theory, has yet to be truly defined [99, 100].
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Although populations of stem cell-like cells are recognized in melanoma cell lines, the frequency
of these cells is highly variable, ranging from less than 1% up to nearly 25% [66, 98]. The incidence of
cancer stem cells seems dependent upon the in vivo model, the biomarker used for identification, and the
tumor microenvironment [62, 101]. Conflicting reports indicate that tumor samples enriched for CIC
markers have enhanced tumor forming capacity. Quintana [98] showed tumorigenic cells are
phenotypically heterogeneous in melanomas, as significant in vivo tumor growth was marginal based on
select CIC biomarkers. Despite these findings, numerous studies report superior tumor forming capabilities
of cells enriched for melanoma stem cell biomarkers including ABCB5 [102], CD133 [94], CD271 [95],
and ALDH (aldehyde dehydrogenase) [103].
ALDH is a family of detoxifying enzymes responsible for metabolism of certain alkylating agents
such as cyclophosphamide. Enrichment for melanoma initiating cells by intracellular ALDH staining
(protocol reviewed in [104]) has come with mixed reviews; however, most evidence supports ALDH as a
CIC biomarker [103, 105-107]. ALDH expression has also successfully been used to detect CICs in breast
and colon cancer models [108, 109]. The use of ALDH as a biomarker is based on its involvement in
vitamin A metabolism [110]. ALDH has also been researched as a therapeutic target in human melanomas
and its inhibition has been shown to decrease melanoma cell tumorigenicity and metastasis [111],
indicating a primary role in melanomagenesis and progression. Interestingly, ALDH-high cells may also
serve a role as an adjuvant in vaccine-based therapies for melanoma [112].
Throughout this dissertation, ALDH-high fractions of cells derived from several melanoma lines
were utilized to assess the effects of Lunasin on melanoma CICs compared to “bulk” tumor cells with the
ALDH-low phenotype. The complex mechanisms underlying the contributions of ALDH in CIC function
have yet to be fully elucidated. While the work presented in this dissertation does not immediately delve
into these intricacies regarding ALDH function in CICs, it will serve as a foundation for using ALDH as a
CIC biomarker and supports the notion that ALDH-high cells harbor a highly tumorigenic and invasive
population of melanoma cells. In order to indisputably determine whether melanomas follow a hierarchal
or stochastic model of tumorigenesis, additional research must be conducted using a standardized and well
defined classification and identification system for CSCs. Simply collecting cells based on a single
biomarker will most likely not suffice, but long-term propagation in an in vivo system may help categorize
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subsets of tumors cells in terms of tumorigenic capacity and self-renewal. Data presented throughout this
dissertation and how it relates to what is currently known about the CSC theory (Reviewed in [113]) will be
discussed in subsequent chapters of this work.

Traditional approaches to treating melanomas and future perspectives
It is becoming clear that late-stage and recurrent melanoma may be due to the presence of
melanoma stem cells which repopulate the heterogeneity of melanoma tumor tissues throughout the body.
An emerging issue in treatment strategies involving late-stage cancers is the fact that traditional
chemotherapeutic agents (e.g. alkylating agents) can actually expand the CIC compartment while
simultaneously causing an initial regression of the primary tumor [114-116]. Recent studies have found
that several traditional chemotherapies, including many used in the treatment of malignant melanomas, can
increase the number of cells in the CIC compartment [117-120]. In addition to selecting for CICs, these
chemotherapeutic regimens can increase genetic instability leading to phenotypic abnormalities such as
increased invasiveness or enhanced tumorigenicity [121]. Therefore, the strategy of using differentiationinducing agents to reduced CIC populations prior to, in combination with, or immediately following
therapeutic intervention is an emerging area of research [122].
The standard protocol for treating melanoma has largely depended on the stage at diagnosis; early
melanomas (stage I and II) can generally be surgically resected without fear of recurrence [123, 124].
However, late stage (stage III and IV) melanomas are treated much more aggressively and traditional
treatment usually includes surgical resection, radiation, chemotherapy, or a combination of these therapies
[123, 124]. Dacarbazine, temazolomide, cisplatin, and paclitaxel have primarily been used as the
chemotherapeutic arm of traditional treatment strategies [125-127]. While these therapies have been shown
to induce apoptosis in many melanomas and provide relief in the form of an initial tumor regression, many
patients will experience recurrence and subsequent metastasis of chemoresistant tumor populations within
months of treatment; patients with stage IV melanomas given the standardized treatment of care (i.e.
dacarbazine) had median overall survival times ranging from 5.6 – 7.8 months and a response rate of only 7
– 12% [83, 128-131]. These facts, taken in conjunction with the high cytotoxicity and ongoing list of
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adverse effects of traditional anticancer pharmacologics, make it very clear to see why the demand for
efficacious yet safe treatment options are needed.
The past decade has seen the implementation of several novel strategies for the treatment of late
stage melanomas including targeted therapy (e.g. vemurafenib) [132] and immunotherapies, which consist
of several subcategories including adoptive cell transfer [133], oncolytic viral therapy [134], and
checkpoint blockade (e.g. nivolumab) [135]. Due to the strong immunogenicity of melanomas [136], the
use of immunotherapies for modulating melanoma progression has received strong interest from
researchers and pharmaceutical companies and will likely be a major focus moving forward. While
immunotherapies have shown great promise in clinical trials [137-139], the fact that these drugs are just
now being implemented clinically raises the question as to whether these agents can sustain improved
patient responses and increased overall survival rates. Therefore, the continual development of novel
antimelanoma drugs is necessary to combat this particularly deadly and inherently common disease. With
respect to Lunasin, a particularly intriguing aspect of the recent development and approval of
immunotherapies is the fact that Lunasin has been shown to enhance components of both innate and
adaptive immunity [13, 41, 42]. While strategies dedicated to eliciting cell-mediated immune responses
seem to be receiving heightened interest, inducing an overall immune response by activating several
constituents of the immune system may provide a more robust antitumor effect. At the very least, it will be
interesting to see what the future holds for immunomodulatory therapies, and whether or not they become a
mainstay in anticancer treatments.
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1.2 SPECIFIC AIMS AND GOALS OF THE DISSERTATION
Overall Goals
The principle goal of this dissertation is to expand upon the existing knowledge that Lunasin has
significant anticancer activity. Initial data from the Davis lab indicated that Lunasin may have potential
utility against NSCLC. The hypothesis of this dissertation extends upon previous studies in the Davis lab
to suggest that Lunasin may have potential clinical utility against melanoma. Malignant melanoma cell
lines derived from both human and murine origins were used to investigate the functional effects on cancer
cells when they are treated with Lunasin, and additionally, to demonstrate through preclinical studies that
these effects could provide a potential therapeutic benefit in clinical applications. Initially, it was observed
that Lunasin had a modest effect in vitro; however, these effects were more robust in vivo. The importance
of CICs in melanoma mortality [140] led to the question as to whether or not Lunasin might have a
selective effect on this population of cells. This was especially important due to the problematic and
challenging nature of melanoma recurrence and chemoresistance due to the presence of CICs [140]. A
principle goal of this study was to characterize the effects of Lunasin on melanoma cells through analysis
of proliferative, apoptotic, differentiation, and senescence markers. Previously described mechanisms of
Lunasin’s anticancer activity including alterations in histone acetylation and integrin signaling were
investigated to reveal which mechanism(s) was responsible for the effects seen in melanoma models. The
driving hypothesis of this study is that Lunasin decreases tumorigenicity and proliferation of melanoma cell
lines by inhibiting integrin signal transduction.
Recent findings in NSCLC [10] indicated that Lunasin’s interaction with integrins comprised a
significant portion of its anticancer activity; therefore, those studies were used as a stepping stone to further
explore melanoma as a model to discover novel functions of the Lunasin peptide. Because of the central
role of both CICs and integrins in metastatic dissemination [62], it was imperative to assess whether
Lunasin, through its changes in integrin signal transduction and selective targeting of CICs, would
significantly suppress metastatic outgrowth in a murine model of metastasis. In terms of clinical relevance,
the use of Lunasin as an adjuvant in combination with the commonly prescribed B-Raf inhibitor
vemurafenib was utilized to assess any additional gain in therapeutic benefit. Taken together, it was
expected that these findings would advance Lunasin as a potential drug candidate for further development,
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not only in malignant melanoma, but in malignant diseases in which the presence of CICs has the potential
to cause patient relapse.
Specific Aims
1.

Identify the mechanisms in which Lunasin exerts its anticancer effects in melanoma

Sub Aim A. Assess the ability of Lunasin to reduce populations expressing CIC and stem-associated
markers
Sub Aim B. Characterize the effects of Lunasin on CICs through analysis of proliferative, apoptotic, and
differentiation markers
Lunasin’s effects on melanoma had yet to be documented prior to the Davis lab’s initial study
[141]; however, the recent findings in NSCLC would suggest that these effects are conserved throughout
many different cancer cell types. It was revealed that NSCLC proliferation was significantly inhibited
when cancer cells were treated with Lunasin, and additionally, that this effect was differentially dependent
upon expression of specific integrin subunits [10]. These results would suggest that integrin signaling is
strongly linked to the initial results which demonstrated that Lunasin diminished the ability of cells to form
colonies in soft agar as well as had a very modest effect on melanoma cells in proliferation assays. Firstly,
this dissertation aimed to identify and characterize the effects that Lunasin had on parental melanoma cells
through assessment of markers for proliferation, apoptosis, differentiation, and senescence. Secondly, this
work planned to identify whether or not Lunasin had a significant effect on biomarkers for melanoma CICs
including ALDH, CD271, and CD133. Categorizing these effects as described would justify subsequent
aims geared toward elucidating specific mechanisms of Lunasin in melanoma CICs.
2.

Evaluate the interaction between Lunasin and integrin subunits

Sub Aim A. Specify the explicit integrin subunits interacting with Lunasin and identify the downstream
mediators of integrin signal transduction
Sub Aim B. Mutate the Lunasin peptide to discriminate the effects caused by histone acetyltransferase
inhibition and integrin antagonism
Sub Aim C. Genome-wide microarray analysis to discover Lunasin associated gene targets
Recent work in the Davis laboratory has focused on using NSCLC as a model to investigate the
specific mechanisms in which Lunasin exerts its effects on cancer cells. It was observed that in NSCLC,
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integrin signaling was significantly suppressed in cells treated with Lunasin. Using these results as a
stepping stone, it was next investigated if these effects were conserved in models of melanoma. Therefore,
this dissertation proposed to investigate the interactions between RGD-recognizing integrin subunits and
the Lunasin peptide as well as assessed the downstream effects through integrin-associated intracellular
kinases (e.g. FAK) caused by this interaction. Because Lunasin has been reported to have significant
effects on global histone acetylation patterns [142], it was next asked whether these effects could be driven
by alterations in chromatin structure (via histone acetylation) compared to suppressed integrin signaling.
Using synthesized peptides with mutated activity domains, this study aimed to test whether the RGD
domain or the poly-aspartic acid tail were necessary for Lunasin’s activity in melanoma.
Integrin signal transduction has been linked to several oncogenic signaling pathways [143]; for
example, integrins have been shown to cooperate with the MAPK signaling cascade [144]. The ubiquitous
nature of integrin-mediated signaling makes it difficult to accurately pinpoint precise mechanisms involved
in Lunasin’s activity. Thus, a genome-wide microarray screen was employed in order to distinguish any
signaling pathways that may overlap with either integrin signal transduction or histone acetylation causing
the effects observed in previous studies. Using Lunasin as a tool to probe for novel therapeutic targets or
identify connected hubs of proteins associated with these targets may allow researchers to explore this
multifaceted peptide as a viable treatment option for malignant melanoma.
3. Investigate the antimetastatic effects of Lunasin
Metastatic dissemination due to circulating tumor cells that have undergone epithelial to
mesenchymal transition (EMT) is the foremost reason for poor prognosis due to the high mortality rates
caused by secondary tumor growth [145]. Prevention of initial metastatic seeding and sequential
colonization of distant tissues is at the forefront of several clinical trials, and remains a major focus for
oncologists and researchers [146, 147]. Even after metastatic outgrowth from the primary tumor, shrinkage
of these initial lesions and prevention of metastatic spread can successfully improve overall patient
survival. Therefore, it was next investigated whether or not Lunasin could provide any antimetastatic
benefit in a syngenic model of experimental metastasis. These data, if supportive of the proposed
hypothesis, could potentially provide significant clinical implications for the development of Lunasin as an
adjuvant therapy in malignant diseases.
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CHAPTER 2: EXPERIMENTAL PROCEDURES AND METHODOLOGY
2.1 Lunasin Isolation and Purification
Lunasin was isolated from “white flake,” a product resulting from the flaking and defatting of
soybeans via hexane extraction. The extraction and purification was scaled and performed by Kentucky
BioProcessing (KBP) as previously described [16]. Briefly, Lunasin was extracted from defatted soy flour
in a 12.5: 1 ratio of extraction buffer (20 mM sodium phosphate/150 mM NaCl/20 mM ascorbic acid/10
mM sodium metabisulfite, pH 7.4) to soy flour. This solution was mixed for one hour at room temperature.
A diatomite filter aid (Advanced Minerals Corporation) was added to the solution after mixing, and the
mixture was then passed through a filter press (ErtelAlsop, 1 μm filter pads). The filter cake was dried and
once again washed with extraction buffer, and the resulting mixture was added to the initial extract. Anion
exchange chromatography was performed at Kentucky BioProcessing using a 20x13 cm Q-Sepharose FF
column on a Pharmacia 10 mm BioProcess System Skid after both column and skid were sanitized with 1
N NaOH and preconditioned with equilibration buffer (20 mM sodium phosphate/150 mM NaCl, pH 7.4).
Clarified extracted was applied to the column for a residence time of approximately 3 min, and washed
with 14.8 CV (column volumes) of equilibration buffer. Lunasin was eluted using a linear gradient of
sodium chloride (0.29 – 0.48 M, pH = 7.4), and the Lunasin-containing fractions were filtered through a 0.2
μm capsule filter. Dithiothreitol (DTT) was added to the fraction containing Lunasin to a final
concentration of 2 mM, and the mixture was mixed at room temperature for one hour. DTT-containing
fractions were then subjected to ultrafiltration using 30 kDa polyethersulfone membranes and a Sartorious
Sartocon Slice unit (Sartorious Stedium Biotech). The final step in the purification process utilized
reverse-phase chromatography (RPC) using a 10x9.2 cm Source RPC column on an AKTA pilot system
(GE Healthcare). Fractions were applied to the column with a residence time of precisely 2.5 min. and
subsequently washed with equilibration buffer followed by a step elution process using 20% up to 100%
elution buffer (17 mM sodium phosphate/127.5 mM NaCl/15% n-propanol/pH 7.4) in which the 100%
buffer was the Lunasin-containing fraction. This fraction was concentrated using a 0.5 m2 2 kDa cellulose
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cassette (Sarorious Stedium Biotech). RPC elution buffer was replaced with 50 mM sodium phosphate (pH
7.4) via diafiltration, and passed through a 0.2 μm filter. Sodium dodecyl sulfate polyacrylamide gel
electrophoresis (SDS-PAGE) analysis indicate these Lunasin preparations have >99% purity (Figure 4).
Subsequent experiments utilizing Lunasin as a treatment used these stock preparations, which had been
diluted to a final concentration of 4.7 mg/mL of Lunasin (in 50 mM sodium phosphate) in 10 mL sterile
glass vials and stored at 4˚ C.

Figure 4: SDS-PAGE analysis of lunasin purified from soybean white flake. A total of 5 μg total
protein was subjected to SDS-PAGE using a 15% gel (BioRad) followed by staining with Coomassie
Brilliant Blue (BioRad). Labels indicate migration of SeeBlue Plus2 (Life Technologies) protein standards.

2.2 Cell Culture and Reagents
B16-F10, SKMEL-28, and A375 cell lines were obtained from American Type Culture Collection
(Rockville, MD), and further authenticated by short tandem repeat profiling (Promega). Cells were
monitored for mycoplasma contamination every 6 months. All cell lines were grown in Dulbecco’s
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Modified Eagles Medium (DMEM) supplemented with 10% Fetal Bovine Serum (FBS), Penicillin (100
U/mL), and Streptomycin (100 μg/mL). Cells were incubated at 37 °C at 5% CO2 and sub-cultured every
72 h. ALDH+ cells were purified by fluorescence-activated cell sorting (FACS) and were grown in
DMEM/F-12 serum-free media containing 1x N-2 Supplement (Gibco) 10 ng/mL basic fibroblast growth
factor (Gibco), and 10 ng/mL epidermal growth factor (Gibco). For soft agar assays, DMEM media
(Invitrogen) powder was reconstituted in ultrapure water (500 mL) and supplemented with 20% FBS,
Penicillin (200 U/mL), and Streptomycin(200 μg/mL). Vemurafenib (a selective B-Raf inhibitor) was
obtained from Selleck Chemicals (PLX4032, RG7204). Vemurafenib was dissolved in dimethyl sulfoxide
(DMSO) at a stock concentration of 1 mM and stored at -20˚C until use. The A375R cell line was created
in the Davis lab to mimic acquired vemurafenib resistance. A375R cells are derived from A375 melanoma
cells which were cultured in 1 μM vemurafenib for 4 weeks. The resulting cell phenotype had decreased
sensitivity to vemurafenib compared to parental A375 cells.
2.3 Proliferation Assays
Manufacturer protocols were followed to determine the effects of Lunasin on melanoma cell
proliferation (Promega Cell titer-96 Aqueous Reagent). Initial seeding densities were standardized at 7.5x
103 cells/cm2 in 100 μL culture media. Briefly, cells were plated and incubated at 37˚C, 5% CO2 for 4 h.
Media were drained from each well and replaced with media containing varying concentrations of vehicle,
Lunasin, or vemurafenib. Treatment media were replaced every 24 h during the 72 h treatment period.
After 72 h of treatment, wells were drained of expired media and refilled with 100 μL of fresh media. 20
μL of [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium
(MTS) reagent was added to each well and the plate was incubated for 2-3 h. Absorbance was read at 490
nm on a plate reader (Biotek Instruments). Average absorbance of media containing no cells (i.e.
background absorbance) was subtracted from all absorbance values. Absorbance values were then
normalized to control and expressed as percent control ± s.d.
2.4 Soft Agar Colony Forming Assay
A lower, cell-free layer of 0.5% Bacto agar and cell culture media (1:1 suspension) was plated in
6-well tissue culture plates and allowed to solidify at room temperature in a laminar flow cabinet. An upper
layer of 0.35% agar and culture media (1:1) containing 1000 melanoma cells plus vehicle, Lunasin or
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vemurafenib was plated over the solid lower layer. Plates were incubated at 37 °C and 5% CO2 for 10–18
days until colonies grew to approximately 100 μm in diameter. After seeding, plates were fed with culture
media containing vehicle (PB) or Lunasin twice weekly. Plates were stained with crystal violet solution
(0.005%; Sigma-Aldrich), photographed, and scanned (1000 dpi; EPSO Expression 1680 scanner). Average
colony size and total colony area for each sample were analyzed using Image-J software (National
Institutes of Health).
2.5 ALDEFLUOR Staining
The ALDH positive population was identified using a commercial kit (ALDEFLUOR™, Stem
Cell Technologies) according to manufacturer’s directions. A375, SKMEL-28, and B16-F10 cells were
grown to approximately 80% confluence in DMEM cell culture medium and treated with Lunasin for 24 h.
Cells (1 × 106 cells/mL) were washed and resuspended in ALDEFLUOR™ Assay Buffer. ALDEFLUOR™
reagent (5 µL/mL) was added to the cell suspension. The sample was mixed, and a portion was added to a
fresh tube containing the N,N-diethylaminobenzaldehyde (DEAB) inhibitor. Another portion was placed in
a fresh tube for staining with 10 μg/mL propidium iodide (PI). Samples were incubated in 37 °C for 45 min
and mixed occasionally by inversion. Flow cytometry was performed using FACS Calibur (BD
Biosciences). A representative histogram showing SKMEL-28 melanoma cells stained with ALDEFLUOR
reagent is presented in Figure 5.
2.6 Flow Cytometry (Apoptosis)
Annexin V binding assays were conducted using FITC conjugated antibodies against
phosphatidylserine (BD Bioscience) and propidium iodide to measure rates of apoptosis and cell death.
Cells were harvested and resuspended in 1x binding buffer (0.1 M HEPES, pH 7.4; 1.4 M NaCl; 25 mM
CaCl2) at a concentration of 1x106 cells per mL. Briefly, 1x105 melanoma cells were incubated with 100
μM Lunasin for 24 h. After the 24 h treatment, cells were harvested using enzyme-free dissociation media
(TrypLE, Life Technologies), counted, and subjected to staining. Cells were suspended in 0.5 mL binding
buffer and stained with 5 μL PI, 5 μL Annexin antibody, or both for 15 min at room temperature. Gates
were set based on controls (unstained, PI only, Annexin only), and compensation controls were performed
in FlowJo V10 (FlowJo, LLC). 1x104 events were collected per run on a FACS Calibur flow cytometer
(BD Biosciences).
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For identifying ALDHhigh cells, melanoma cells were assayed for high ALDH activity as
described above (Section 2.5). ALDHhigh and ALDHlow melanoma cells were sorted using a MoFlo cell
sorter (Beckman Coulter) or a FACS Aria II with FACS Diva software (BD Biosciences). Sorted
ALDHhigh cells (1 × 103 cells/mL) were plated in low-attachment 6-well plates (Corning) in DMEM/F-12
serum-free media. Cells were either treated with Lunasin (100 μM) or vehicle and labelled with Annexin V
or PI. Labelled cells were analyzed by flow cytometry using FACSCalibur (BD Biosciences) as outlined
above.

Figure 5: SKMEL-28 cells stained with ALDEFLUOR reagent +/- DEAB. SKMEL-28 melanoma
cells were grown in adherent culture, harvested, and stained for ALDH activity. This histogram represents
a typical ALDH staining profile for the SKMEL-28 cell line run on a MoFlo cell sorter, and shows
subpopulations both negative (A) and positive (B) for ALDH activity.
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2.7 Flow Cytometry (Cell Cycle)
Cell cycle analysis was performed on synchronized melanoma cells; cells were serum starved for
72 h and then released by addition of 10% FBS culture media containing Lunasin or vehicle for 24 h.
1x106 cells were harvested and resuspended in 200 μL of PBS. Cells were slowly added to 4 mL ice cold
70% ethanol for overnight fixation at -20˚C. After fixation, cells were spun down at 300 xg for 10 min and
resuspended in 0.5 mL of PI master mix (40 μg/mL PI, 100 μg/mL DNase in PBS) and incubated at 37˚C
for 30 min prior to flow analysis using a BD FACS Calibur. Resulting data were analyzed using FlowJo
V10 cell cycle analysis tool.
2.8 Fluorescence-assisted Cell Sorting
Cell sorting was performed on a Beckman MoFlo or BD Aria II instrument equipped with a 20
milliwatt blue argon laser (488 nm) using the ALDEFLUORTM kit as previously described (Section 2.5).
ALDHhigh and ALDHlow fractions were detected using a FITC filter set (530/30 emission) on FL-1 (FITC)
channel and collected for subsequent in vitro and in vivo experiments. Sorted cells were confirmed to be
positively stained for ALDH by fluorescent microscopy on a Nikon NiE microscope (Nikon) under a 488
nm laser and GFP (530/20) filter set. Batch sorting reports derived from Aria II FACS equipment are
provided to represent typical staining profiles for A375 (Figure 6) and B16-F10 (Figure 7) melanoma cell
lines. Melanoma cells which do not express ALDH (i.e. ALDH-negative) are captured in the left gate (set
by the DEAB control), and those staining for high ALDH activity are captured in the gate to the right.
Cells which express intermediate (i.e. between the left and right gate) levels of ALDH represent an ALDHpositive population that did not demonstrate a one log shift in fluorescence, and thus, were not isolated in
our ALDHhigh sorted fractions.
2.9 Formation of Multicellular Oncospheres
B16-F10, A375 and SKMEL-28 melanoma cells were sorted for ALDH activity as described
above. ALDHhigh cells were sorted using a MoFlo flow cytometer (Beckman Coulter) or a FACS Aria II
(BD Biosciences). Gates were set based upon DEAB controls for each cell line and reflected at least a onelog shift between negatively and positively stained cells. Sorted cells were cultured in low-adherent T-25
flasks (Corning) in DMEM/F-12 serum-free media at a density of 1 × 103 cells/mL. Cultures were grown
for up to 14 days and treated with fresh media containing either Lunasin (100 μM) or vehicle twice per
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week. Oncospheres (>100 μm) were harvested and passed through a 70 μm nylon filter (BD Biosciences) to
remove single cells and small cell clumps. Spheres were imaged and analyzed using Image-J software
[148].

Figure 6: Batch report for A375 melanoma cells stained with ALDEFLUOR reagent. Parental A375
cell lines were subjected to FACS after being stained with ALDEFLUOR reagent. DEAB was used as a
negative control in order to set appropriate gates for ALDH-negative cells (A). ALDHhigh cells reflect at
least a one log shift in fluorescence intensity (B). Sorted cells were analyzed and isolated using a BD Aria
II FACS and batch reports were generated using FACS Diva software.

2.10 In vivo Xenograft Model
Male athymic nude mice (Jackson #002019) were used at 6-8 weeks of age. All mice were
handled in accordance with the Association for Assessment and Accreditation of Laboratory Animals Care
international guidelines with the approval of the appropriate Institutional Animal Care and Use Committees
at the University of Louisville (protocol #12091) and Indiana University, Bloomington (Protocol # 14-019-
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4). Mice were injected subcutaneously (s.c.) with 2.5 × 106 A375 cells in phosphate buffered saline (PBS;
100 μL) on the right hind flank. Mice received daily intraperitoneal (i.p.) injections of either Lunasin (30
mg/kg) or vehicle (PB) starting the same day that cells were implanted and repeated until mice were
sacrificed. Noticeable tumor formation was observed approximately 14 days post-injection and measured
every other day thereafter. Experimental endpoint was set at tumor volumes exceeding 20 mm in diameter
(~ 2 cm2 total area) or upon ulceration of tumor tissues. At endpoint, mice were sacrificed, and organs and
whole blood samples were taken for subsequent analyses.

Figure 7: Batch report for B16-F10 melanoma cells stained with ALDEFLUOR reagent. Parental
B16-F10 cell lines were subjected to FACS after being stained with ALDEFLUOR reagent. DEAB was
used as a negative control in order to set appropriate gates for ALDH-negative cells (A). ALDHhigh cells
reflect at least a one log shift in fluorescence intensity (B). Sorted cells were analyzed and isolated using a
BD Aria II FACS and batch reports were generated using FACS Diva software.

To test the in vivo properties of CICs, ALDHhigh A375 cells were sorted as described above.
ALDHhigh cells were suspended in Hank’s Balanced Salt Solution (HBSS) +calcium +magnesium

24

(Invitrogen) and mixed at a ratio of 1:1 with Matrigel (growth factor reduced, without phenol red; BD
Biosciences). A total of 100 μL of this Matrigel-cell suspension containing 1x104 melanoma cells was
implanted s.c. on the dorsal side of the athymic nude mice. Tumor size was monitored thrice weekly until
animals were sacrificed due to tumor burden. Tumor volume [V = L × W2 × (π / 6)] was determined by
measuring the greatest linear dimensions in length (L) and width (W).
2.11 SDS-PAGE and Immunoblot
Cultured cells were treated with 100 μM Lunasin or vehicle and harvested by using enzyme free
dissociation buffer (TrypLE, Gibco) to minimize protein degradation. Cells were pelleted by centrifugation
at 300 xg and resuspended in appropriate amounts of RIPA buffer (250 mM Tris-HCl, pH 7.5, 5 mM
EDTA, 750 mM NaCl, 0.5% Lauryl sulfate, 2.5% Deoxycholic acid, 5% Igepal CA-630, Protease inhibitor
cocktail containing 4-(2-aminoethyl) benzenesulfonyl fluoride (AEBSF), pepstatin A, bestatin, leupeptin,
aprotinin and trans-epoxysuccinyl-L-leucyl-amido(4-guanidino)-butane (E-64) (Sigma-Aldrich). Protein
concentrations of cell lysates were determined by a bicinchoninic acid (BCA) assay (Thermo Fisher
Scientific, Waltham, MA). Total protein ranging from 20 - 40 μg were loaded in 10% polyacrylamide gels
(BioRad, Hercules, CA) and resolved at 100 volts for 1 h. The protein was then transferred to a
polyvinylidene difluoride (PVDF) membrane (BioRad) at 350 milliamps (mA) for 1 h. Membranes were
stained with Ponceau S (BioRad) to ensure equal loading and transfer of protein into the membrane. In
some cases, PVDF membranes were then cut into halves, leaving two duplicate membranes that were
subsequently probed for various proteins. In some cases, images of immunoblots presented in this
dissertation represent chemiluminescent signal resulting from these duplicate membranes. Individual
PVDF membranes were blocked with 5% bovine serum albumin (BSA) or non-fat dry milk for 1 h. After
several washing steps in Tris Buffered Saline with 0.1% Tween (TTBS), primary antibodies were incubated
with the PVDF membrane at 4˚C overnight with constant agitation. Lysates were probed with antibodies
that recognize human Microphthalmia-associated transcription factor (MITF, Cell Signaling #12590),
Tyrosinase (EMD Millipore #05-647), poly ADP ribose polymerase (PARP, Santa Cruz #sc-7150),
Caspase-3 (Santa Cruz #sc-56055), NANOG (EMD Millipore #MABD24), β-Actin (Santa Cruz #sc47778), phosphorylated AKT (Cell Signaling #9916S), phosphorylated FAK (Cell Signaling #9330S),
phosphorylated ERK 1/2 (Cell Signaling #4094), H3K9 (EMD Millipore #07-352), H4K12 (EMD
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Millipore #04-119), H4K8 (EMD Millipore #07-328), and H3K14 (EMD Millipore #07-353) diluted in
TTBS at 1:1000 – 1:2000 v/v. After three washes in TTBS, secondary antibodies at 1:10,000 dilutions
(Cell Signaling) were incubated with the membrane for 1 h at RT. Electrochemiluminescent (ECL)
substrate and enhancer solutions (Thermo Fisher) were allowed to activate horseradish peroxidase (HRP)
signal on membrane for 2-3 min; Chemiluminescence was developed on x-ray film and/or detected using a
ChemiDoc station (BioRad). In some cases, membranes were stripped using a harsh stripping buffer (0.5
M Tris HCL, pH = 6.8, 10% SDS, 1% 2-mercaptoethanol). Briefly, PVDF membranes were allowed to
incubate in an appropriate amount of stripping buffer in a dry incubator (Thermo Fisher) for approximately
20 min at 50˚ C under constant agitation. After removal of the antibodies, membranes were washed in
TTBS at least 5 times for a minimum of 5 min per wash. To ensure removal of all primary and secondary
antibodies, ECL substrate was applied to the stripped membrane as described above. After a 2-3 min
incubation with ECL substrate, membranes were reimaged to confirm the efficient removal of all
antibodies. In some cases, a second incubation with stripping buffer was necessary to remove all bands
from previously imaged membranes. Efficiently stripped membranes were blocked in an appropriate
blocking buffer as described above, and subsequently probed using a different primary antibody. All band
densities, including the loading control (β-Actin), were normalized to vehicle-treated cells and are shown
above the appropriate representative protein band.
2.12 Non-steroidal anti-inflammatory drug (NSAID) Toxicological Panel and Complete Blood Count
(CBC)
Whole blood was drawn from athymic nude mice by cardiac puncture immediately following CO2
asphyxiation and collected in serum separator tubes (BD Biosciences) or EDTA coated collection tubes
(BD Biosciences). Aliquots of whole blood (25 μL) were collected in EDTA coated tubes and sent to the
Research Resources Center (RRC) at the University of Louisville for CBC analysis. After 1 h postcollection, whole blood collected in serum separator tubes were centrifuged for 10 min at 10,000 xg. 250
μL of serum was removed from each sample, collected in a 1.5 mL Eppendorf tube, and send to the RRC
facility for NSAID toxicological analysis. Liver damage was assessed by levels of alanine aminotransferase
(ALT), aspartate aminotransferase (AST), and alkaline phosphatase (ALKP). Kidney damage was assessed
by level of blood urea nitrogen (BUN) and creatinine (CREA).
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2.13 In vivo Limiting Dilution Assay and ALDH Activity in Primary Tumors
In order to determine the viability of using ALDH as a practical biomarker for identifying CICs, in
vivo limiting dilution assays were employed. A375 melanoma cells were isolated by FACS based on
ALDHhigh and ALDHlow activity as described above (Section 2.5). These cells were counted and assessed
for high viability (> 95%) by trypan blue exclusion assays. Cells were resuspended in HBSS and mixed in
a 1:1 ratio of Matrigel as previously described in this chapter (Section 2.10). Dilutions of 100, 1,000, and
10,000 cells were s.c. injected into the hind flanks of athymic nude mice in a total volume of 100 μL.
Tumor growth initiated by both ALDHhigh and ALDHlow cells was observed for each dilution group. Upon
experimental endpoint, tumors were excised, and subjected to collagenase treatment to dissociate primary
tumors to single cell suspensions. After resection, tumor tissues were minced using a scalpel and incubated
at 37˚ C with dissociation media (DMEM/F12 containing 1 mg/ mL collagenase, 20 μg/ mL DNase, and
1% penicillin/streptomycin) for up to 4 h. Samples were strained using a 70 μm nylon filter to remove
aggregates of tumor tissue and collect single cells into a 15 mL conical tube. Samples from ALDHhigh and
ALDHlow tumors were pooled before analysis of ALDH activity. Samples from each group were counted
and assessed for viability by trypan blue exclusion assays, and subjected to staining for ALDH activity as
previously described. In order to discriminate mouse from human cells, all samples were labelled with a
human-specific antibody against CD147 (BioLegend). Positively-gated CD147 cells were then analyzed
for ALDH activity by ALDEFLUORTM staining as previously described.
2.14 β-Galactosidase Staining
Senescence-associated (SA) β-Galactosidase staining (Cell Signaling) was utilized to assess the
degree of cellular senescence induced by Lunasin treatment; vemurafenib was used as an experimental
control. Melanoma cells were plated at 1x105 cells per well in 6-well culture plates (Corning) and treated
with vehicle (PB), 100 μM Lunasin, or 1 μM vemurafenib for up to 24 h. Treated cells were washed twice
with PBS, and incubated with 1x fixative solution for 15 min at RT. Cells were again washed twice with
PBS and incubated with 1x staining solution (pH 6.0) overnight in a dry incubator at 37˚ C. Staining was
analyzed and imaged using an EVOS light microscope. A total of 500 cells were counted from 5
independent fields and averaged for the total number of stained (blue) cells. The mean number of
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positively stained cells was averaged from three independent experiments and represented as a percentage ±
s.d.
2.15 Liquid Overlay Generation of Multicellular Tumor Spheres
Cell culture plates (96-well, Corning) were coated with 100 μL per well of a 1:1 mixture of
warmed DMEM culture media and cell culture-grade agarose (1.5% final concentration) and allowed to air
dry at RT. 1x103 A375 and A375R melanoma cells were plated in 100 μL of DMEM culture media
containing vehicle, 100 μM Lunasin, 1 μM vemurafenib, or a combination of vemurafenib and Lunasin.
Cells were allowed to grow in an incubator at 37˚C and 5% CO2 for up to 96 h. Tumor sphere
measurements were taken after the formation of multicellular spheres (~72 - 96 h), and measured for up to
an additional 96 h after sphere formation using ImageJ software (National Institutes of Health, NIH).
Tumor sphere diameters were measured and plotted as mean sphere diameter ± s.d.
2.16 Microarray
Parental A375 cells and A375 ALDHhigh cells from three independent cultures were treated with
vehicle or 100 μM Lunasin for 72 h in adherent and nonadherent conditions, respectively. After treatment,
cells were harvested, homogenized, and RNA was extracted using the RNeasy Mini Kit (Qiagen)
complemented with the QIAshredder kit (Qiagen). RNA concentration was quantitated using a Nanodrop
1000 system (Thermo Fisher) and quality was analyzed by an Expert 2100 BioAnalyzer (Agilent). All
RNA used had RNA integrity numbers (RIN) of 8 or greater. cDNA was generated using the Ovation Pico
WTA V2 system (NuGen), and analyzed for integrity on the Bioanalyzer. Fragmentation and labeling of 5
μg total DNA was carried out using an Encore Biotin Module (NuGen) which is optimized for use with
Affymetrix gene chips. Hybridization and raw data analysis were carried out by staff at the University of
Louisville Microarray Core (Louisville, KY). Gene expression and analysis were performed using
MetaCore software (Thomson Reuters) with a fold-change cut-off of 1.3 (p < 0.05).
2.17 Immunofluorescence Microscopy
A375 cells were plated in DMEM culture media at a density of 1 x 104 cells per well in an 8chambered microscope slide. Cells were allowed to adhere for 4 h before removal of media and
replacement with media containing vehicle (PB) or 100 μM Lunasin. Cells were allowed to incubate with
treatment media for up to 24 h. Cells were washed with PBS, fixed with 4% paraformaldehyde, and
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permeabilized with 0.1% Triton X-100. Cells were incubated at -20˚C in 100% methanol before blocking
with 1% bovine serum albumin. Cells were incubated with anti-Lunasin (1:1000) rabbit polyclonal
antibody [16] and anti-αV (1:100) mouse monoclonal antibody (Santa Cruz #376156) in blocking solution.
Following overnight incubation, cells were washed and incubated with appropriate secondary antibodies
conjugated to AlexaFluor-488 or AlexaFluor-647 fluorophores (Jackson ImmunoResearch). After
washing, mounting media containing DAPI (Thermo Fisher) was dropped onto slides, and a cover slip was
sealed on top of the slide using clear fingernail polish prior to fluorescent analysis. Images were taken on a
Nikon NiE upright microscope using Nikon Elements software (Nikon).
For Lunasin uptake experiments, the same protocol was followed; however, time points were
standardized at 0, 5, 10, 30, and 60 min post-treatment. Additionally, A375 melanoma cells were treated
with both Lunasin containing the native (RGD) sequence as well as a mutated (RAD) peptide at a
concentration of 100 μM. Melanoma cells were again fixed and labelled with Lunasin monoclonal
antibody, counterstained with DAPI, and imaged on a Nikon NiE fluorescent microscope using Nikon
Elements software.
2.18 Proximity ligation assay (PLA)
A375 ALDHhigh cells were isolated by FACS as described in Section 2.5. Following isolation,
ALDHhigh cells were treated for 24 h with 100 μM Lunasin. Treated cells were washed twice with PBS,
plated on glass coverslips coated with poly-lysine (Sigma), and allowed to air dry in a biological safety
cabinet. Coverslips were washed twice with PBS for 5 min per wash and fixed in 4% paraformaldehyde
(PFA) for 10 min. Coverslips were then washed three times with PBS for 5 min per wash and
permeabilized using 0.5% Triton X-100 in PBS for 10 min. After permeabilization, cells were washed
three times with TTBS for 5 min per wash, and blocked in 1% BSA in TTBS. Cells were incubated
overnight at 4˚C with appropriate antibody combinations against Lunasin [16], phosphorylated focal
adhesion kinase (FAK, Abcam #ab4803), integrin-linked kinase (ILK, Cell Signaling #3862), and integrin
αV (Cell Signaling #4711), β1 (Abcam #ab134179), and β3 (Millipore #AB2984) subunits as described [10].
Antibodies were then labelled using the Duolink in situ red starter kit (Sigma) following the recommended
manufacturer’s protocol, and subsequently imaged on a Nikon NiE upright microscope with Nikon
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Elements software. Exposure settings were kept consistent throughout image collection. Fluorescence
analysis of the resulting images representing a single layer was analyzed using ImageJ software (NIH).
2.19 Transwell invasion assay
A375 and B16-F10 cells were plated in 6-well culture plates at a density of 1x105 cells per well in
2 mL of DMEM culture media. After 4 h, the media were removed and replaced with media containing
vehicle or 100 μM Lunasin for 24 h. After treatment, cells were washed once with PBS, and harvested with
TrypLE dissociation media (Gibco). Cells were counted and viability was assessed by trypan blue
exclusion assay; > 95% viability was observed for all samples. Cells were replated at a density of 1x105
viable cells in serum-free DMEM culture media containing vehicle or Lunasin into a transwell Boyden
chamber (pore size = 8 μm) coated with Matrigel basement membrane (Corning). The bottom chamber
was filled with DMEM culture media containing 10% FBS to promote invasion from the top chamber.
After 24 h at 37˚C, cells were removed from the top chamber by using a cotton-tipped swab, and cells
adhered on the bottom layer of the insert were fixed in 100% methanol and stained in a 1% Toluidine Blue
in 1% borax solution. After several washes in distilled water, membranes were allowed to air dry, mounted
onto slides with mounting solution, covered, and sealed with a 60 mm cover slip and clear fingernail polish.
A total of 5 fields per insert were counted and averaged to obtain the average number of cells per field.
2.20 Murine model of experimental metastasis
All mice were handled in accordance with the Association for Assessment and Accreditation of
Laboratory Animals Care international guidelines with the approval of the appropriate Institutional Animal
Care and Use Committees at Indiana University, Bloomington (Protocol # 14–019–4). B16-F10 cells (2.5
x 105 ) were suspended in 100 μL phosphate buffered saline (PBS) and injected intravenously (i.v.) into 4-6
week old, female C57Bl/6 mice (Harlan) via the lateral tail vein. Immediately following transplantation of
melanoma cells, mice were dosed with Lunasin (30 mg / kg) or vehicle by intraperitoneal (i.p.) injection.
Mice received daily i.p. injections of Lunasin or vehicle until the end of the experiment 18 days posttransplantation of cells. Upon sacrificing the mice, lungs were resected and imaged using a Leica M205
Stereoscope (Leica). Tissues were fixed in 10% formalin for 72 h and processed for subsequent
histological staining.
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2.21 Histology
After fixation in 10% formalin, lungs were transferred to 70% ethanol and stored overnight at
room temperature. Tissues were dehydrated through a series of graded alcohols, and infiltrated with
paraffin (Electron Microscopy Sciences). Tissues were embedded in paraffin and sectioned (thickness = 7
μm) on a microtome. Sections were transferred to SuperFrost Plus slides (Fisher) and allowed to dry
overnight on a slide warmer (Fisher). Paraffin removal was initiated by several washes in xylene, and
followed by rehydration of the tissues in a series of graded alcohols. Tissues were stained in hematoxylin
and eosin (H&E) solutions followed by a clearing solution of xylene. After staining, PermountTM mounting
medium (Fisher) was applied to each slide and covered with a 60 mm cover slip (Fisher). Slides were
allowed to dry at room temperature overnight and then placed in a drying oven until completely dry.
Images of H&E stained slides were taken using a Leica M205 Stereoscope (Leica) as well as an EVOS
light microscope (Life Technologies). Macrometastases were counted under 4.32x magnification on the
Leica M205 Stereoscope. Micrometastases were counted from H&E stained non-sequential sections (n =
5) from each tissue sample using an EVOS light microscope. Images were subsequently analyzed for total
tumor area using ImageJ software (NIH).
2.22 Differentiation of ALDHhigh cells
ALDHhigh and ALDHlow cells were isolated from A375 and SKMEL-28 cell lines as described
above. These cells were counted, assessed for viability by trypan blue exclusion, and plated into 6-well cell
culture plates at a density of 1x105 cells per well in fresh DMEM culture media. Cells were allowed to
grow in standard growth conditions in an incubator for up to 7 days. ALDH activity was assessed on day 3
and on day 7 and subsequent analysis was performed to assess the proportion of cells remaining in the
ALDHhigh compartment using methods previously described in Section 2.5. Analysis was performed using
FlowJo V10 software using gates set upon a DEAB negative control.
2.23 Statistical Analysis
GraphPad Prism 5.0 software (GraphPad Prism Software, Inc., La Jolla, CA) was used for all
statistical analyses. For all in vitro studies, two-group comparisons between control and test samples were
done by two-tailed student’s t-tests and represent data from three independent experiments. For
experiments in which a significant difference was observed, p-values are provided above the statistically
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significant (from control group) treatment group. If statistical significance is observed between
experimental groups, an asterisk will be used to denote significance between the indicated treatment
groups. P-values between groups which were not determined to be statistically significant are not provided
in their respective figures. For the in vivo tumor measurement studies, group comparisons were done using
two-way ANOVA. For all tests, statistical significance was assumed when p < 0.05. In vitro results are
shown as means ± s.d. In vivo experiments were analyzed using GraphPad Prism ANOVA analysis tool
are shown as means ± s.e.m. Mean tumor volumes for individual days were compared by unpaired
student’s t test (p<0.05) to determine significance between control and treatment groups. Experimental
metastasis data were analyzed for significance using two-tailed student’s t-tests. Interactions between
Lunasin and vemurafenib were determined to be antagonistic (< 1), additive (1), or synergistic (> 1) by
calculating the Drewinko Index (DI). All samples were normalized to appropriate controls and applied to
the formula DI =

�𝑆𝑆𝑆𝑆1 �(𝑆𝑆𝑆𝑆2 )
𝑆𝑆𝑆𝑆3

in which SF1 is equal to the surviving fraction of drug1, SF2 is equal to the

surviving fraction of drug2, and SF3 is equal to the surviving fraction of the combination of drug1 and drug2.
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CHAPTER 3: LUNASIN IS A NOVEL THERPEUTIC TARGETING MELANOMA STEM CELLS
3.1 INTRODUCTION
Nearly 20% of all Americans will develop some form of skin cancer during their lifetime [149].
Annual treatment costs for skin cancers are estimated at $8.1 billion; approximately $4.8 billion and $3.3
billion for non-melanoma and melanoma skin cancers, respectively [150]. Although less frequent than
non-melanoma skin cancers, rates of melanoma are steadily rising and account for nearly all skin cancerassociated deaths [74]. Recurrent disease is the major cause of morbidity and mortality associated with
melanoma. Although significant progress has been made in preventing or delaying disease, additional nontoxic approaches are needed to reduce the risk of recurrence. Studies in preclinical models of
carcinogenesis have shown that an enrichment of melanoma CICs is likely to occur after conventional
chemotherapeutic regimens, implicating CICs in treatment resistance and cancer recurrence [151-154].
Thus, successful elimination of CICs, along with the proliferating bulk tumor melanoma cells could be an
effective therapeutic strategy to achieve higher rates of complete remission, especially in patients with late
stage melanoma.
Melanoma CICs have been shown to represent about 1–25% of all tumor cells and can form
tumors by injection of a single cell [98]. Identification of a universal biomarker for CICs remains a major
research focus [155]; however, most markers appear to be model specific. Melanoma cells with stem celllike plasticity were initially discovered in patient tumors that overexpressed CD20 [93] and CD133 [94].
These subsets of cells displayed characteristics of stem cells and an enhanced ability to form palpable
tumors in immunodeficient mice. Ensuing studies have identified ABCB5 [66] and CD271 [95] as potential
melanoma CIC biomarkers. More recently, melanoma cells expressing Aldehyde Dehydrogenase (ALDH)
have been shown to display stem cell-like properties with enhanced in vivo tumorigenic capacity [103].
Other studies utilizing solid tumor models of the colon [108], breast [109], and lung [156] provide further
evidence for utilizing expression levels of ALDH as a CIC marker. This hypothesis is supported by data
showing ALDH1 expression correlates with poor prognosis in breast [157], ovarian [158], and lung [159]
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cancers, and that ALDH is critical in the development and differentiation of hematopoietic stem cells [160,
161] by modulating retinoid signaling through the conversion of vitamin A (retinol) to retinoic acid [162], a
ligand for downstream nuclear receptors retinoic acid receptor (RAR) and retinoid X receptor (RXR) [163].
Lunasin has three putative functional domains including an aspartic acid tail, an RGD domain, and
a chromatin-binding helical domain [15, 16]. Lunasin has been shown to exhibit robust chemopreventive
and chemotherapeutic activities [9, 11-14]. Lunasin has chemotherapeutic activity both in vitro and in vivo
in various cancer models, including colon [35, 36, 164] and breast [34] cancer. Previous studies have
established a novel functional role for Lunasin in decreasing proliferation of NSCLC cells by suppressing
integrin signaling through αvβ3 [10, 165]. This finding is consistent with results from previous studies that
demonstrated that Lunasin is internalized via αvβ3 integrin [12, 38]. When compared to melanoma cells,
the expression of αvβ3 integrins are lower in non-transformed epithelial cells [53]; the expression levels of
αvβ3 correlate with the metastatic potential and the conversion of melanoma neoplasms to a metastatic
phenotype [55].
In light of recent studies that clearly link integrin-matrix interactions to cancer cell survival [166]
(including the maintenance and survival of CICs through integrin-FAK signaling [64, 167-174]), it seemed
logical to ask whether Lunasin can target melanoma CICs and, if yes, is this anti-CIC activity critical for its
in vivo antitumorigenic effects. This dissertation will aim to show, for the first time, that Lunasin
specifically targets ALDHhigh CICs in human melanoma cell lines. Lunasin treatment decreases the
expression of surrogate CIC markers in vitro and reduces their in vivo tumorigenicity. Lunasin treatment
significantly reduces formation of CIC-enriched melanoma oncospheres and more importantly, induces
expression of melanocyte-associated differentiation markers while suppressing stem-associated factors.
Taken together, these results delineate the ability of Lunasin to regulate melanoma CIC properties and
provide a compelling argument for developing Lunasin as a therapeutic agent to reduce melanoma
recurrence.
3.2 MATERIALS AND METHODS
Isolation and purification of Lunasin
Isolation and purification of Lunasin was performed as described in Section 2.1. These Lunasin
stock preparations were used throughout the work in this dissertation.
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ALDH assay
ALDH activity was assessed using the ALDEFLUOR kit (StemCell Technologies) as described in
Section 2.5. FACS was performed to isolate fractions of cells based on ALDH activity as previously
described in Section 2.5.
Annexin V binding assays
Apoptosis was assessed using a commercially available Annexin V binding assay (BD
Biosciences) as described in Section 2.6.
Melanoma oncosphere culture
Generation of melanoma oncospheres from sorted cells was performed as described in Section 2.9.
Xenograft experiments
Subcutaneous xenograft models to assess tumor growth characteristics of parental and ALDHhigh
melanoma cells were utilized as described in Section 2.10.
In vivo limiting dilution assay
In order to investigate the tumorigenic properties and frequency of CICs in ALDH-sorted
compartments, A375 cells were subjected to FACS as described in Section 2.5. These cells were then
injected s.c. at various dilutions in order to determine the extent of their tumorigenic potential as outlined in
Section 2.10.
Immunoblot analysis
Lysate preparation, SDS-PAGE, and immunoblot analysis were performed as outlined in Section
2.11.
Toxicological analysis
Kidney and liver function as well as complete blood analysis were evaluated by NSAID
toxicological and CBC panels as previously described in Section 2.12.
SA β-Galactosidase staining
A375 ALDHhigh cells were isolated by FACS and subsequently treated with vehicle, Lunasin, or
vemurafenib. After 24 h treatment, cells were stained as described in Section 2.14.
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Liquid overlay generation of multicellular tumor spheres
Liquid overlay was used to help characterize the interaction between vemurafenib and Lunasin as
described in Section 2.15.
Statistical analysis
Statistical analysis of data presented in Chapter 3 was performed as described in Section 2.23.

3.3 RESULTS
Lunasin inhibits anchorage-independent growth in human melanoma cell lines
Previous studies of NSCLC demonstrated that Lunasin had a modest or no effect on most cell
lines when grown under standard adherent culture conditions whereas all cell lines tested were sensitive
under non-adherent conditions [165]. It was found that this was also the case with human melanoma cell
lines. A375 and SKMEL-28 cells did not show any decrease in proliferation when treated with a
concentration range of 10 to 100 µM over three days when assayed using a standard MTS-based assay
(Figure 8). Additionally, no indication of apoptosis in parental A375 or SKMEL-28 melanoma cells was
observed (Figure 9) when cells were treated with Lunasin and subjected to labelling using an Annexin V
binding assay (Figure 9A-D). No significant induction of cleaved caspase 3 or PARP was observed
following treatment with Lunasin for 24 h in either cell line (Figure 9E). However, A375 and SKMEL-28
melanoma cells exhibited a significant dose-dependent decrease in colony formation in soft agar assays
upon exposure to Lunasin (Figure 10). When compared to cells treated with vehicle alone; colony
formation by A375 cells was reduced by 37% upon treatment with Lunasin (100 µM) (Figure 10A, 10B,
and 10E), while Lunasin-treated SKMEL-28 cells exhibited a 23% inhibition of colony formation (Figure
10C, 10D and 10F). The size of colonies formed by single melanoma cells was also decreased upon
exposure to Lunasin (Figure 10A–D). These results establish that Lunasin inhibits anchorage-independent
growth of melanoma in vitro and provides the first demonstration that Lunasin may offer potential
therapeutic effects on human melanoma cells.
Lunasin inhibits tumor growth of melanoma cells in vivo
To evaluate whether the inhibition of in vitro anchorage-independent growth of melanoma cells
can be recapitulated in vivo, tumor xenografts were generated by s.c. implantation of A375 cells in athymic
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nude mice. Tumor cell implantation was followed by concurrent and subsequent daily i.p. injections of
Lunasin (30 mg/kg body weight). Dosing was determined by a combination of previous in vivo
experiments [175] with the objective of obtaining a significant host response while minimizing toxicity,
and established dosing regimens for previously established biologics (e.g. cilengitide). While no
significant reduction in palpable tumor formation was observed, a significant reduction in the tumor growth
rate was observed in the Lunasin-treated mice when compared to mice injected with vehicle alone
(Figure 10G). Tumors were measured at 14 days after initial implantation; however, it was observed that
mice in the Lunasin-treated group displayed tumors that were significantly smaller (< 50 mm3) and difficult
to measure due to their small size and lack of depth. Mice treated with Lunasin over a 34 day period
exhibited significant reductions in tumor volume (55%) and total tumor mass (46%) when compared to
those measured in the vehicle-treated mice (Figure 10G and 10H). This model established that Lunasin
was biologically active in athymic nude mice, and its anticancer effects persists in vivo.

Figure 8: Lunasin did not have an antiproliferative effect on A375 or SKMEL-28 melanoma cells in
adherent culture. Parental A375 (A) and SKMEL-28 (B) cells were plated and treated with vehicle or
varying concentrations of Lunasin for up to 72 h. It was observed that Lunasin treatment caused no
significant antiproliferative effect on these cell lines when utilizing the MTS/MTT tetrazolium-based
proliferation assay in an adherent format. These data are consistent with the modest effects observed when
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several NSCLC, breast, and colon cancer cell lines were treated with Lunasin at similar concentrations.
Graphs were generated using data gathered from three independent experiments, and statistical analysis
was performed by student’s t-test. P-values of less than 0.05 were considered statistically significant.

Figure 9: Lunasin did not induce apoptosis in parental melanoma cell lines. A375 (A, C) and
SKMEL-28 (B, D) cell lines were treated with Lunasin (100 μM) for 24 h, and subsequently analyzed for
apoptosis. No significant induction of apoptosis or necrosis was observed with Lunasin treatments. These
results were corroborated by findings that Lunasin did not increase levels of cleaved PARP and active
Caspase 3 when assessed by immunoblot analysis (E). Data were gathered from three independent
experiments, and analyzed using FlowJo V10. Statistical significance between control and Lunasin
treatment groups was determined by student’s t-test (p < 0.05).
Lunasin reduces the melanoma CIC subpopulation in established cell lines
ALDH is an intracellular enzyme highly expressed by stem-like cells [176] and recent studies
suggest that high ALDH activity is a property of CICs in human melanoma [103]. To measure ALDH
activity in melanoma cells, ALDEFLUOR reagent was used. ALDEFLUOR is a commercially available
molecule that freely diffuses into cells and is a substrate for the ALDH enzyme. ALDH cleaves
ALDEFLUOR and yields a fluorescent product that can no longer diffuse across the cell membrane. ALDH
activity within the cells is then assayed by incubating cells with a fluorescent ALDH substrate followed by
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flow cytometry. For this assay, ALDHhigh CICs were identified by comparing the fluorescence in a test
sample to that in a control sample containing DEAB, a specific inhibitor of ALDH. These data demonstrate
that treatment of A375 melanoma cells with Lunasin (100 µM) for 24 h significantly reduced the size of the
ALDHhigh CIC subpopulation (Figure 11A – 11C). Similarly, SKMEL-28 ALDHhigh subpopulations were
reduced after a 24 h treatment with Lunasin (Figure 11D- 11F). Immunofluorescence analyses for the
ALDH marker expression corroborated the findings that Lunasin treatment dramatically diminished the
ALDH expression levels in both A375 and SKMEL-28 melanoma cells and significantly reduced the
ALDHhigh subpopulation (Figure 11A–11F).

Figure 10: In vitro efficacy of Lunasin in malignant melanomas. Representative images of colonies
grown in soft agar for vehicle-treated (A, C) and Lunasin-treated (B, D) A375 (A,B) and SKMEL-28 (C,D)
cells (magnification at 40x). Scale bars on images represent 100 μm. Anchorage-independent growth
conditions sensitized melanoma cells to Lunasin resulting in a significant decrease in colony formation in
A375 (E) and SKMEL-28 (F) cells. Statistical significance between treatment groups is denoted by an
asterisks (*) and p-values are provided for each significant difference. Two asterisks (**) signifies a
difference between 30 μM and 100 μM Lunasin treatment groups. Data are presented as mean ± s.d. from
6

three independent experiments. For xenograft studies, 2.5 X 10 A375 cells were injected s.c. into nude
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mice and subsequently treated with vehicle (PB) (n = 8) or Lunasin (n = 10) for a total of 34 d. Lunasin
reduced tumor volume by 55% (G) and wet tumor weight by 46% (H). Lunasin-treated mice differed
significantly in tumor volume (p < 0.001) from control treated mice as assessed by GraphPad ANOVA
analysis. The corresponding reductions in wet tumor weights were determined to be significant by
unpaired student’s t-test (p = 0.003) and statistical significance is denoted by an asterisk. In vivo data are
presented as mean ± s.e.m.

Figure 11: Lunasin depleted populations of cells displaying high ALDH activity. A375 and SKMEL28 cells showed a substantial decrease in ALDH positive populations when treated with Lunasin for 24 h.
DEAB was used as a negative control, and served as a tool for gating ALDH negative populations.
Representative flow cytometry plots and corresponding fluorescent microscopy images were taken 24 h
post-treatment and provided for DEAB (A, D), control (B, E), and Lunasin-treated (C,F) groups. Lunasin
reduced the number ALDH

high

cells in A375 and SKMEL-28 cell lines when compared to vehicle-treated

cells (G). Statistical significance was determined from three independent experiments and assessed by
student t-test (p < 0.05). Fluorescence microscopy images were taken at 40x magnification. Data are
presented as mean ± S.D and represent data gathered from three independent experiments. Statistical
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analyses were performed using student’s t-test with p-values of less than 0.05 being considered statistically
significant.
Lunasin suppresses the functional properties of melanoma CICs
CICs are characterized by having stem cell-like properties, including the ability to self-renew.
Oncosphere formation assays have been widely used to measure the functional activity of CICs, and
previous studies have indicated that the ALDHhigh melanoma cells represent the CIC-enriched compartment
[103]. To determine the effects of Lunasin on melanoma CIC functional properties, clonogenic and sphere
formation assays were performed using isolated ALDHhigh A375 and SKMEL-28 melanoma cells. Stringent
assay conditions in which spheres (floating) and colonies (formed in soft agar) are all of clonal origin were
first established. Under these conditions, Lunasin treatment (100 µM), when compared to control vehicle
treatment, significantly inhibited sphere establishment in ALDHhigh A375 melanoma cells and in ALDHhigh
SKMEL-28 melanoma cells (Figure 12A-C). Similarly, when compared to vehicle-treated cells, Lunasintreatment at both 30 µM and 100 µM drug doses significantly affected colony forming ability in purified
ALDHhigh A375 melanoma cells (Figure 12D, 12E, and 12H) as well as in ALDHhigh SKMEL-28 cells
(Figure 12F, 12G, and 12I). Collectively, these results indicate that treatment with Lunasin negatively
regulates melanoma CIC functional properties in vitro. In these assays, it was demonstrated that Lunasin
functionally represses the clonogenic ability of melanoma CICs by inhibiting their potential to form
oncospheres in non-adherent conditions as well as self-renewal capacity when suspended in soft agar.
Lunasin limits in vivo growth of tumors initiated by melanoma CIC-enriched ALDHhigh cells
It was further investigated if the anti-CIC activity of Lunasin in melanoma cells in vitro translated
into better therapeutic efficacy against in vivo melanoma CIC-initiated tumor growth. ALDHhigh A375 cells
isolated from the parental line were subcutaneously injected into the dorsal side of nude mice and
subsequently treated via the intraperitoneal route with 30 mg/kg of Lunasin or vehicle control as described
in Section 2.5. All mice eventually formed palpable tumors regardless of treatment group; however, a
significant reduction in the tumor growth rate was observed in the Lunasin-treated group when compared to
that in vehicle treated mice (Figure 13A and B). Notably, tumor volumes in Lunasin-treated mice were
reduced by 73% (p < 0.001; Figure 13A) upon experimental endpoint (i.e. 38 days post-transplantation).
Also, wet weights of tumors isolated from Lunasin-treated groups were reduced by 67% when compared to
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tumor weights from vehicle-treated mice (p < 0.001; Figure 13B) upon experimental endpoint.
Additionally, a significant lag time until palpable tumors (> 50 mm3) were formed was observed in the
Lunasin-treated group when compared to vehicle-treated animals.
It was evaluated if any toxicological effects are associated with chronic Lunasin treatment. Mice
receiving Lunasin treatment did not display significantly altered liver enzymes or creatinine levels when
compared to the control group; however, significantly lower BUN levels were observed in Lunasin-treated
mice (Figure 14A-B). Additionally, CBC analysis showed no significant difference in blood cell counts
between vehicle-treated and Lunasin-treated mice (Figure 14C-E). These studies indicate that melanoma
CICs were very sensitive to Lunasin treatment in vivo, and that this treatment regimen resulted in minimal
toxicity.

Figure 12: Lunasin reduced self-renewal capacity and oncosphere formation of CICs. ALDH

high

populations of melanoma cells were plated in low adherent culture for 21 d and treated with vehicle or
Lunasin twice weekly. Representative images taken at 7 d (A) and 21 d (B) illustrate the ability of Lunasin
to disrupt sphere formation of A375 ALDHhigh melanoma cells. Lunasin treatment decreased sphere
formation by 81% and 55% in A375 ALDHhigh and SKMEL-28 ALDHhigh cell lines, respectively (C).
ALDH

high

melanoma cells showed increased sensitivity to Lunasin versus their parental counterparts when

treated in soft agar. Lunasin-treated ALDHhigh cells derived from A375 and SKMEL-28 lines demonstrated
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a decreased ability to form colonies in soft agar. Representative images for A375 and SKMEL-28 colonies
treated with vehicle (D, F) or Lunasin (E, G) illustrate the morphological differences between treatment
groups. The number of colonies formed by Lunasin-treated cells were decreased in size and density in
ALDHhigh fractions of A375 (H) and SKMEL-28 (I) cell lines. Significance (p < 0.05) was determined
from three independent experiments and assessed by student’s t-test (p < 0.05). Scale bars on images
represent 100 μm. All representative images were taken at 40x magnification. Data are presented as mean
± s.d.

Figure 13: Lunasin inhibited CIC tumorigenesis in vivo. Athymic nude mice were injected s.c. with 1
4

x 10 A375 ALDH

high

cells and subsequently dosed with 30 mg/kg of Lunasin or vehicle every day for 38

d. Upon endpoint, average tumor volumes in Lunasin-treated mice (n = 9) were significantly lower
compared to mean tumor volume in vehicle-treated mice (n = 8) (A). Upon resection of tumor tissues, wet
tumor weights were determined (B). Statistical significance between mean tumor volumes of control and
treatment groups was determined using GraphPad ANOVA analysis tool (p < 0.05). Wet tumor weights
determined at experimental endpoint were determined to be statistically significant by student’s t-tests, and
significant differences are denoted by an asterisk (*). Data are represented as mean ± s.e.m.
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Figure 14: Long-term Lunasin treatment did not induce toxic side effects. Nude mice were treated
with Lunasin (30 mg/kg) for several weeks. Upon experimental endpoint, blood serum and whole blood
fractions derived from mice in the Lunasin and control groups (n = 17) were analyzed for liver (A), kidney
(B) and CBC (C-E) toxicity, respectively. A significant decrease in BUN was observed in Lunasin-treated
mice. Liver and kidney function did not appear to be affected by long-term Lunasin treatment. Statistical
significance between Lunasin and control groups was determined by student’s t-test (p < 0.05).

Limiting dilution assays demonstrate differential growth patterns between ALDHhigh and ALDHlow
phenotypes
To assess in vivo tumorigenicity of ALDH-sorted populations derived from A375 melanoma cells,
varying concentrations of cells were injected into nude mice (Figure 15). All mice injected with ALDHlow
cells produced tumors when injected with 1x103 and 1x104 cells; however, only 2/3 mice injected with
1x102 ALDHlow cells produced tumors. All mice transplanted with ALDHhigh cells produced palpable
tumors (9/9). Although the sample size in these experiments was not large enough to produce a statistical
significance in tumor formation, a significant difference in tumor growth curves between ALDHhigh and
ALDHlow cells was observed (Figure 15A-C) when tumor growth rates were analyzed by GraphPad
ANOVA analysis tool as described in Section 2.5. When 1x102 ALDHhigh cells were injected into mice,
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tumors formed quicker and had higher proliferation rates when compared to tumors initiated by ALDHlow
cells (p < 0.007). Despite this statistically significant difference, these results were potentially driven by
one large tumor produced in the ALDHhigh group. Conversely, ALDHlow cells had higher proliferative
capacity when compared to ALDHhigh cells when 1x104 cells were transplanted (p < 0.001). The
intermediate dilution of 1x103 cells produced no observable differences in tumor growth (p = 0.98).
Representative images demonstrate the differences in final tumor size between tumors initiated by
ALDHhigh and ALDHlow cells (Figure 15D-F).
Tumors initiated by ALDHhigh cells had a higher propensity to stay in the ALDHhigh compartment
when compared to tumors initiated by ALDHlow cells
With the observable differences in tumor growth rates from limiting dilution assays, it was next
investigated whether or not the proportion of ALDHhigh cells would significantly vary between tumors
initiated by ALDHhigh and ALDHlow phenotypes (Figure 15G). In order to discriminate between human
melanoma cells with elevated ALDH activity and mouse cells which may also have intrinsic ALDH
activity, human cells were selected for by using a human-specific PE-conjugated antibody against CD147
(top). This allowed for the gating and analysis of ALDH activity in only A375-derived cells (bottom).
Cells dissociated from tumors initiated by ALDHhigh melanoma cells had a population with high ALDH
activity which represented 6.24% of PE+ cells. In ALDHlow initiated tumors, high ALDH activity was seen
in only 1.25% of PE+ cells. These data raise several questions as to the function and responses of
melanoma CICs to the surrounding microenvironment, and whether bulk tumor cells play a major role in
the differentiation and self-renewal of these stem-like cells.
In vitro, a small population of cells with low ALDH activity derived from both A375 and
SKMEL-28 melanoma cell lines had the intrinsic capability to (de)differentiate to form ALDHhigh cells
(Figure 16). ALDHhigh and ALDHlow cells were monitored for up to a week in serum-free stem cell media
in low-adherent culture conditions following FACS. After 3d and 7d in culture, cells were stained with
ALDEFLUOR reagent and reanalyzed for the percentage of cells displaying high ALDH activity. Samples
derived from A375 (Figure 16A) and SKMEL-28 (Figure 16B) showed a significant portion of ALDHhigh
cells had differentiated into the ALDHlow compartment. Unexpectedly, it was also observed that some cells
isolated in the ALDHlow compartment had the ability to undergo a phenotype switch into the ALDHhigh

45

compartment. Whether this phenomenon is due to the high plasticity and heterogeneity of melanoma cells,
a byproduct of using cultured cell lines, or the fact that these studies used a singular marker to define a
complex hierarchy of cells has yet to be determined. Additional studies to define the cellular hierarchy and
differential capacity to differentiate and dedifferentiate between melanoma stem cells and bulk tumor cells
are necessary to 1) determine if melanoma truly fits the model proposed by the cancer stem cell theory, 2)
determine if cultured cell lines truly represent the heterogeneity of primary melanoma tissues, and 3)
determine if ALDH is a practical biomarker for potential CIC identification.
CIC markers are heterogeneously expressed in different melanoma cell lines
Although ALDH was used as a surrogate marker for identification and isolation of melanoma
CICs, this study aims to investigate whether or not other potential biomarkers for CICs were present in the
melanoma cell lines used. Flow cytometry was used to assessed the level of expression of several cancer
stem cell biomarkers reported for melanomas and for other cancer models including CD44/CD24, CD133,
and CD271 (Figure 17). These data indicate that both A375 and SKMEL-28 cells have a highly abundant
population of cells with a CD44+/CD24- phenotype (Figure 17A). Conversely, both cells lines failed to
show populations of cells that were labelled with a CD133 antibody (Figure 17B). Differential expression
of CD271 was observed between A375 (93%) and SKMEL-28 (28.1%) cell lines suggesting that
melanomas display high heterogeneity even between commonly used cell lines (Figure 17C).
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Figure 15: Limiting dilution assays demonstrate the high tumorigenicity of A375 ALDHhigh cells.
Xenografted A375 ALDHhigh and ALDHlow melanoma cells were observed for differences in tumor
proliferation and tumorigenicity when injected into nude mice at decreasing dilutions (A-C). ALDHhigh
cells produced tumors in all mice injected (9/9 total), and were tumorigenic with cell dilutions down to 100
cells. ALDHlow cells also displayed high tumorigenicity yet, only produced 2/3 tumors in nude mice when
injected with 100 cells. Tumor growth rates were also dilution-dependent; ALDHlow cells proliferated
much more quickly at a lower cell dilution (1x104), but less rapidly at higher concentrations (1x102) when
compared to ALDHhigh cells. No significant difference was observed between growth curves at the
intermediate dilution (1x103). NT = no tumor. Statistical analyses were performed using GraphPad
ANOVA analysis tool with statistical significance considered when p < 0.05. Representative images of
tumors derived from both ALDH-sorted groups in dilutions of 1x104 (D), 1x103 (E), and 1x102 (F) are
shown to illustrate the differential growth patterns of tumors initiated by each phenotype (zoom = 4.32x).
Tumors initiated by 1x102 ALDHlow and ALDHhigh melanoma cells were dissociated, counted, and pooled to
generate samples subsequently analyzed for ALDH activity. ALDHhigh and ALDHlow cells of human origin
(i.e. A375 melanoma cells) were labelled with an anti-CD147 antibody (G, top). PE+ cells were analyzed
for ALDH activity; Tumor cells derived from the ALDHhigh phenotype had a higher proportion of cells
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remaining in the ALDHhigh compartment (6.25%) when compared to tumors initiated by ALDHlow
melanoma cells (1.26%) (G, bottom).
Lunasin induces expression of differentiation markers in melanoma CICs
To test if the Lunasin-induced decrease in CIC function is due to induction of apoptotic cell death
in the isolated CICs, cell viability and apoptosis assays (Annexin V/PI staining) were performed following
Lunasin treatment on isolated ALDHhigh cells. Interestingly, these assays failed to detect any significant
reduction in cell viability with Lunasin treatment in ALDHhigh CICs obtained from either A375 or SKMEL28 cell lines when compared to that in vehicle-treated ALDHhigh CICs (Figure 18A and 18B). Consistent
with these results, there was no apparent difference in the protein expression of apoptotic signaling
mediators, PARP and Caspase-3 in vehicle and Lunasin-treated ALDHhigh CICs from both A375 and
SKMEL-28 melanoma cell lines (Figure 18C). Caspase-3 is cleaved (i.e. activated) in response to
activation of the apoptotic cascade and in turn, cleaves PARP to carry out cellular deconstruction. Thus,
the absence of active Caspase-3 and cleaved PARP in Lunasin-treated samples indicates that apoptosis was
not induced.
Recent studies established that reduced expression of MITF yielded G1-arrested cells with an
invasive stem cell-like phenotype, whereas high MITF expression generated either proliferating cells or
cells with a differentiated pigment-producing phenotype depending on the status of MITF’s posttranslational modifications [177, 178]. Other studies provide supportive evidence to this claim and show
that TGF-β signaling can mediate MITF expression, which is critical for the generation and maintenance of
melanoma stem cells [179]. In accordance with these reported studies, the authors observed a reduced
expression of MITF in CIC-enriched ALDHhigh A375 and SKMEL-28 cells in comparison to MITF
expression in ALDHlow A375 and SKMEL-28 cells (Figure 19A).
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Figure 16: Differentiation of ALDHhigh cells derived from A375 and SKMEL-28 melanoma lines.
Sorted melanoma cells were replated in normal culture media and cultured in 6-well culture dishes for up to
7 d. Cells were assayed for ALDH activity at day 3 (top) and day 7 (bottom). After sorting, ALDHhigh
cells represented a significantly smaller proportion of cells in both A375 (A) and SKMEL-28 (B) after only
3 days in culture and ALDHhigh populations further decreased in both cell lines at day 7. Interestingly, it
was observed that a small population of ALDHlow cells had the capacity to revert back to an ALDHhigh
phenotype in both cell lines.

Whether or not Lunasin treatment can modulate MITF expression in CICs and thereby, trigger a
phenotypic switch in CICs that will ultimately drive the Lunasin exposed melanoma CICs towards
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differentiation was next investigated. To test this hypothesis, ALDHhigh cells isolated from A375 and
SKMEL-28 melanoma lines were cultured in the presence or absence of Lunasin (100 µM) for 24 h under
serum-free, non-adherent culture conditions. Lunasin-treated and vehicle-treated cultures were then
analyzed for MITF protein expression as well as for the expression of its downstream differentiationassociated protein, Tyrosinase. It was observed that Lunasin treatment increased the expression of MITF
and Tyrosinase proteins in A375- and SKMEL-28-derived ALDHhigh cells compared to vehicle-treated
controls (Figure 19B). Additionally, Lunasin-treated ALDHhigh cells from both A375 and SKMEL-28
melanoma lines showed reduced expression of the stem-associated transcription factor, NANOG (Figure
19C). Taken together, these experiments provide substantial experimental evidence to support the notion
that Lunasin treatment negatively influenced melanoma CICs’ tumorigenicity and self-renewal abilities by
regulating MITF signaling, one of the key drivers in inducing a differentiated phenotype in melanoma
CICs, as well as suppressing levels of the key stemness factor Nanog.
Lunasin did not induce a significant senescent response in ALDHhigh melanoma cells
A375 melanoma cells were sorted based on ALDH activity. These cells were treated with vehicle,
Lunasin, or vemurafenib for 24 h. Representative images for positively-stained melanoma cells in vehicle,
Lunasin, and vemurafenib-treated samples are shown (Figure 20A). No significant difference in positively
stained cells (Figure 20B) between vehicle or Lunasin treatment groups (p = 0.09) was observed. The
positive control, vemurafenib, induced a significant senescent response in nearly 25% of all cells, and
represented a significant increase from control and Lunasin-treated cells (p < 0.001).
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Figure 17: CIC biomarkers are heterogeneously expressed in melanoma cell lines. Utilizing flow
cytometry A375 (left) and SKMEL-28 (right) melanoma cell lines were labelled and assessed for
expression of commonly used CIC identification markers. Both cell lines had an abundant CD44+/CD24population (A). Neither cell line had a significant population of cells that express the CD133 CIC
biomarker (B). When A375 cells were labelled with anti-CD271 antibody, it was observed that the
majority of the cells were CD271+; however, in the SKMEL-28 cell line, only a small proportion (28.1%)
expressed CD271 (C). Isotype controls were represented by the appropriate host-specific PE- and APCconjugated IgG1 antibodies.
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Figure 18: Lunasin did not induce an apoptotic response in ALDHhigh melanoma cells. Annexin V
binding assays were used to assess apoptotic populations of melanoma cells sorted for high ALDH activity
and subsequently treated with Lunasin or vehicle for 24 h. Representative flow cytometry plots for A375
ALDHhigh cells in each treatment group are shown (A). No significant decrease in cell viability of
ALDHhigh subpopulations derived from A375 or SKMEL-28 cells were observed when stained with
Annexin V/ PI. Additionally, there was no observed significant increase in apoptotic or necrotic
populations after Lunasin treatment (B) when compared to control. It was further confirmed that Lunasin
did not induce apoptosis by immunoblot analysis for the apoptotic markers active Caspase-3 and cleaved
PARP, which were absent in both control and Lunasin-treated samples (C). Significance was determined
by student’s t-test from three independent experiments with a p-value of < 0.05 representing statistical
significance from control samples. Data are represented as mean ± s.d.
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Figure 19: Lunasin modulated expression of melanocyte differentiation and stem-associated
markers. Sorted subpopulations of ALDHlow and ALDH

high

cells displayed differential expression of the

melanocyte-associated transcription factor MITF, with ALDH
than ALDH

high

low

cells expressing higher levels of MITF

populations in both A375 and SKMEL-28 cell lines (A). MITF and the downstream

melanocyte differentiation marker Tyrosinase were strongly induced in ALDH

high

cells treated with Lunasin

for 24 h (B). Immunoblot analysis revealed that NANOG, a stem-associated marker, was repressed in
Lunasin-treated ALDH

high

samples (C). Actin was used as a loading control.

Lunasin may enhance the efficacy of vemurafenib in vemurafenib-resistant melanomas
Proliferation (Figure 21A), colony-forming (Figure 21B), and liquid overlay assays (Figure 21C)
were performed on parental A375 cells and vemurafenib-resistant A375R cells. In MTS assays, a
significant decrease in the number of viable A375 cells when 300 nM vemurafenib was combined with 10
and 100 μM Lunasin (p < 0.05) was observed. In A375R cells, a significant decrease in viable cell counts
in combinations of 100 μM Lunasin and several concentrations of vemurafenib (p < 0.05) was observed.
Similarly, a significant difference in the ability of A375 cells to form colonies in soft agar at concentrations
of 30 and 100 μM Lunasin alone and 100 μM Lunasin in combination with 300 and 1000 nM vemurafenib
(p < 0.05) was observed. While Lunasin did not cause a significant decrease in colony formation in A375R
cells, it did significantly reduce colony formation when A375R cells were treated in combination with 300
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nM and 1000 nM vemurafenib (Figure 21B). Interestingly, the authors observed that when A375R cells
were grown in anchorage-independent culture conditions (i.e. suspended in soft agar), they were much
more sensitive to vemurafenib when compared to adherent culture. Liquid overlay assays were utilized to
generate multicellular oncospheres and assess their growth characteristics after treatment with
combinations of Lunasin and vemurafenib. Lunasin (100 μM) did not significantly decrease the total area
of the oncospheres in either A375 or A375R cells; vemurafenib-treated cells were significantly smaller in
total area in both A375 and A375R cells (p < 0.05). However, when Lunasin was combined with
vemurafenib, sphere area was significantly decreased in both A375 (p < 0.001) and A375R (p = 0.04)
tumor spheres (Figure 21C) compared to vemurafenib controls. For each assay described, DI values were
calculated based on the effect of each drug on melanoma cell proliferation. It was observed that Lunasin
had an additive effect (DI values between 0.9 and 1.1) when used in combination with vemurafenib for all
of the aforementioned assays.

Figure 20: Lunasin did not induce a significant senescent response in A375 ALDHhigh melanoma cells.
When A375 ALDHhigh cells were treated with vehicle, Lunasin, and vemurafenib, no observable increase in
senescence between control (2.6%) and Lunasin-treated (4.2%) samples was detected, despite a modest
increase in cells staining positive for β-Galactosidase activity in the Lunasin-treated cells (A,B).
Vemurafenib was statistically significant from both groups with nearly 25% of cells staining positive after a
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24 h treatment. Representative images for each treatment group are shown at 200x magnification (A) and
represent data from two independent experiments. Statistical analysis was performed using student’s t-test
with a p-value of less than 0.05 considered statistically significant.

Figure 21: Combinations of Lunasin and vemurafenib yielded an additive interaction that may
benefit treatment of chemoresistant populations of melanoma cells. A375 and A375R (i.e.
vemurafenib-resistant) cells were treated with combinations of vemurafenib and Lunasin and efficacy was
assessed by MTS (A), soft agar (B), and liquid overlay assays (C). C = control, L = Lunasin, V =
vemurafenib, V + L = combination. Concentrations of Lunasin are indicated in the respective graph
legends (A, B). Significant differences between control and treatment groups were determined by student’s
t-test and were observed for several combination treatments as denoted by asterisks (*). Results represent
data taken from three independent experiments and are expressed as mean ± s.d. Representative images for
liquid overlay assays were taken at 100x magnification.

In Annexin V binding assays, a significant decrease in cell viability (PI-A-) was observed in cells
treated with 1 μM vemurafenib and 1 μM vemurafenib in combination with 100 μM Lunasin after 72 h of
treatment (Figure 22). No significant differences in viable (PI-A-), apoptotic (PI-A+/PI+A+), or necrotic
(PI+A-) populations were observed between treatment groups and control samples at either 24h or 48 h time
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points. At 72 h, a significant increase in cells positively stained with PI (PI+A-) was observed in cells
treated with a combination of Lunasin and vemurafenib when compared to vehicle-treated cells indicating
that Lunasin may increase necrotic cell death in A375 cells treated with vemurafenib (Figure 22A).
Representative dot plots for A375 cells treated with vehicle, Lunasin, vemurafenib, and combination
therapy demonstrate the potential of Lunasin in conjunction with vemurafenib (Figure 22B). Combined
with the results from the in vitro proliferation assays, it would seem logical that Lunasin may lend some
therapeutic benefit as an adjuvant therapy in melanoma patients receiving vemurafenib treatment.

Figure 22: Lunasin in combination with vemurafenib kills A375 melanoma cells. Annexin V binding
assays were performed on A375 melanoma cells treated for 24, 48, and 72 h (A). A significant difference
was observed in cell viability after 72 h in vemurafenib and combination treatment groups compared to
control (p < 0.05). PI-stained cells were significantly increased in combination treatment when compared
to control samples (p < 0.05). Data were obtained from three independent experiments and are represented
as mean percent ± s.d. Representative dot plots are shown for vehicle, Lunasin, vemurafenib, and
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combination treatments at the 72 h time point (B). Statistical analysis was performed using the student’s ttest. Groups were considered statistically significant when p < 0.05.

3.4 DISCUSSION
Consumption of large amounts of soy-derived foods is associated with a lower risk of a number of
chronic diseases including cancer [180-182]. The anticancer effects of soy components have been attributed
to secondary metabolites such as isoflavones and specific protein fractions [183, 184]; however, no
epidemiological evidence directly correlating soy consumption with decreased melanomagenesis has come
to light. Lunasin, a peptide present in crude soy protein, has been proposed to be an important
chemoprevention agent in soy [9]. Lunasin is a 43–44-amino acid polypeptide [16, 18] that is encoded
within the soybean GM2S-1 gene. The 22-amino acid N-terminal sequence (with no known function) of
Lunasin is followed by a putative helix domain proposed to target Lunasin to chromatin, and the C-terminal
end that includes a RGD cell adhesion motif followed by a poly-aspartic acid tail [15, 16]. Lunasin’s
potential chemopreventive activity has been established by studies which show that Lunasin prevents
cellular transformation by chemical carcinogens and viral oncogenes [9]. Recent studies have shown that
Lunasin can inhibit the in vitro and in vivo growth of breast [34, 185], leukemia [186], colon [35, 187], and
lung cancers [10]. These findings of this dissertation reveal that Lunasin has potential therapeutic effects
against melanoma in both non-adherent in vitro assays and in vivo xenograft studies.
The ALDHhigh melanoma cancer cell subpopulation has been reported to harbor the tumorinitiating and metastatic cells and is enriched in several of the self-renewal genes including NANOG [188,
189]. A recent study has shown that siRNA-mediated knockdown of ALDH in melanoma cells inhibited in
vivo tumor development and metastatic properties [106]. Mechanistically, the ALDHhigh melanoma cells
have been shown to possess higher tumorigenic, invasive, and self-renewal capacities than ALDHlow cells
and thus, can serve as a potential therapeutic target [103, 111, 188]. These studies implicate high ALDH
activity as a relevant biomarker for identifying melanoma CICs, and the significant inhibition of ALDH
activity that was observed with Lunasin phenocopies the antimelanoma/anti-CIC effects observed in cells
silenced for ALDH. Thus, using Lunasin to reduce this aggressive populations of cells may serve as an
invaluable tool in melanomas which display cells with CIC-like abilities. Using surrogate assays for CIC
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identification, it was demonstrated that sorted cell populations based on the ALDH biomarker were
sensitive to Lunasin treatment in non-adherent melanosphere formation assays as well as colony formation
in soft agar. As presented in these data, Lunasin functionally blocked the self-renewal capacity of isolated
melanoma CICs. The activity of Lunasin both in vitro and in vivo on melanoma CICs suggests the
intriguing possibility that Lunasin can target these quiescent and drug-resistant cells and is consistent with a
recently published study on colon cancer [164]. Using the CIC surface markers CD133 and CD44, the
authors showed that soy bioactives in combination with the antidiabetic drug, Metformin, reduced
populations of cells capable of self-renewal by modulating the PTEN/PI3K/FASN axis. Taken in
combination with results gathered in this dissertation, these data represent a novel idea that Lunasin and
other soy derivatives may alleviate patient relapse by decreasing cancer stem cell populations.
An important and most intriguing aspect of this study is that the potential anticancer effects of
Lunasin were enduring in vivo. Despite somewhat modest effects in vitro, it was observed that Lunasin
had a highly significant effect on tumor growth when cells were transplanted into immunodeficient mice.
Lunasin-treated mice had a significantly reduced tumor burden in both parental (46%) and ALDHhigh (73%)
A375 cells when compared to their vehicle-treated counterparts. In fact, Lunasin has been described to
have immunomodulatory functions [13, 42] adding another feature to this multifaceted peptide. In these
studies, Lunasin was shown to enhance activation of innate immunity. Lunasin-treated dendritic cells
expressed higher levels of cytokines and chemokines, and induced expansion of CD4+ T cells [42].
Additionally, Lunasin-treated mice had improved responses when compared to control mice in models
which were challenged with OVA-expressing influenza as well as lymphoma [42]. Specific to
immunotherapy, Lunasin was shown to synergistically enhance NK cell mediated cytotoxicity when used
in combination with IL-2 or IL-12 in a lymphoma model [13]. These studies open the possibility that
mouse models with intact innate immunity may provide a substantial boost to the anticancer activity of the
Lunasin peptide.
While the study was too small to measure a significant difference between in vivo tumorigenicity
between ALDHhigh and ALDHlow A375 cells, limiting dilutions assays did provide the intriguing possibility
that the number of cells in the ALDHhigh compartment may be dependent upon the number of tumor cells
within the tumor microenvironment (TME). Data from these serial dilution assays would suggest a
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differential ability to proliferate and form palpable tumors in ALDHlow and ALDHhigh A375 cells in a
dilution-dependent manner. Additionally, samples from tumors initiated by the lowest dilution of cells
demonstrated that ALDHhigh cells had a higher population of cells remaining in the ALDHhigh compartment
after tumor formation when compared to samples derived from ALDHlow cells. It is well known that the
TME can regulate the stem cell niche through cell-cell contact, secretion of proteins, and hypoxia [190192]. Though these data may be a result of the abundance of tumor cells (or lack thereof), it might also
indicate that A375 cells display high plasticity, and CICs derived from the ALDHhigh compartment may
revert to a non-stem cell compartment and vice versa. Indeed, melanoma has been described as a highly
plastic malignancy [193]. While ALDHlow cells may display a high degree of tumorigenicity in the in vivo
models used in this study, the authors did not study long-term propagation and self-renewal capacity in
vivo, a central feature of stem cells, of either ALDHhigh or ALDHlow cells. Therefore, any conclusive
evidence as to how these isolated CICs are functioning in vivo in comparison to their non-CIC counterparts
will need to be explored further. Until the caveats limiting the CIC hypothesis are further addressed (i.e.
improved experimental systems or a defined molecular phenotype for CIC identification), it is likely that
the abundant support for the CIC theory will be met with equally abundant skepticism.
With regard to potential mechanisms of action, Lunasin contains a RGD domain and has been
shown to bind specific integrins that recognize this cell adhesion motif [38]. Integrins are heterodimeric
cell surface proteins that play critical roles in adhesion to the extracellular matrix, transmitting extracellular
signals that affect cell migration and the regulation of signaling pathways involved in cell survival and
proliferation. Recent studies [10, 12, 36, 194] strongly suggest that Lunasin bound to integrins containing
combinations of the α5, αv, β1, and β3 subunits and modulated the ILK and FAK signaling pathways.
Additionally, it is becoming clear that there is a strong linkage of integrin-matrix interactions to cancer cell
initiation and progression (reviewed in [64]), including the maintenance and survival of CICs through
integrin-FAK signaling [reviewed in [195]]. Interestingly, the current data indicate that sorted fractions of
ALDHhigh melanoma cells are more sensitive to Lunasin than the unsorted cell fractions. One possible
explanation for this differential sensitivity is that when compared to the bulk of tumor cells, the ALDHhigh
subpopulation of melanoma cells exhibit altered integrin expression profiles. It is also possible that the
ALDHhigh melanoma CICs rely more heavily and specifically on ‘outside-in’ signal transduction
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mechanisms mediated via integrin networks compared to ALDHlow cells. Such differential integrin
signaling in CICs could confer an increased sensitivity to Lunasin’s anticancer activity. In fact, it has been
reported that metastatic melanomas, compared to primary melanomas, favor the expression of particular
integrins, including integrin αvβ3 [61], a known Lunasin target [10]. Differential expression of integrins in
CICs is not only restricted to melanoma but have been reported in CICs from other cancers including
prostate [196, 197], breast [198], and neuroglia cancers [172]. Given the strong interaction between
Lunasin and integrins [10, 12, 38], it is tempting to speculate that Lunasin specifically targets CICs by
modulating integrin signaling circuits that are differentially expressed in melanoma CICs. Although the
mode of action of Lunasin’s anti-CIC activity remains to be clearly defined, future studies in the Davis lab
will focus on identifying the specific integrin-mediated signaling modules required for Lunasin sensitivity
against melanoma CICs.
MITF, commonly referred to as a “master controller” gene for melanocyte development strictly
regulates melanocyte proliferation and differentiation [199]. Recent studies have identified the existence of
slow-cycling, low MITF-expressing CICs in melanoma cell populations with intrinsic chemoresistant and
tumorigenic phenotypes [200]. Additionally, this subpopulation of melanoma cells expressed high levels of
the stem cell-associated markers Oct-4 and Nanog [200]. One of the most significant findings from this
study is that treatment of melanoma ALDHhigh CICs with Lunasin induced a more differentiated phenotype
by increasing the expression of MITF as well as the expression of the downstream melanocyte
differentiation marker, Tyrosinase, an enzyme directly involved in melanin synthesis. Concomitant with the
Lunasin-induced phenotypic shift, a significant reduction in the expression of NANOG, a transcription
factor implicated in migration, invasion, self-renewal, and dedifferentiation of melanoma cells [201-203]
was observed in both A375 and SKMEL-28 cells. This represents a novel activity for Lunasin that has not
been reported in any cancer model to date.
The encouraging functional effects that were observed in melanoma CICs lead to the investigation
of whether or not Lunasin could be used in conjunction with a clinically relevant therapeutic for the
treatment of malignant melanoma. Lunasin in combination with vemurafenib, a selective B-Raf inhibitor,
was used to demonstrate the potential of Lunasin as an adjuvant therapeutic. When proliferation and
colony formation in soft agar were assessed, DI values indicate that Lunasin and vemurafenib did not
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interact synergistically, but did have an additive effect; the highest DI values were observed using
combinations using 100 μM Lunasin. At 100 μM, Lunasin increased the efficacy of vemurafenib in A375
cells with acquired vemurafenib-resistance to treatment in both adherent (proliferation assays) and nonadherent formats (soft agar). Multicellular generation of oncospheres was used to determine the growth
characteristics when parental and resistant A375 cells were treated with combinations of Lunasin and
vemurafenib. In both models, combination treatment with Lunasin and vemurafenib significantly reduced
the total sphere area when compared to vemurafenib treatment alone suggesting that Lunasin enhanced the
antiproliferative effects of vemurafenib. These additive effects may be driven by Lunasin’s interaction
with integrins and the suppression of activating phosphorylations of downstream signal transducers (i.e.
FAK). In fact, research has shown that resistance to vemurafenib may be caused by elevated β1-FAK
signaling [204]. ERK signaling, which is typically activated downstream of integrin-mediated adhesion, is
found to be constitutively activated in B-Raf mutated melanomas [205]; consequently, selective targeting
of ERK or its downstream effectors may provide some therapeutic potential in B-Raf mutated melanomas.
Combinations of B-Raf and MEK/ERK inhibitors continues to be a field of great interest to researchers
trying to overcome chemoresistant melanomas [206]. Given the prominent role of integrins in CIC
maintenance and chemoresistance [207], combining MAPK inhibitors with integrin-targeted therapies
could potentially offer a novel strategy for reducing tumor burden while also targeting CICs.
Taken together, results from the present study and previously published data support the model
(Figure 23) depicting the potential therapeutic benefits of Lunasin in melanoma. Effectively reducing pools
of CICs by driving a movement of cells out of the cancer stem cell-like compartment (i.e. ALDHhigh) and
into a more differentiated phenotype (i.e. ALDHlow), Lunasin may alleviate patient relapse by diminishing
pools of cells with the intrinsic abilities generally conserved in hematopoietic stem cells. By blocking selfrenewal and subsequent expansion of the CIC compartment, Lunasin may ultimately prove to be an
indispensable tool in combating populations of cells with high invasive potential and chemoresistant
characteristics.
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Figure 23: Proposed mechanism for Lunasin’s activity in melanoma CICs. This diagram depicts the
observed effects and possible therapeutic advantage of Lunasin treatment in cases of malignant melanoma.
Lunasin decreased the stem-like properties of ALDHhigh CICs isolated from A375 and SKMEL-28 cell
lines while concurrently decreasing the stem-associated marker NANOG and inducing expression of
melanocyte differentiation markers MITF and Tyrosinase. By effectively reducing this stem cell-like
compartment, Lunasin may alleviate patient relapse caused by the subpopulation of cells with intrinsic
metastatic potential and chemoresistance.

62

CHAPTER 4: LUNASIN SUPPRESSES THE METASTATIC CAPACITY OF MELANOMA
INITIATING CELLS BY INHIBITING INTEGRIN SIGNAL TRANSDUCTION
4.1 INTRODUCTION
Melanoma is a notoriously aggressive form of skin cancer that represents approximately 80% of
all skin cancer related deaths, despite accounting for only 5% of diagnosed cases [208, 209]. New classes
of drugs (i.e. small molecule inhibitors) combating malignant melanomas have yielded mixed results [210212]. Although many patients achieve an initial tumor regression, these agents quickly become ineffective,
and additionally, may promote the spread of a highly aggressive and chemoresistant population of cells
[213-215]. Studies utilizing immunotherapy (extensively reviewed in [216]) to treat malignant melanomas
have been found to be an effective treatment option. However, only a relatively small subset of patients
achieve a sustained complete response [217-219]. More recently, immunotherapies with substantially
improved objective responses in melanoma patients have proven the clinical utility of immunotherapy [138,
220-222]. Nevertheless, adverse safety profiles, chemoresistance, and immune evasion continue to prove
problematic in many of these newly approved immunotherapies [223-225]. Thus, providing patients with
additional novel adjuvant therapies to reduce or even prevent metastatic spread will continue to be needed
for the development for effective treatment strategies.
The process of invasion and metastasis is perhaps the most studied hallmark of cancer due to the
high mortality rates caused by the metastatic dissemination of tumor cells from the primary tumor into
distant organs. Malignant melanomas frequently metastasize to the brain, lymph nodes, gastrointestinal
tract, liver, and most commonly the lungs [226]. Primary tumor formation and subsequent metastatic
outgrowth is maintained by a subset of cells with innate stem cell-like abilities that enable them to invade
and colonize surrounding tissues, while preserving a population of highly proliferative bulk tumor cells [66,
93]. The heterogeneous nature of melanomas make an intriguing model to study metastatic dissemination
as they have been reported, among many classes of solid tumors, to harbor CIC populations identified by
several biomarkers including ALDH [103, 106], CD20 [93], CD133 [94], CD271 [95], and ABCB5 [66].
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Lunasin is a peptide isolated from soy that has been shown to have chemopreventive and
chemotherapeutic activity [9, 10, 26, 27, 32, 35, 186, 227, 228]. Lunasin has three domains implicated in its
anticancer activity; a RGD motif, a helical domain with a sequence conserved in chromatin binding
proteins, and a poly-aspartic acid tail (Figure 24) [229]. Chapter 3 of this dissertation reported that Lunasin
significantly reduced a melanoma stem cell population expressing elevated levels of ALDH [228].
Additionally, it was shown that in vivo tumor growth initiated by this putative CIC population was
significantly impaired in mice treated with Lunasin [228].

Figure 24: Full amino acid sequence of the Lunasin peptide. Lunasin is a 44 amino acid peptide with 3
functional domains attributed with its anticancer activity: 1) a helical regional conserved in chromatinbinding proteins (blue), 2) a RGD motif recognized by integrins (red), and 3) a poly-D tail involved in
histone tail binding (green).

Previously, Lunasin was shown to inhibit metastasis of malignant colon cancer cells and
additionally, potentiated the antimetastatic effects of oxaliplatin [36]; however, studies linking Lunasin to
suppressed metastatic dissemination are largely lacking. With the encouraging effects of Lunasin on breast
and melanoma CICs [228, 230], it is plausible to speculate that by reducing expansion of the CIC
compartment, Lunasin would ultimately decrease the ability of tumor cells to invade, survive, and colonize
distant tissues. Mechanistic studies to date support that Lunasin’s anticancer activity may be due to effects
on histone acetylation and integrin signaling.
Preliminary studies of Lunasin suggested that a primary anticancer mechanism was derived from
its activity as a HAT inhibitor [9]. Both HAT inhibitors and their inverse, histone deacetylase (HDAC)
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inhibitors, have been shown to have potential clinical utility in malignant melanoma [231, 232]; however,
some epigenetic modulating agents may also contribute to undesirable effects. For example, it was recently
published the HDAC inhibitor, valproic acid, caused breast cancer cells to dedifferentiate toward a
chemoresistant stem-like state [233]. With regard to Lunasin, it was indeed found that histone acetylation
patterns are altered in melanoma models; however, it is an open question as to whether or not it is the
driving mechanism in Lunasin’s chemotherapeutic activity. Equally, it is proposed that although HAT
inhibition may cause many anticancer effects in Lunasin treated cancers, inhibition of integrin signaling
stimulates the effects seen in melanoma as well as NSCLC [10]. The intertwining mechanisms between
histone acetylation and integrin signal transduction remains unclear. One major question that remains to be
answered is whether integrin signaling can modulate epigenetic histone modifications or vice versa?
Two key signaling pathways involved in the metastatic cascade are the integrin-FAK axis [195]
and the downstream PI3K/AKT pathway [234]. FAK is a critical mediator of cell proliferation,
differentiation, angiogenesis, and invasion as it promotes cytoskeletal remodeling through interactions with
several proteins including Src kinases [235]. The PI3K/AKT pathway is also found to be aberrantly
regulated in a variety of cancers including melanoma [236]. Although generally thought of as a central
protein involved in cell survival and cell cycling, AKT has been shown to bind and regulate FAK
phosphorylation suggesting an important role in metastatic adhesion [237]. Dual targeting of these
dysregulated pathways by disrupting upstream (integrin) signaling remains a promising therapeutic
approach despite the fact that there are few clinical applications using this approach. Pharmacologic
targeting of integrins is currently undergoing clinical trials for the treatment of malignant melanomas [68].
Due to the central role of integrins in several oncogenic signaling pathways [64], blockade of integrin
signal transduction seems a likely candidate for future drug development. While the potential clinical
benefit of integrin antagonists seems hopeful, the future of this class of drug will likely depend upon the
development of novel first line anticancer drugs as integrin antagonists are generally utilized in
combination with more traditional chemotherapeutics as antiangiogenic agents [238-241].
The present study significantly extends upon previous work by demonstrating that Lunasin
inhibits metastasis-associated activities in melanoma CICs both in vitro and in vivo. Additionally, it is
proposed that Lunasin is a multifaceted peptide with a complementary array of mechanisms which provides

65

the potential for a significant therapeutic benefit as an adjuvant therapy against malignant melanomas
compared to single-agent treatment strategies. By altering histone acetylation patterns as well as inhibiting
integrin signaling, Lunasin exerts a significant anticancer effect in melanoma models both in vitro and in
vivo.
4.2 MATERIALS AND METHODS
Purification of Lunasin from defatted soy and synthesis of mutated peptides
Lunasin was isolated from defatted soy flour as described in Section 2.1 [16]. Mutated peptides
were synthesized by China Peptides (China) with a purity > 95% as assessed by HPLC/MS. Full sequences
are provided (Figure 25) along with validation that these sequences were recognized by the anti-Lunasin
rabbit polyclonal antibody (Figure 26) used in immunoblot and immunofluorescent assays. Peptides were
dissolved in 50 mM sodium phosphate buffer pH = 7.4 (PB), and dialyzed overnight to remove any
contaminating salts. Protein concentrations from the resulting peptide solutions were determined using a
bicinchoninic acid (BCA) assay (Pierce). Peptide solutions were filter sterilized by passing through a 0.22
μm filter (Millipore), aliquoted, and stored at -20˚C until use.

Figure 25: Full sequences of synthesized peptides. Peptides based on Lunasin’s initial 43 amino acid
sequence were synthesized by China Peptides to represent altered functional domains. Mutated amino acid
sequences for each peptide are underlined in red. KBP-Lunasin was used in all experimental conditions,
and varies from the native Lunasin sequence by a single asparagine residue on the C-terminal end.

Figure 26: Validation of Lunasin antibody recognizing mutated peptides. 200 ng of total peptide were
electrophoresed in 15% polyacrylamide gels, transferred to a PVDF membrane, and probed for Lunasin
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using a rabbit polyclonal antibody. This confirmed that the antibody used in these studies will indeed
recognize the mutated peptide sequences. Lunasin is represented by the 5 kDa band; a slight degree of
oligomerization can be seen as represented by the fainter band above the 5 kDa Lunasin band.

Cell culture and reagents
All cell cultures and reagents utilized in Chapter 4 were described in Section 2.2.
Genome-wide microarray analysis
All RNA extractions, cDNA generation, and hybridization protocols were followed as outlined in
Section 2.16. RNA integrity values as assessed by the Bioanalyzer are shown in Figure 27.

Figure 27: RNA integrity values assessed on an Agilent Bioanalyzer. Isolated RNA from parental A375
cells treated with vehicle (1-3) or Lunasin (4-6) were assessed for RNA degradation and sample integrity
before generation of the cDNA template for microarray analysis. A375 ALDHhigh cells were also treated
with either vehicle (7-9) or Lunasin (10-12), and subsequently assessed on the Bioanalyzer. RNA integrity
values were confirmed to be greater than 8 which indicates minimal samples degradation.
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Immunofluorescence
Immunofluorescent microscopy was used for colocalization analysis and Lunasin uptake
experiments as described in Section 2.17.
Proximity ligation assay (PLA)
PLA assays were performed as described in Section 2.18.
Oncosphere formation assay
Generation of melanoma oncospheres was performed as outlines in Section 2.15.
Flow cytometry
Flow cytometry experiments to assess cell cycle and apoptosis have been detailed in Sections 2.6
and 2.7, respectively.
Transwell invasion assay
In vitro invasion assays were performed on ALDHhigh melanoma cells as described in Section 2.19.
Murine model of experimental metastasis
In vivo metastasis models were utilized to investigate the antimetastatic properties of Lunasin as
outlined in Section 2.20.
Histology
Tissues resected from primary melanoma lesions were prepared, sectioned, and stained as
described in Section 2.21.
Histone Extraction and Immunoblot Analysis
Cultured cells were treated with PB or Lunasin (100 μM) for 24 h. Acid extraction of histones was
performed as described [242]. Briefly, cells were washed in PBS and harvested into 15 mL conical tubes.
Cells were pelleted by spinning at 300 xg for 10 min and the resulting cell pellet was resuspended in an
appropriate amount of hypotonic lysis buffer (10 mM Tris–Cl pH 8.0, 1 mM KCl, 1.5 mM MgCl2 and 1
mM DTT). Cell pellets were incubated at 37˚ C for 30 min with agitation to promote cell swelling and
lysis. Lysates were pelleted by centrifugation at 10,000 xg for 10 min at 4˚ C on a tabletop centrifuge
(Eppendorf). The supernatant was discarded and the remaining nuclei were suspended in 0.4 N H2SO4 and
allowed to sit overnight at 4˚ C with constant agitation. Samples were centrifuged at 16,000 xg for 10 min
to remove nuclear debris and the resulting supernatant containing histones was transferred to a fresh 1.5 mL
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tube. A volume of 132 μL of 100 % trichloroacetic acid (TCA) was added to each sample to a final
concentration of 33% TCA v/v. Histones were precipitated in TCA overnight at 4˚ C. The supernatant was
removed and the histones were pelleted by centrifugation at 16,000 xg for 10 min. The pellet was washed
three times with ice-cold acetone to remove any remaining acid with spins at 16,000 xg for 10 min between
each wash. After the final wash, the supernatant was removed and the pellet was allowed to air-dry for 30
min at RT. The dried pellet was dissolved in 100 – 200 μL of ultrapure water and diluted to a concentration
of 1 mg/ mL as assessed by BCA method. Purified histones (10 μg) were prepared, loaded, and
electrophoresed in 15% gels (Lonza) at 100 V for 120 min. Transfer to PVDF membranes and antibody
incubations were performed as described in Section 2.11.
Statistical Analysis
Statistical analysis of data obtained from in vitro and in vivo experiments in this Chapter were
analyzed for statistical significant as described in Section 2.23.

4.3 RESULTS
Genome-wide microarray analysis reveals Lunasin-targeted genes and identifies a unique gene
signature in ALDHhigh melanoma cells compared to parental cells
The initial focus in this Chapter was to validate that ALDHhigh melanoma cells harbor the CIC
population in the A375 cell line. Additionally, gene expression profiling was utilized as a tool to expose
potential mechanisms for the selective effects seen when ALDHhigh cells were treated with Lunasin. The
initial datasets compared parental A375 cells in vehicle and Lunasin-treated samples (Table 1). While only
a modest effect (fold-change is shown in parentheses) on gene expression was observed, some genes of
interest included MAP2K7 (-1.34), MAPK11 (-1.31), RARα (-1.29), WNT3A (1.28), WNT5A (-1.28),
RARϒ (-1.27), and FOXP1 (1.52). MAP2K7 and MAPK11 are components of the MAPK signaling
pathway which is commonly mutated in cancers [243], thus, reducing expression of these genes may reduce
oncogenic signaling through MAPK-associated proteins. Retinoic acid (RA) and its receptors (RARs) are
centrally involved in stem cell differentiation [161, 244] and have been reported to induce cell cycle arrest
and apoptosis in melanomas [245-247]. While an exact mechanism for Lunasin’s induction of melanocyteassociated differentiation markers as well as the phenotype switch out of the CIC compartment has yet to
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be elucidated, the fact that two RARs were identified in the microarray analysis suggests a potential link
considering that ALDH metabolizes vitamin A into RA. To complicate the potential connection between
Lunasin and RARs, it has been reported that co-repressors and co-activators of RARs have intrinsic HAT
and HDAC activity, respectively [248]. Yet, there also exists a mechanism by which RARs are
interconnected to cellular adhesion molecules [249, 250] and more specifically integrins [251]. Given the
reports that Lunasin can alter histone acetylation patterns [142] as well as antagonize integrin signaling
[10], the mechanisms for this effect remain unclear. Wnt/β-catenin signaling is a relatively controversial
therapeutic target in cancer; several models support the inhibition of the pathway in order to induce a
therapeutic response [252, 253], while other models support activation of Wnt/β-catenin [254, 255]. Others
argue that the response may be context dependent [256]. Also of interest, it was found that WNT5A
antagonized the proliferation induced by Wnt/β-catenin activation [257]. FOXP1 is a member of the FOX
transcription factor family, and has been shown to be a therapeutic target in tumors in which it is
overexpressed [258]. In contrast, low levels of FOXP1 expression in neuroblastoma correlates with a poor
prognosis, and re-expression of the transcription factor significantly reduced tumor cell proliferation and
diminished tumorigenicity [259]. While these genes have been linked to a functional therapeutic response
in some cancer cell types, further pathway analysis is necessary to reveal novel mechanisms suggested by
this initial screen.
Next, A375 ALDHhigh cells treated with vehicle or Lunasin (Table 2) were compared in order to
discriminate any specific genes targeted in this cell population as opposed to the parental A375 cell line.
Several genes in which Lunasin had a modest effect were identified; many have been found to significantly
contribute to melanoma progression and metastasis. Genes of interest identified in this study were FOXP1
(-1.46), AKT1 (-1.31), KAT2B (-1.30), ERBB2 (-1.28), TGFB3 (-1.25), FOS (1.31), TP73 (1.31), SMAD5
(1.35), IGF1R (1.38), RAC1 (1.43). In parental cells, FOXP1 was up-regulated while in CICs treated with
Lunasin a significant down-regulation of the gene. AKT represents the major signaling protein of the
PI3K/AKT pathway and has been discussed previously. A down-regulation in AKT expression would
presumably confer an antisurvival signal, which may help explain why A375R cells were sensitized to
vemurafenib in combination treatments (discussed in Chapter 3, page 48). Given its involvement in
integrin signal transduction and regulation of histone acetylation machinery, these changes in expression of

70

AKT signaling components were somewhat expected. KAT2B encodes for the PCAF protein, and directly
regulates transcription as it has HAT activity. Again, these results are not surprising as Lunasin has been
proposed to alter histone acetylation patterns; however, this is the first report that Lunasin may directly
change gene expression of HATs. ERBB2/ERBB3 heterodimers (and its activator NRG1 [-1.26]) in
melanoma has been shown to modulate AKT activation and promote cell growth, survival, and metastasis
[260, 261]. The TGF-β/Smad pathway regulates the progression and metastasis of melanoma [262]. The
fact that SMAD5 is up-regulated while TGFB3 is down-regulated may suggest a mechanism for Smadindependent TGF-β responses.
Finally, gene expression in untreated cells derived from parental A375 cells and ALDHhigh A375
cells was compared in order to identify a unique gene set that was expressed in ALDHhigh cells, but not in
the parental line. Several genes associated with invasion and epithelial to mesenchymal transition (EMT)
were upregulated in ALDHhigh cells compared to parental cells (Table 3). Several genes of interest were
identified including MMP13 (-1.82), BMP4 (1.27), SNAI1 (1.28), TGFB2 (1.31), WNT5A (1.33), SKI
(1.33), SMAD6 (1.34), BCL2L11 (1.37), ETS1 (1.37), WNT11 (1.37), TLN2 (1.37), BCL2 (1.37), SMAD7
(1.37), MMP1 (1.39), EGFR (1.39), FN1 (1.44), JUN (1.46), JAG1 (1.59), SNAI2 (1.60), FOS (1.66),
FOSB (1.80), and BMP2 (1.86). Several critical mediators of the TGF-β, BMP, and β-catenin signaling
pathways were identified by analysis of the microarray dataset. These pathways have been implicated to
regulate key processes involved in melanoma development and progression [263-265] indicating that the
increased expression seen in ALDHhigh cells may confer some selective advantage when invading and
proliferating in distant tissue. FN1, the gene encoding fibronectin, was upregulated in ALDHhigh cells when
compared to parental cells, and is implicated in melanoma cell invasion [266]. Additionally, SNAI1 and
SNAI2, regulators of EMT [267], are both upregulated in ALDHhigh cells compared to parental cells.
Interestingly, MMP-1 and MMP-13 are inversely affected. While MMP-1 has been implicated in
melanoma invasion [268], MMP-13 has also been linked to metastasis [269] and may also mediate cell
cycling [270]. Finally, the AP-1 transcription factor components, JUN and FOS (and FOSB) were
upregulated in ALDHhigh cells compared to the parental line. Despite their well-known connection to
MAPK signaling [271], these proto-oncogenes have several functions in melanomas including metastatic
dissemination and chemoresistance [272-274]. These data would indicate that ALDHhigh cells express
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genes associated with melanoma progression through EMT, invasion, and proliferation which supports the
function of ALDH as a biomarker for CICs in melanoma.
Principle component analysis (PCA) (Figure 28A) shows the disparity between gene signatures of
parental A375 cells and ALDH-sorted populations. Additionally, Lunasin-treated ALDHhigh cells appeared
to deviate from vehicle-treated cells more so than when their parental counterparts were treated with
Lunasin, despite having a similar trend. Sources of error were scored using mean F-ratio to assess the
authenticity of the microarray analysis (Figure 28B). The greatest difference between groups came from
the cell type, meaning the highest variance was between parental cells and ALDH-sorted populations. This
demonstrates that ALDHhigh cells displayed a significantly altered gene signature from the parental A375
populations; this may potentially confirm the results discussed previously describing the upregulation of
several genes associated with EMT, invasion, and stemness in ALDHhigh cells when compared to parental
populations. Treatment with Lunasin accounted for the second highest source of variation, followed by
replicates and human error, respectively.
Table 1: Microarray dataset (threshold = 1.25, p < 0.05) for parental A375
List Report
Network Object
Name

Gene Symbol

Gene Name

Object Type

Description

p-value

-1.44444

0.0206268

Phospholamban

PLN

phospholamban

Generic binding
protein

NF-AT

NFATC4

nuclear factor of activated T-cells 4

Transcription
factor

NF-AT3(NFATC4)

NFATC4

nuclear factor of activated T-cells 4

Transcription
factor

Nuclear factor of activated T-cells,
cytoplasmic 4

-1.42274 0.00795497

Arrestin 3

ARR3

arrestin 3 retinal (X-arrestin)

Generic binding
protein

Arrestin-C

-1.40384 0.000620583

Desmin

DES

desmin

Generic binding
protein

Desmin

-1.39849 0.00816461

GRAP2

GRAP2

GRB2-related adaptor protein 2

Generic binding
protein

GRB2-related adapter protein 2

-1.39079

SIA7E

ST6GALNAC5 ST6 N-acetylgalactosaminide alpha-2,6sialyltransferase 5

Generic enzyme

Alpha-N-acetylgalactosaminide
alpha-2,6-sialyltransferase 5

-1.38735 0.00809087

Calpain 10

CAPN10

calpain 10

Generic protease

Calpain-10

-1.38007

G3ST3

GAL3ST3

galactose-3-O-sulfotransferase 3

Generic enzyme

Galactose-3-O-sulfotransferase 3

-1.35473 0.00908722

Epiregulin

EREG

epiregulin

Protein

Proepiregulin

-1.35302

MKK7 (MAP2K7)

MAP2K7

mitogen-activated protein kinase kinase 7

Protein kinase

Dual specificity mitogen-activated
protein kinase kinase 7

-1.33896 0.00316078

ABO system
transferase

ABO

Generic enzyme

Histo-blood group ABO system
transferase

-1.33629

0.0348191

CalDAG-GEFII

RASGRP1

ABO blood group (transferase A, alpha 1-3-Nacetylgalactosaminyltransferase; transferase B,
alpha 1-3galactosyltransferase)
RAS guanyl releasing protein 1

Regulators (GDI,
GAP, GEF)

RAS guanyl-releasing protein 1

-1.3217

0.0466738
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Cardiac phospholamban

Signal

-1.42274 0.00795497

0.0330518

0.0309494

0.0101828

ACACB

ACACB

acetyl-CoA carboxylase beta

Protein

Acetyl-CoA carboxylase 2

-1.31886

0.0146277

ACE1

ACE

angiotensin I converting enzyme

Generic protease

Angiotensin-converting enzyme

-1.31409

0.0139762

p38 MAPK

MAPK11

mitogen-activated protein kinase 11

Protein kinase

-1.30969

0.0162317

p38beta (MAPK11) MAPK11

mitogen-activated protein kinase 11

Protein kinase

Mitogen-activated protein kinase
11

-1.30969

0.0162317

BAIAP2

BAIAP2

BAI1 associated protein 2

Generic binding
protein

Brain-specific angiogenesis
inhibitor 1-associated protein 2

-1.30952 0.00163325

Galpha(s)-specific
amine
GPCRs
Tissue kallikreins

HRH2

histamine receptor H2

Generic receptor

-1.29861

0.0393267

KLK10

kallikrein related peptidase 10

Generic protease

-1.29669

0.0358496

RARalpha

RARA

retinoic acid receptor alpha

Transcription
factor

WNT

WNT3A

Wnt family member 3A

Receptor ligand

WNT3A

WNT3A

Wnt family member 3A

Receptor ligand

Retinoic acid receptor alpha

-1.28836 0.00247536

-1.28404

0.0302277

Protein Wnt-3a

-1.28404

0.0302277

Voltage-dependent L-type calcium
channel subunit alpha-1C

-1.27809

0.0123255

L-type
Ca(II) CACNA1C
channel, alpha 1C
subunit
WNT
WNT5A

calcium voltage-gated channel subunit alpha1 C

Voltage-gated ion
channel

Wnt family member 5A

Receptor ligand

WNT5A

WNT5A

Wnt family member 5A

Receptor ligand

RARgamma

RARG

retinoic acid receptor gamma

Transcription factor Retinoic acid receptor gamma

HXK4

GCK

glucokinase

Generic kinase

Tissue kallikreins

KLK12

kallikrein related peptidase 12

Generic protease

HGF

HGF

hepatocyte growth factor

Receptor ligand

NR1

GRIN1

CYP4F2

-1.2726 0.00115524

Protein Wnt-5a

Glucokinase

-1.2726 0.00115524

-1.2701 0.00193338

-1.26848 0.00158031

-1.26669

0.0488501

Hepatocyte growth factor

-1.26587

0.0187103

glutamate ionotropic receptor NMDA type subunit 1 Ligand-gated ion
channel

Glutamate receptor ionotropic,
NMDA 1

-1.26439

0.0494182

CYP4F2

cytochrome P450 family 4 subfamily F member 2

Generic enzyme

Phylloquinone omega-hydroxylase
CYP4F2

-1.26402 0.00367679

c-Maf

MAF

MAF bZIP transcription factor

Transcription factor Transcription factor Maf

-1.26355

0.0364182

IGH@

IGH

immunoglobulin heavy locus

Receptor ligand

immunoglobulin heavy locus

-1.26164

0.0240856

Synaptotagmin VII SYT7

synaptotagmin 7

Protein

Synaptotagmin-7

-1.26021

0.0222702

Sirtuin6

SIRT6

sirtuin 6

Generic enzyme

NAD-dependent protein
deacetylase sirtuin-6

-1.25989

0.0426655

IRF5

IRF5

interferon regulatory factor 5

Transcription factor Interferon regulatory factor 5

-1.25985

0.0210335

PLC-delta

PLCD3

phospholipase C delta 3

Generic
phospholipase

-1.25942

0.0122591

GRK6

GRK6

G protein-coupled receptor kinase 6

Protein kinase

G protein-coupled receptor kinase
6

-1.25853

0.0138678

GLUT2

SLC2A2

solute carrier family 2 member 2

Transporter

Solute carrier family 2, facilitated
glucose transporter member 2

-1.25405

0.0335012

PP2A regulatory

PPP2R5D

protein phosphatase 2 regulatory subunit B'delta

Generic binding
protein

-1.21491

0.0285902

Tissue kallikreins

KLK7

kallikrein related peptidase 7

Generic protease

-1.19423

0.0352611
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Tissue kallikreins

KLK6

kallikrein related peptidase 6

Generic protease

-1.18227

0.0432625

NF-AT

NFAT5

nuclear factor of activated T-cells 5, tonicityresponsive

Transcription factor

-1.17732

0.0265163

Tubulin alpha

TUBA3C

tubulin alpha 3c

Generic binding
protein

-1.14922

0.0266541

Tubulin alpha

TUBA3D

tubulin alpha 3d

Generic binding
protein

-1.14922

0.0266541

Galpha(s)-specific HTR7
amine
GPCRs
NF-AT
NFATC2

5-hydroxytryptamine receptor 7

Generic receptor

-1.11885

0.0112545

nuclear factor of activated T-cells 2

Transcription factor

1.06543

0.0432984

PLC-beta

PLCB1

phospholipase C beta 1

Generic
phospholipase

1.18758

0.0301776

MUNC13-1

UNC13A

unc-13 homolog A (C. elegans)

Generic binding
protein

1.25565

0.0376234

PARD6

PARD6B

par-6 family cell polarity regulator beta

Generic binding
protein

1.25711

0.0376021

P2Y1

P2RY1

purinergic receptor P2Y1

GPCR

P2Y purinoceptor 1

1.27086 9.23061E-05

Heme oxygenase 1 HMOX1

heme oxygenase 1

Generic enzyme

Heme oxygenase 1

1.27173 0.000507197

p130

RBL2

RB transcriptional corepressor like 2

Generic binding
protein

Retinoblastoma-like protein 2

1.28053

CACNA1D

CACNA1D

calcium voltage-gated channel subunit alpha1 D

Voltage-gated ion
channel

Voltage-dependent L-type calcium
channel subunit alpha-1D

1.29206 0.00864385

PACAP

ADCYAP1

adenylate cyclase activating polypeptide 1

Receptor ligand

Pituitary
adenylate
cyclaseactivating polypeptide

1.31848

GCL reg

GCLM

glutamate-cysteine ligase modifier subunit

Generic enzyme

Glutamate--cysteine
regulatory subunit

1.32293 0.00125117

TLR1

TLR1

toll like receptor 1

Generic receptor

Toll-like receptor 1

Tubulin alpha

EHHADH

enoyl-CoA, hydratase/3-hydroxyacyl CoA
dehydrogenase

Generic binding
protein

Sec8

EXOC4

exocyst complex component 4

Generic binding
protein

AMPK alpha
subunit

PRKAA1

protein kinase AMP-activated catalytic subunit
alpha 1

Protein kinase

1.36607 0.00164903

PLC-beta

PLCB4

phospholipase C beta 4

Generic
phospholipase

1.37036 0.00733205

Carboxypeptidase CPM
M

carboxypeptidase M

Generic protease

Carboxypeptidase M

1.37297

0.0184119

LAMP2

LAMP2

lysosomal associated membrane protein 2

Generic binding
protein

Lysosome-associated membrane
glycoprotein 2

1.38197

0.0109799

EGF

EGF

epidermal growth factor

Receptor ligand

Pro-epidermal growth factor

1.38549

0.0313874

PP2A regulatory

PPP2R2B

protein phosphatase 2 regulatory subunit Bbeta

Generic binding
protein

RECK

RECK

reversion inducing cysteine rich protein with kazal
motifs

Generic binding
protein

70Z-PEP

PTPN22

protein tyrosine phosphatase, non-receptor type 22 Protein
phosphatase

FOXP1

FOXP1

forkhead box P1

Protein unc-13 homolog A

1.32839

0.0327697

0.0275434

1.32991 0.00604937

Exocyst complex component 4

1.33531

0.033613

1.39363 0.00776675

Reversion-inducing cysteine-rich
protein with Kazal motifs

1.40929 0.00514642

Tyrosine-protein
phosphatase
nonreceptor type 22

1.47127 0.00577936

Transcription factor Forkhead box protein P1
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ligase

0.0362018

1.52131 0.00252521

Table 2: Microarray dataset (threshold = 1.25, p < 0.05) for ALDH-high A375 cells
List Report
Network Object
Name

Gene
Symbol

Gene Name

Object Type

Description

Signal

p-value

Protein kinase G

PRKG1

protein kinase, cGMP-dependent, type I Protein kinase

FOXP1

FOXP1

forkhead box P1

Transcription factor Forkhead box protein P1

-1.46271

KCRU

CKMT1A

creatine kinase, mitochondrial 1A

Generic kinase

Creatine kinase U-type, mitochondrial

-1.45383 0.00150056

KCRU

CKMT1B

creatine kinase, mitochondrial 1B

Generic kinase

Creatine kinase U-type, mitochondrial

-1.45383 0.00150056

PP2A regulatory

PTPA

protein phosphatase 2 phosphatase
activator

Generic binding
protein

CARD8

CARD8

caspase recruitment domain family
member 8

Generic binding
protein

Caspase recruitment domain-containing
protein 8

Bim

BCL2L11

BCL2 like 11

Generic binding
protein

Bcl-2-like protein 11

-1.3764

0.0226245

MSP

MST1

macrophage stimulating 1

Receptor ligand

Hepatocyte growth factorlike protein

-1.3685

0.0243488

Schwannomin (NF2) NF2

neurofibromin 2 (merlin)

Generic binding
protein

Merlin

-1.36212

0.0331648

MEK6(MAP2K6)

MAP2K6

mitogen-activated protein kinase kinase Protein kinase
6

Dual specificity mitogenactivated protein
kinase kinase 6

-1.34109

0.0465563

cAMP-GEFII

RAPGEF4

Rap guanine nucleotide exchange factor Regulators (GDI,
4
GAP, GEF)

Rap guanine nucleotide exchange factor 4

-1.33651

0.0162899

CNTN1 (F3)

CNTN1

contactin 1

Generic binding
protein

Contactin-1

-1.3314

0.0458024

Intersectin

ITSN1

intersectin 1

Regulators (GDI,
GAP, GEF)

Intersectin-1

NALP2

NLRP2

NLR family pyrin domain containing 2

Generic binding
protein

NACHT, LRR and PYD
domains-containing protein 2

GP-IB alpha

GP1BA

glycoprotein Ib platelet alpha subunit

GPCR

Platelet glycoprotein Ib alpha chain

-1.31542

0.0457474

GAB2

GAB2

GRB2 associated binding protein 2

Generic binding
protein

GRB2-associated-binding protein 2

-1.31488

0.0380525

CD70(TNFSF7)

CD70

CD70 molecule

Receptor ligand

CD70 antigen

-1.30677

0.0111134

AKT(PKB)

AKT1

AKT serine/threonine kinase 1

Protein kinase

AKT1

AKT1

AKT serine/threonine kinase 1

Protein kinase

HIVEP2

HIVEP2

human immunodeficiency virus type I
enhancer binding protein 2

Transcription factor Transcription factor
HIVEP2

-1.29905 0.00355775

Ephrin-A receptors

EPHA3

EPH receptor A3

Generic receptor

-1.29764 0.000542762

PCAF

KAT2B

lysine acetyltransferase 2B

Generic enzyme

Histone acetyltransferase
KAT2B

-1.29653 0.00198854

PPARGC1 (PGC1alpha)

PPARGC1A PPARG coactivator 1 alpha

Generic binding
protein

Peroxisome proliferatoractivated receptor
gamma coactivator 1-alpha

-1.29602

0.0191075

B-chimaerin

CHN2

chimerin 2

Regulators (GDI,
GAP, GEF)

Beta-chimaerin

-1.29129

0.0233722

ELF5

ELF5

E74 like ETS transcription factor 5

Transcription factor ETS-related transcription factor Elf-5

-1.29026

0.0487005

Ephrin-B receptor 1 EPHB1

EPH receptor B1

Receptor with
enzyme activity

-1.28997

0.0450225

Ephrin-B receptors

EPH receptor B1

Generic receptor

-1.28997

0.0450225

EPHB1
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-1.5701 0.00337114

0.0125002

-1.42442 0.00947514

-1.40269 0.00466734

-1.32506 0.000236297

-1.3211 0.00221173

-1.30416 0.000226758

RAC-alpha serine/threonineprotein kinase

Ephrin type-B receptor 1

-1.30416 0.000226758

PP2A regulatory

PPP2R5D

protein phosphatase 2 regulatory
subunit B'delta

Generic binding
protein

MSK1

RPS6KA5

ribosomal protein S6 kinase A5

Protein kinase

MSK1/2
(RPS6KA5/4)

RPS6KA5

ribosomal protein S6 kinase A5

Protein kinase

MNK1

MKNK1

MAP kinase interacting serine/threonine Protein kinase
kinase 1

MAP kinase-interacting serine/threonineprotein kinase 1

-1.28634 0.00102042

ErbB2

ERBB2

erb-b2 receptor tyrosine kinase 2

Receptor tyrosine-protein kinase erbB-2

-1.28262

IGHG1

IGHG1

immunoglobulin heavy constant gamma Receptor ligand
1 (G1m marker)

Ig gamma-1 chain C region

-1.27369 0.00748698

eIF4A

EIF4A1

eukaryotic translation initiation factor
4A1

Generic enzyme

CARD7

NLRP1

NLR family pyrin domain containing 1

Generic binding
protein

DR5(TNFRSF10B)

TNFRSF10B tumor necrosis factor receptor
superfamily member 10b

ADAM17

ADAM17

CD36

Receptor with
enzyme activity

-1.28952 0.00831128

Ribosomal protein S6 kinase alpha-5

-1.28643

0.0290961

-1.28643

0.0290961

0.0183775

-1.27351

0.0120587

NACHT, LRR and PYD
domains-containing protein 1

-1.27181

0.0355684

Receptor with
enzyme activity

Tumor necrosis factor
receptor superfamily member 10B

-1.26909 0.000643637

ADAM metallopeptidase domain 17

Metalloprotease

Disintegrin
and
metalloproteinase
domaincontaining protein 17

-1.26776

0.0033431

CD36

CD36 molecule

Generic receptor

Platelet glycoprotein 4

-1.26623

0.018395

IL4RA

IL4R

interleukin 4 receptor

Generic receptor

Interleukin-4 receptor subunit alpha

-1.26512

0.0191704

NKG2A

KLRC1

killer cell lectin like receptor C1

Generic receptor

NKG2-A/NKG2-B type II integral membrane -1.26289
protein

0.0334868

GRB10

GRB10

growth factor receptor bound protein 10 Generic binding
protein

Growth factor receptorbound protein 10

0.0157259

FKHR

FOXO1

forkhead box O1

Transcription factor Forkhead box protein O1

-1.25939 0.00206426

Neurotractin

NEGR1

neuronal growth regulator 1

Generic binding
protein

Neuronal growth regulator 1

-1.25895 0.00424239

Neuregulin 1

NRG1

neuregulin 1

Receptor ligand

Pro-neuregulin-1, membrane-bound isoform

-1.25677

CLIP3

CLIP3

CAP-Gly domain containing linker
protein 3

Protein

CAP-Gly domain-containing linker protein 3

-1.25409 0.00303439

HGF

HGF

hepatocyte growth factor

Receptor ligand

Hepatocyte growth factor

-1.25234

TGF-beta

TGFB3

transforming growth factor beta 3

Receptor ligand

Ephrin-A receptors

EPHA4

EPH receptor A4

Generic receptor

-1.2152

0.0120193

Adenylate cyclase

ADCY7

adenylate cyclase 7

Generic enzyme

-1.192

0.0181893

eIF4G1/3

EIF4G1

eukaryotic translation initiation factor 4 Generic binding
gamma 1
protein

-1.11566

0.0103837

AKT(PKB)

AKT2

AKT serine/threonine kinase 2

-1.10513 0.00858131

MHC class I

HLA-E

major histocompatibility complex, class Generic receptor
I, E

HSP90

HSP90AB1 heat shock protein 90kDa alpha family
class B member 1

Generic binding
protein

AKT(PKB)

AKT3

AKT serine/threonine kinase 3

14-3-3

YWHAQ

14-3-3

YWHAE

tyrosine 3-monooxygenase/tryptophan
5monooxygenase activation protein
theta
tyrosine 3-monooxygenase/tryptophan
5monooxygenase activation protein
epsilon

Protein kinase

-1.26127

0.0236608

0.0229854

-1.25052 0.00532903

-1.10479

0.0367323

-1.02524

0.0469378

Protein kinase

1.08838

0.0379968

Generic binding
protein

1.09529 0.000338352

Generic binding
protein
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1.1424

0.005047

14-3-3

YWHAG

tyrosine 3-monooxygenase/tryptophan Generic binding
5monooxygenase activation protein
protein
gamma
myosin light chain 12A
Generic binding
protein

1.14443

MRLC

MYL12A

PP2A regulatory

PPP2R5E

HSP90

0.0106333

protein phosphatase 2 regulatory
subunit B'epsilon

Generic binding
protein

1.18192

HSP90AA1 heat shock protein 90kDa alpha family
class A member 1

Generic binding
protein

1.21348 0.00543915

Ephrin-A receptors

EPHA5

EPH receptor A5

Generic receptor

1.23325 0.00135816

MHC class I

HLA-G

major histocompatibility complex, class Generic receptor
I, G

NGF

NGF

nerve growth factor

Receptor ligand

Adenylate cyclase

ADCY8

adenylate cyclase 8 (brain)

Generic enzyme

Adenylate cyclase
type VIII

ADCY8

adenylate cyclase 8 (brain)

Generic enzyme

Brca2

BRCA2

BRCA2, DNA repair associated

ABR

ABR

LRRK2

1.14548 0.00470967

0.0478546

1.23695

0.0262767

1.25368

0.0133639

1.25427

0.0112251

Adenylate cyclase type 8

1.25427

0.0112251

Generic binding
protein

Breast cancer type 2 susceptibility protein

1.25438 0.000775725

active BCR-related

Regulators (GDI,
GAP, GEF)

Active breakpoint cluster region-related
protein

1.25461 0.00190559

LRRK2

leucine rich repeat kinase 2

Protein kinase

Leucine-rich repeat
protein kinase 2

SMAD1

SMAD1

SMAD family member 1

Transcription factor

Mothers against decapentaplegic homolog 1

1.25784 0.00175723

RacGAP1

RACGAP1

Rac GTPase activating protein 1

Regulators (GDI,
GAP, GEF)

Rac GTPase-activating protein 1

1.26471 0.00486122

EBP50

SLC9A3R1

SLC9A3 regulator 1

Generic binding
protein

1.26562 0.00298857

E3b1(ABI-1)

ABI1

abl interactor 1

Generic binding
protein

Na(+)/H(+) exchange
regulatory cofactor NHERF1
Abl interactor 1

1.26599 0.000897763

Cathepsin B

CTSB

cathepsin B

Generic protease

Cathepsin B

1.26656

0.0253929

P2X7

P2RX7

purinergic receptor P2X 7

Ligand-gated ion
channel

P2X purinoceptor 7

1.26689

0.0271523

CREB1

CREB1

cAMP responsive element binding
protein 1

Transcription factor

Cyclic AMP-responsive element-binding
protein 1

1.26771 0.00371316

eIF4B

EIF4B

eukaryotic translation initiation factor 4B Generic binding
protein

Eukaryotic translation initiation factor 4B

1.26771

p18

CDKN2C

cyclin dependent kinase inhibitor 2C

Cyclin-dependent kinase 4 inhibitor C

1.27536 0.00174692

OATP-A

SLCO1A2

solute carrier organic anion transporter Transporter
family member 1A2

PP2A regulatory

PPP2R5B

protein phosphatase 2 regulatory
subunit B'beta

Rictor

RICTOR

RPTOR independent
MTOR complex 2

Perforin

PRF1

perforin 1

KAP3

KIFAP3

kinesin associated protein 3

ALPL

ALPL

alkaline phosphatase, liver/bone/kidney Generic phosphatase Alkaline
isozyme

Tob1

TOB1

transducer of ERBB2, 1

Generic binding
protein

Protein Tob1

1.29203 0.00351566

CCL2

CCL2

C-C motif chemokine ligand 2

Receptor ligand

C-C motif chemokine 2

1.29588

companion

Generic binding
protein

Beta-nerve growth factor

serine/threonine-

Solute carrier organic anion
transporter family member 1A2

Generic binding
protein
of Generic binding
protein

1.2566 0.00710897

0.0362407

1.2768

0.0127423

1.28013

0.028923

Rapamycin-insensitive companion of mTOR

1.28306 0.00299417

Transporter

Perforin-1

1.28693

Generic binding
protein

Kinesin-associated protein 3

1.28759 0.00119856
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phosphatase,

tissue-nonspecific

1.29131

0.0356184

0.0245732

0.0249862

MR-GEF

RAPGEF5

Rap guanine nucleotide exchange
factor 5

Regulators (GDI,
GAP, GEF)

Rap guanine nucleotide exchange factor 5

1.29627

0.0364294

STK4

STK4

serine/threonine kinase 4

Protein kinase

Serine/threonine-protein kinase 4

1.2963

0.0067006

RHAMM

HMMR

hyaluronan mediated motility receptor

Generic receptor

Hyaluronan mediated motility receptor

1.29916 0.00116314

RhoGAP5

ARHGAP5

Rho GTPase activating protein 5

Regulators (GDI,
GAP, GEF)

Rho GTPase-activating protein 5

1.29932 0.00320296

SOD2

SOD2

superoxide dismutase 2, mitochondrial Generic enzyme

Superoxide dismutase [Mn], mitochondrial

1.30008 0.000133145

PARP-1

PARP1

poly(ADP-ribose) polymerase 1

Generic enzyme

Poly [ADP-ribose] polymerase 1

MPP5

MPP5

membrane palmitoylated protein 5

Generic binding
protein

MAGUK p55 subfamily member 5

1.30188 0.00231735

APC protein

APC

WNT signaling pathway regulator

Generic binding
protein

Adenomatous polyposis coli protein

1.30488

0.0062747

RAP-1A

RAP1A

RAP1A, member of RAS oncogene
family

RAS - superfamily

Ras-related protein Rap-1A

1.30488

0.0416244

PSAT

PSAT1

phosphoserine aminotransferase 1

Generic enzyme

Phosphoserine aminotransferase

1.30787 0.000502575

c-Fos

FOS

Fos proto-oncogene, AP-1 transcription Transcription factor Proto-oncogene c-Fos
factor subunit

p73

TP73

tumor protein p73

Transcription factor Tumor protein p73

14-3-3

YWHAZ

Generic binding
protein

14-3-3 zeta/delta

YWHAZ

mGluR1

GRM1

tyrosine 3-monooxygenase/tryptophan
5monooxygenase activation protein
zeta
tyrosine 3-monooxygenase/tryptophan
5monooxygenase activation protein
zeta
glutamate metabotropic receptor 1

MHC class I

HLA-F

major histocompatibility complex, class Generic receptor
I, F

IL-1RI

IL1R1

interleukin 1 receptor type 1

Generic receptor

Interleukin-1 receptor type 1

Syndecan-2

SDC2

syndecan 2

Generic receptor

Syndecan-2

IRF1

IRF1

interferon regulatory factor 1

Transcription factor Interferon regulatory factor
1

eIF4G1/3

EIF4G3

ATF-1

1.3017

0.0167984

1.30873 0.000144963

1.3132

0.0179451

1.31677

0.0236916

Generic binding
protein

14-3-3 protein zeta/delta

1.31677

0.0236916

GPCR

Metabotropic glutamate receptor 1

1.31864

0.0051418

1.31998 0.00676518

1.3234 0.00954023

1.32432 0.000543997

1.32567

0.0148805

eukaryotic translation initiation factor 4 Generic binding
gamma 3
protein

1.32688

0.0240793

ATF1

activating transcription factor 1

Transcription factor Cyclic AMP-dependent transcription factor
ATF-1

1.33141 0.00862807

PP2A regulatory

PPP2R3A

protein phosphatase 2 regulatory
subunit B''alpha

Generic binding
protein

Caspase-2

CASP2

caspase 2

Generic protease

SMAD5

SMAD5

SMAD family member 5

Transcription factor Mothers against decapentaplegic homolog 5

RASSF5

RASSF5

Ras association domain family member Generic binding
5
protein

Ras association domaincontaining protein 5

Nucleophosmin

NPM1

nucleophosmin (nucleolar
phosphoprotein B23, numatrin)

Generic binding
protein

Nucleophosmin

1.36901 0.00132591

Endoplasmin

HSP90B1

heat shock protein 90kDa beta family
member 1

Generic binding
protein

Endoplasmin

1.37222

0.0376878

HSP90

HSP90B1

heat shock protein 90kDa beta family
member 1

Generic binding
protein

1.37222

0.0376878

RHEB2

RHEB

Ras homolog enriched in brain

RAS - superfamily
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1.3348 0.00213492

Caspase-2

GTP-binding protein Rheb

1.34305 0.00221027

1.34693

0.012205

1.3648 0.00616737

1.37269 0.00391466

MHC class I

B2M

beta-2-microglobulin

Generic receptor

BMPR1A

BMPR1A

bone morphogenetic protein receptor
type 1A

Receptor with
enzyme activity

FAP-1

PTPN13

protein tyrosine
receptor type 13

IGF-1 receptor

IGF1R

insulin like growth factor 1 receptor

Dynorphin A(1-13)

PDYN

Leu-enkephalin

1.37655 0.00262384

Bone morphogenetic protein receptor type-1A

1.37717 0.00542215

Tyrosine-protein phosphatase non-receptor
type 13

1.37852

Receptor with
enzyme activity

Insulin-like growth factor 1 receptor

1.38488 0.00124826

prodynorphin

Receptor ligand

Dynorphin-A(1-13)

1.38832 0.00114984

PDYN

prodynorphin

Receptor ligand

Leu-enkephalin

1.38832 0.00114984

Proenkephalin-B

PDYN

prodynorphin

Receptor ligand

Proenkephalin-B

1.38832 0.00114984

Caspase-8

CASP8

caspase 8

Generic protease

Caspase-8

1.39804

0.0119021

ESR2

ESR2

estrogen receptor 2

Transcription factor Estrogen receptor beta

1.40974

0.0236654

LAMP2

LAMP2

lysosomal associated membrane
protein 2

Generic binding
protein

Lysosome-associated membrane
glycoprotein 2

1.41288 0.000310979

Rac1

RAC1

RAS - superfamily

Ras-related C3 botulinum toxin substrate 1

1.43303 0.00759662

MRLC

MYL12B

ras-related C3 botulinum toxin
substrate 1 (rho family, small GTP
binding protein Rac1)
myosin light chain 12B

Generic binding
protein

1.50417 0.000444727

Adenylate cyclase

ADCY1

adenylate cyclase 1 (brain)

Generic enzyme

1.52523 2.81187E-06

Adenylate cyclase
type I

ADCY1

adenylate cyclase 1 (brain)

Generic enzyme

Adenylate cyclase type 1

1.52523 2.81187E-06

KIR2DL1

KIR2DL1

Generic receptor

Killer cell immunoglobulinlike receptor 2DL1

1.84246

0.022848

KIR2DL2

KIR2DL2

Generic receptor

Killer cell immunoglobulinlike receptor 2DL2

1.84246

0.022848

KIR2DL3

KIR2DL3

Generic receptor

Killer cell immunoglobulinlike receptor 2DL3

1.84246

0.022848

KIR2DL4

KIR2DL4

Generic receptor

Killer cell immunoglobulinlike receptor 2DL4

1.84246

0.022848

KIR2DL5

KIR2DL5A

killer cell immunoglobulin like receptor,
two Ig domains and long cytoplasmic
tail 1
killer cell immunoglobulin like receptor,
two Ig domains and long cytoplasmic
tail 2
killer cell immunoglobulin like receptor,
two Ig domains and long cytoplasmic
tail 3
killer cell immunoglobulin like receptor,
two Ig domains and long cytoplasmic
tail 4
killer cell immunoglobulin like receptor,
two Ig domains and long cytoplasmic
tail 5A

Generic receptor

Killer cell immunoglobulinlike receptor 2DL5A

1.84246

0.022848

phosphatase,

non- Generic
phosphatase

0.0181538

Table 3: Parental versus ALDH-high A375 cells (Untreated)
List Report
Network Object
Name

Gene
Symbol

Gene Name

Object Type

Description
Signal

p-value

CCL2

CCL2

C-C motif chemokine ligand 2

Receptor ligand

C-C motif chemokine 2

-2.36328 1.66572E-05

p57

CDKN1C

cyclin dependent kinase inhibitor 1C

Generic binding
protein

Cyclin-dependent kinase inhibitor 1C

-2.35549 7.53913E-07

MHC class II

HLA-DOA

major histocompatibility complex, class Generic receptor
II, DO alpha

MMP-13

MMP13

matrix metallopeptidase 13

Metalloprotease

Collagenase 3

-1.81956 0.00133048

MEF2C

MEF2C

myocyte enhancer factor 2C

Transcription factor

Myocyte-specific enhancer factor 2C

-1.72111 0.000499586

TRAF1

TRAF1

TNF receptor associated factor 1

Generic binding
protein

TNF receptor-associated factor 1

-1.56675 0.000152341
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-1.88445 1.96402E-05

MEK6(MAP2K6)

MAP2K6

mitogen-activated protein kinase kinase Protein kinase
6

Dual specificity mitogen-activated protein
kinase kinase 6

eIF4A

EIF4A2

eukaryotic translation initiation factor
4A2

MHC class II

HLA-DOB

major histocompatibility complex, class Generic receptor
II, DO beta

Osteopontin

SPP1

secreted phosphoprotein 1

Receptor ligand

Osteopontin

-1.37772 1.37342E-05

GAB1

GAB1

GRB2 associated binding protein 1

Generic binding
protein

GRB2-associated-binding protein 1

-1.36772

Histone H4

HIST1H4A

histone cluster 1, H4a

Generic binding
protein

Histone H4

-1.3674 0.000812007

Histone H4

HIST1H4B

histone cluster 1, H4b

Generic binding
protein

Histone H4

-1.3674 0.000812007

Histone H4

HIST1H4C

histone cluster 1, H4c

Generic binding
protein

Histone H4

-1.3674 0.000812007

Histone H4

HIST1H4D

histone cluster 1, H4d

Generic binding
protein

Histone H4

-1.3674 0.000812007

Histone H4

HIST1H4E

histone cluster 1, H4e

Generic binding
protein

Histone H4

-1.3674 0.000812007

Histone H4

HIST1H4F

histone cluster 1, H4f

Generic binding
protein

Histone H4

-1.3674 0.000812007

Histone H4

HIST1H4H

histone cluster 1, H4h

Generic binding
protein

Histone H4

-1.3674 0.000812007

Histone H4

HIST1H4I

histone cluster 1, H4i

Generic binding
protein

Histone H4

-1.3674 0.000812007

Histone H4

HIST1H4J

histone cluster 1, H4j

Generic binding
protein

Histone H4

-1.3674 0.000812007

Histone H4

HIST1H4K

histone cluster 1, H4k

Generic binding
protein

Histone H4

-1.3674 0.000812007

Histone H4

HIST1H4L

histone cluster 1, H4l

Generic binding
protein

Histone H4

-1.3674 0.000812007

Histone H4

HIST2H4A

histone cluster 2, H4a

Generic binding
protein

Histone H4

-1.3674 0.000812007

Histone H4

HIST2H4B

histone cluster 2, H4b

Generic binding
protein

Histone H4

-1.3674 0.000812007

Histone H4

HIST4H4

histone cluster 4, H4

Generic binding
protein

Histone H4

-1.3674 0.000812007

CD40(TNFRSF5
)

CD40

CD40 molecule

Generic receptor

Tumor necrosis factor receptor superfamily
member 5

PP2A regulatory

PPP2R3A

protein phosphatase 2 regulatory
subunit B''alpha

Generic binding
protein

PLP1

PLP1

proteolipid protein 1

Generic binding
protein

MHC class II

HLA-DMB

major histocompatibility complex, class Generic receptor
II, DM beta

von Willebrand
factor

VWF

von Willebrand factor

Receptor ligand

von Willebrand factor

Fc gamma RII alpha FCGR2A

Fc fragment of IgG receptor IIa

Generic receptor

Low affinity immunoglobulin gamma Fc
region receptor II-a

VDR

VDR

vitamin D (1,25- dihydroxyvitamin D3)
receptor

Transcription factor Vitamin D3 receptor

-1.31617 0.00300324

c-Maf

MAF

MAF bZIP transcription factor

Transcription factor Transcription factor Maf

-1.30398

0.021578

Frizzled

FZD4

frizzled class receptor 4

GPCR

-1.30301

0.0233367

COL1A1

COL1A1

collagen type I alpha 1

Generic binding
protein

-1.29164

0.0279799

Generic enzyme
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-1.5054 3.59244E-05

-1.46238 0.000581214

-1.43366

-1.36382

0.0276582

0.0477614

0.0110669

-1.36311 0.00139958

Myelin proteolipid protein

-1.35525

0.0103633

-1.35184 3.44602E-05

Collagen alpha-1(I) chain

-1.3206

0.0210621

-1.31836 0.00296042

Adenylate cyclase

ADCY6

adenylate cyclase 6

Generic enzyme

-1.28938 0.00835718

PDGF receptor

PDGFRB

platelet derived growth factor receptor
beta

Receptor with
enzyme activity

-1.28614 0.00403004

PDGF-R-beta

PDGFRB

platelet derived growth factor receptor
beta

Receptor with
enzyme activity

Platelet-derived growth factor receptor beta

Follistatin

FST

follistatin

Generic binding
protein

Follistatin

PP2A structural

PPP2R1B

protein phosphatase 2 scaffold subunit Generic binding
Abeta
protein

CDK6

CDK6

cyclin dependent kinase 6

Protein kinase

MLCK

MYLK

myosin light chain kinase

Protein kinase

MYLK1

MYLK

myosin light chain kinase

Protein kinase

Myosin light chain kinase, smooth muscle

-1.2671 0.00395734

TAB1

TAB1

TGF-beta activated kinase 1/MAP3K7
binding protein 1

Generic binding
protein

TGF-beta-activated kinase 1 and
MAP3K7binding protein 1

-1.2654 0.00263249

p38 MAPK

MAPK11

mitogen-activated protein kinase 11

Protein kinase

p38beta
(MAPK11)

MAPK11

mitogen-activated protein kinase 11

Protein kinase

NGF

NGF

nerve growth factor

Receptor ligand

MHC class II

HLA-DPB1

IP3 receptor

-1.28614 0.00403004

-1.2848 0.000024051

-1.28221

Cyclin-dependent kinase 6

0.0177006

-1.27706 0.00107739

-1.2671 0.00395734

-1.25439

0.0342748

Mitogen-activated protein kinase 11

-1.25439

0.0342748

Beta-nerve growth factor

-1.25013

0.0141866

major histocompatibility complex, class Generic receptor
II, DP beta 1

-1.24615

0.0241933

ITPR2

inositol 1,4,5-trisphosphate receptor
type 2

-1.24373

0.0308373

MHC class II

HLA-DMA

major histocompatibility complex, class Generic receptor
II, DM alpha

-1.23692 0.00037169

PKC

PRKCZ

protein kinase C zeta

-1.22047

0.0013793

MHC class II

HLA-DRA

major histocompatibility complex, class Generic receptor
II, DR alpha

-1.214

0.0283084

MHC class II

HLA-DQA1

major histocompatibility complex, class Generic receptor
II, DQ alpha 1

-1.21032 0.00112998

Adenylate cyclase

ADCY1

adenylate cyclase 1 (brain)

Generic enzyme

-1.18377 0.00169305

PP2A regulatory

PPP2R5C

protein phosphatase 2 regulatory
subunit B'gamma

Generic binding
protein

-1.17906

0.0275376

Histone H2

HIST1H2AC histone cluster 1, H2ac

Generic binding
protein

-1.17575

0.033901

p38 MAPK

MAPK12

mitogen-activated protein kinase 12

Protein kinase

-1.17095 0.00706191

MHC class II

HLA-DPA1

major histocompatibility complex, class Generic receptor
II, DP alpha 1

-1.16399

0.027006

PP2A regulatory

PPP2R3B

protein phosphatase 2 regulatory
subunit B''beta

Generic binding
protein

-1.15891

0.0157553

Histone H2

HIST1H2BH histone cluster 1, H2bh

Generic binding
protein

-1.14047

0.0249971

SOS

SOS1

SOS Ras/Rac guanine nucleotide
exchange factor 1

Regulators (GDI,
GAP, GEF)

-1.10822

0.0208185

p90Rsk

RPS6KA1

ribosomal protein S6 kinase A1

Protein kinase

-1.09743

0.0387703

WNT

WNT2

Wnt family member 2

Receptor ligand

-1.09671

0.0484961

Histone H2

HIST2H2AC histone cluster 2, H2ac

Generic binding
protein

-1.09121

0.0183897

Ligand-gated ion
channel

Protein kinase
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MHC class II

HLA-DRB3

major histocompatibility complex, class Generic receptor
II, DR beta 3

-1.08555

0.0133047

MHC class II

HLA-DRB4

major histocompatibility complex, class Generic receptor
II, DR beta 4

-1.08555

0.0133047

MHC class II

HLA-DRB5

major histocompatibility complex, class Generic receptor
II, DR beta 5

-1.08555

0.0133047

G-protein alpha-i
family

GNAI2

G protein subunit alpha i2

G-alpha

-1.07362 0.00354277

Collagen IV

COL4A4

collagen type IV alpha 4 chain

Generic binding
protein

-1.05384

0.0498416

IP3 receptor

ITPR3

inositol 1,4,5-trisphosphate receptor
type 3

Ligand-gated ion
channel

1.1381

0.0477303

Collagen IV

COL4A2

collagen type IV alpha 2

Generic binding
protein

1.17528

5.54546E05

eIF4A

EIF4A1

eukaryotic translation initiation factor
4A1

Generic enzyme

1.18902

0.0112779

PKC

PRKCA

protein kinase C alpha

Protein kinase

1.19457 0.00355992

Histone H2

HIST1H2BD histone cluster 1, H2bd

Generic binding
protein

1.22971 0.00741417

PKC

PRKD3

protein kinase D3

Protein kinase

1.25218

0.0170282

EDNRA

EDNRA

endothelin receptor type A

GPCR

1.25971

0.0455197

AP-1

FOSL1

FOS like 1, AP-1 transcription factor
subunit

Transcription factor

Fra-1

FOSL1

FOS like 1, AP-1 transcription factor
subunit

Transcription factor

Fos-related antigen 1

1.26072 0.00083762

KLF5

KLF5

Kruppel like factor 5

Transcription factor

Krueppel-like factor 5

1.26959 0.00193235

Histone H3

H3F3A

H3 histone, family 3A

Generic binding
protein

1.27027

0.0349977

Histone H3

H3F3B

H3 histone, family 3B (H3.3B)

Generic binding
protein

1.27027

0.0349977

BMP4

BMP4

bone morphogenetic protein 4

Receptor ligand

1.27237

0.0042337

G-protein alpha-i
family

GNAI1

G protein subunit alpha i1

G-alpha

1.27252

8.97476E05

G-protein alphai1

GNAI1

G protein subunit alpha i1

G-alpha

Guanine nucleotide-binding protein G(i)
subunit alpha-1

1.27252

8.97476E05

GCR

NR3C1

nuclear receptor subfamily 3 group C
member 1

Transcription factor

Glucocorticoid receptor

1.27334

1.09912E05

GATA-1

GATA1

GATA binding protein 1

Transcription factor

Erythroid transcription factor

1.27414

0.0193385

SOS

SOS2

SOS Ras/Rho guanine nucleotide
exchange factor 2

Regulators (GDI,
GAP, GEF)

SNAIL1

SNAI1

snail family transcriptional repressor 1

Transcription factor

Zinc finger protein SNAI1

1.27758 0.00712077

LDLR

LDLR

low density lipoprotein receptor

Generic receptor

Low-density lipoprotein receptor

1.27923 0.00008782
1

C/EBPbeta

CEBPB

CCAAT/enhancer binding protein beta

Transcription factor

CCAAT/enhancer-binding protein beta

1.27983 0.00025230
6

TRAF2

TRAF2

TNF receptor associated factor 2

Generic binding
protein

TNF receptor-associated factor 2

1.28784

HSP70

HSPA8

heat shock protein family A (Hsp70)
member 8

Generic binding
protein

1.29043 0.00070906
8

Histone H2

HIST1H2BC histone cluster 1, H2bc

Generic binding
protein

1.29919

Endothelin-1 receptor
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1.26072 0.00083762

Bone morphogenetic protein 4

1.27712 0.00811183

0.0323403

0.0160555

Histone H2

HIST1H2BE histone cluster 1, H2be

Generic binding
protein

1.29919

0.0160555

Histone H2

HIST1H2BF histone cluster 1, H2bf

Generic binding
protein

1.29919

0.0160555

Histone H2

HIST1H2BG histone cluster 1, H2bg

Generic binding
protein

1.29919

0.0160555

Histone H2

HIST1H2BI histone cluster 1, H2bi

Generic binding
protein

1.29919

0.0160555

SOX9

SOX9

SRY-box 9

Transcription factor

Transcription factor SOX-9

1.30548

0.042592

Cytochrome c

CYCS

cytochrome c, somatic

Generic enzyme

Cytochrome c

1.30676

0.0160318

VEGF-A

VEGFA

vascular endothelial growth factor A

Receptor ligand

Vascular endothelial growth factor A

TGF-beta

TGFB2

transforming growth factor beta 2

Receptor ligand

TGF-beta 2

TGFB2

transforming growth factor beta 2

Receptor ligand

IP3 receptor

ITPR1

inositol 1,4,5-trisphosphate receptor
type 1

Ligand-gated ion
channel

PDGF-A

PDGFA

platelet derived growth factor subunit A Receptor ligand

Alpha-actinin

ACTN2

actinin alpha 2

Generic binding
protein

1.31256 0.00387745

Cyclin A

CCNA1

cyclin A1

Generic binding
protein

1.3241 0.00093803
5

WNT

WNT5A

Wnt family member 5A

Receptor ligand

Ski

SKI

SKI proto-oncogene

Generic binding
protein

PTHrP

PTHLH

parathyroid hormone-like hormone

Receptor ligand

p90Rsk

RPS6KA2

ribosomal protein S6 kinase A2

Protein kinase

FSRP

FSTL3

follistatin like 3

Generic binding
protein

Follistatin-related protein 3

1.3342 0.00020716
7

SMAD6

SMAD6

SMAD family member 6

Transcription factor

Mothers against decapentaplegic homolog 6

1.3376 0.00518022

Bim

BCL2L11

BCL2 like 11

Generic binding
protein

Bcl-2-like protein 11

1.3653

0.0252576

AP-1

FOSL2

FOS like 2, AP-1 transcription factor
subunit

Transcription factor

1.36594

0.01046

ETS1

ETS1

ETS proto-oncogene 1, transcription
factor

Transcription factor

WNT

WNT11

Wnt family member 11

Receptor ligand

1.37035

Talin

TLN2

talin 2

Generic binding
protein

1.37124 0.00143352

Bcl-2

BCL2

BCL2, apoptosis regulator

Generic binding
protein

SMAD7

SMAD7

SMAD family member 7

Transcription factor Mothers against decapentaplegic homolog 7

EGR1

EGR1

early growth response 1

Transcription factor Early growth response protein 1

IL4RA

IL4R

interleukin 4 receptor

Generic receptor

Interleukin-4 receptor subunit alpha

MMP-1

MMP1

matrix metallopeptidase 1

Metalloprotease

Interstitial collagenase
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Transforming growth factor beta-2

Platelet-derived growth factor subunit A

1.3092 0.00443429

1.31177

0.0495434

1.31177

0.0495434

1.31212

0.0031542

1.31216 0.00039450
4

1.32631

8.78136E06

Ski oncogene

1.33162

0.0187077

Parathyroid hormone-related protein

1.33186 0.00043387

1.33239 0.00884093

Protein C-ets-1

Apoptosis regulator Bcl-2

1.36672 0.00053754

0.0215301

1.37145 0.00660047

1.3735

0.0013868

1.38222 0.000708757

1.3835 0.00375447

1.38518 0.000936588

EGFR

EGFR

epidermal growth factor receptor

eIF4E

EIF4E

SCUBE3

Receptor with
enzyme activity

Epidermal growth factor receptor

1.39085

0.0112142

eukaryotic translation initiation factor 4E Generic binding
protein

Eukaryotic translation initiation factor 4E

1.40812

0.0168678

SCUBE3

signal peptide, CUB domain and EGF
like domain containing 3

Generic binding
protein

Signal peptide, CUB and EGF-like
domaincontaining protein 3

1.42369 0.000614548

TIMP1

TIMP1

TIMP metallopeptidase inhibitor 1

Generic binding
protein

Metalloproteinase inhibitor 1

1.42794 1.17491E-06

Fibronectin

FN1

fibronectin 1

Receptor ligand

Fibronectin

1.44107 0.000135032

AP-1

JUN

Jun proto-oncogene, AP-1 transcription Transcription factor
factor subunit

1.46266 3.33637E-05

c-Jun

JUN

Jun proto-oncogene, AP-1 transcription Transcription factor Transcription factor AP-1
factor subunit

1.46266 3.33637E-05

c-Jun/c-Fos

JUN

Jun proto-oncogene, AP-1 transcription Transcription factor
factor subunit

1.46266 3.33637E-05

Heme oxygenase 1

HMOX1

heme oxygenase 1

Generic enzyme

Heme oxygenase 1

1.46526 1.99778E-05

TRIO

TRIO

trio Rho guanine nucleotide exchange
factor

Regulators (GDI,
GAP, GEF)

Triple functional domain protein

1.48572 2.28255E-05

CYP24A1

CYP24A1

cytochrome P450 family 24 subfamily A Generic enzyme
member 1

1,25-dihydroxyvitamin D(3) 24-hydroxylase,
mitochondrial

1.51113

MAP2K5 (MEK5)

MAP2K5

mitogen-activated protein kinase kinase Protein kinase
5

Dual specificity mitogen-activated protein
kinase kinase 5

1.51502 0.00417811

Collagen IV

COL4A1

collagen type IV alpha 1 chain

Generic binding
protein

1.51599 0.000878077

FKHR

FOXO1

forkhead box O1

Transcription factor Forkhead box protein O1

1.54368 2.99464E-05

SHP-2

PTPN11

protein tyrosine phosphatase, nonreceptor type 11

Protein phosphatase Tyrosine-protein phosphatase non-receptor
type 11

1.55187

Histone H2

HIST1H2AG histone cluster 1, H2ag

Generic binding
protein

1.58172 0.00195219

Histone H2

HIST1H2AI histone cluster 1, H2ai

Generic binding
protein

1.58172 0.00195219

Histone H2

HIST1H2AK histone cluster 1, H2ak

Generic binding
protein

1.58172 0.00195219

Histone H2

HIST1H2AL histone cluster 1, H2al

Generic binding
protein

1.58172 0.00195219

Histone H2

HIST1H2AM histone cluster 1, H2am

Generic binding
protein

1.58172 0.00195219

Jagged1

JAG1

jagged 1

Receptor ligand

SLUG

SNAI2

snail family transcriptional repressor 2

Transcription factor Zinc finger protein SNAI2

1.59851 3.98516E-05

PAI1

SERPINE1

serpin family E member 1

Receptor ligand

Plasminogen activator inhibitor 1

1.60385 5.49105E-05

Neurofibromin

NF1

neurofibromin 1

Regulators (GDI,
GAP, GEF)

Neurofibromin

1.65278

AP-1

FOS

Fos proto-oncogene, AP-1 transcription Transcription factor
factor subunit

1.6562 0.00330321

c-Fos

FOS

Fos proto-oncogene, AP-1 transcription Transcription factor Proto-oncogene c-Fos
factor subunit

1.6562 0.00330321

c-Jun/c-Fos

FOS

Fos proto-oncogene, AP-1 transcription Transcription factor
factor subunit

1.6562 0.00330321

ID2

ID2

inhibitor of DNA binding 2, HLH protein Transcription factor DNA-binding protein inhibitor ID-2

1.70344 1.43712E-05

Amphiregulin

AREG

amphiregulin

1.71147 3.82709E-07

Receptor ligand
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Protein jagged-1

Amphiregulin

0.0187962

0.02919

1.58718 1.62228E-06

0.0100313

HSP70

HSPA7

heat shock protein family A (Hsp70)
member 7

Generic binding
protein

1.74553 0.00216841

HSP70

HSPA6

heat shock protein family A (Hsp70)
member 6

Generic binding
protein

1.78839 0.00171406

AP-1

FOSB

FosB proto-oncogene, AP-1
transcription factor subunit

Transcription factor

1.80026 0.000011886

FosB

FOSB

FosB proto-oncogene, AP-1
transcription factor subunit

Transcription factor Protein fosB

1.80026 0.000011886

EGR2 (Krox20)

EGR2

early growth response 2

Transcription factor E3 SUMO-protein ligase EGR2

1.85416 7.39307E-05

BMP2

BMP2

bone morphogenetic protein 2

Receptor ligand

Bone morphogenetic protein 2

1.85652 4.92344E-05

COX-2 (PTGS2)

PTGS2

prostaglandin-endoperoxide synthase 2 Generic enzyme

Prostaglandin G/H synthase 2

2.59037 7.57152E-07

Figure 28: Principle component analysis and sources of variation resulting from genome-wide
microarray analysis. Parental A375 cells (red) were compared to ALDHhigh A375 cells (blue). The
response to Lunasin treatment in A375 (purple) and A375 ALDHhigh cells (green) was also compared (A).
The largest source of variation between the experimental groups was cell type (parental vs ALDH)
followed by treatment (vehicle vs Lunasin). Technical replicates and human error accounted for
comparatively little variation with F-ratios of 1.22 and 1.00, respectively (B).

Lunasin uptake correlates with expression of αV integrin subunits
Lunasin internalization is thought to be dependent upon endocytic mechanisms involving integrins
[38]. A375 cells, which overexpress the integrin αVβ3, were treated with vehicle or 100 μM Lunasin, and
analyzed for colocalization of integrin subunits and Lunasin at several time points ranging from 4 to 24 h.
It was observed that Lunasin is abundantly internalized in A375 cells, and present both in the cytoplasm
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and the nucleus. Interestingly, cell morphology was slightly altered at later time points in Lunasin-treated
cells; a decrease in cell size as well as localization of integrins around the nucleus was observed in treated
cells when compared to cells in control wells (Figure 29).
B16-F10 CIC populations were reduced with Lunasin treatment
Previously, it was shown Lunasin reduced ALDH-expressing populations of cells in A375 and
SK-MEL-28 melanoma cell lines (Chapter 3, Figure 11) concomitant with a decreased ability of these cells
to form oncospheres (Chapter 3, Figure 12) when plated in anchorage-independent culture conditions in
serum-free media [228]. To determine if this is the case with a murine model of melanoma, these
experiments were repeated using the aggressive mouse-derived melanoma line B16-F10 (Figure 30).
Treatment with 100 μM Lunasin reduced oncosphere formation by 29% (p = 0.005). Representative
images taken at 7 days post-treatment show the inhibitory effect of Lunasin on oncosphere formation
(Figure 30A). Additionally, a decrease in the ALDHhigh population when cells were treated with 100 μM
Lunasin for 24 h was observed. Treatment reduced the mean percentage of ALDH-positive B16-F10 cells
from 8% in the control samples to 1.9% in the Lunasin-treated samples (p = 0.029). The 4-fold decrease in
ALDHhigh cells is depicted in a representative series of flow cytometry dot-plots (Figure 30C) showing
DEAB, Control, and Lunasin-treated samples. Three populations with varying degrees of ALDH activity
exist within parental B16-F10 cells (Figure 30C); an ALDH-negative population represented at the left of
each dot-plot, an ALDHlow population that displays a baseline expression of ALDH activity (i.e. these cells
are ALDH-positive, but do not significantly shift in fluorescence intensity when exposed to ALDEFLUOR
reagent in the absence of DEAB) represented by the population of cells clustered at a slightly higher
intensity than the ALDH-negative population, and an ALDHhigh population (at least a one-log shift in
fluorescence intensity over DEAB controls) represented by the cells in the gated compartment on the right
of the dot-plot.
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Figure 29: Lunasin is readily internalized in A375 melanoma cells. A375 cells treated with Lunasin for
up to 24 h internalized Lunasin, which was found to colocalize with integrin αV subunits. Additionally,
nuclear localization of Lunasin was observed after 4 h, and Lunasin persisted in cells up to 24 h posttreatment. Florescence intensity of clustered integrin subunits was higher around the nucleus in Lunasintreated cells when compared to vehicle-treated cells where integrin αV subunits appeared on the periphery
of A375 cells. These results demonstrate that Lunasin was readily internalized in A375 cells, and may
support a mechanism in which Lunasin is internalized with integrin αV subunits. Representative images
from three independent experiments were used, and were taken at 40x magnification. (Blue = dapi, green =
Lunasin, red = integrin αV)
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Figure 30: Lunasin disrupted oncosphere formation and reduces ALDHhigh populations. B16-F10
ALDHhigh cells were plated in low adherent culture in stem cell media and allowed to form floating
oncospheres. When media was amended with 100 μM Lunasin, a significant decrease in oncosphere
formation compared to control samples was observed (A, B). V = vehicle, L = Lunasin. ALDH activity
was measured as described in Section 2.5. When B16-F10 cells were treated with Lunasin, a significant
reduction in cells displaying the ALDHhigh phenotype was observed (C,D). Figures represent data obtained
from three independent experiments and are shown as mean ± s.d. Statistical significance (p < 0.05) was
determined by student’s t-test and denoted by an asterisk (*).

Lunasin inhibits invasion of ALDHhigh melanoma stem cells in vitro
A375 and B16-F10 cells were sorted to isolate populations with elevated ALDH activity. These
cells were pretreated with 100 μM Lunasin for 24 h, and subsequently replated in the upper chamber of
transwell inserts containing serum-free DMEM/F12 media amended with PB or Lunasin. After adding
media containing 10% FBS to the lower chamber, plates were incubated for 24 h, and the cells invading
through the Matrigel basement membrane were counted. Invasion of A375 and B16-F10 ALDHhigh was
significantly inhibited in Lunasin-treated wells compared to vehicle-treated wells resulting in a 57% (p =
0.02) and 60% (p = 0.04) decrease in invading cells, respectively (Figure 31A). Representative images
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showing the Toluidine-stained invading cells from the bottom of the inserts illustrate the antimetastatic
effects of Lunasin in vitro (Figure 31B).

Figure 31: CIC invasion was suppressed in Lunasin-treated cells. In vitro invasion assays demonstrate
that Lunasin-treated A375 and B16-F10 ALDHhigh cells had less invasive capacity than cells treated with
vehicle (A). A375 and B16-F10 ALDHhigh cells were plated in the upper compartment of a Boyden
chamber, and allowed to migrate through a Matrigel-coated insert (8 μm pore size) toward a
chemoattractant as described in Section 2.19. Invading cells were stained with toluidine blue and
representative images are shown at 20x magnification (B). Five fields from each insert were counted and
the mean number of stained cells per field in Lunasin-treated wells was normalized to the mean number of
invading cells in vehicle-treated wells. The normalized values were expressed as percent (%) control. Data
from three independent experiments are shown as mean ± s.d. Statistical significance was determined by
student’s t-test and is denoted by an asterisks.

Lunasin abrogates pulmonary metastasis in vivo
To test whether Lunasin’s antimetastatic effects would persist in vivo, a syngeneic mouse model
using the B16-F10 cell line was employed. This system was shown to represent an excellent model to test
Lunasin’s efficacy in inhibiting tumor growth in xenograft experiments [275]. When 2.5x105 B16-F10
cells were intravenously injected into C57Bl/6 mice, pulmonary seeding and subsequent tumor
establishment occurred within 18 days. Throughout the experiment, mice were dosed daily with vehicle or
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Lunasin (30 mg/ kg) by i.p. injection. Upon experimental endpoint, it was observed that Lunasin-treated
mice had significantly reduced metastatic outgrowths when compared to control mice (Figure 32). Mice in
the control group averaged 45 (± 22) observable pulmonary lesions compared to only 9.5 (± 8) in Lunasintreated mice (Figure 32A). These results were consistent with data obtained when observable microscopic
lesions from randomized lung sections of control and Lunasin-treated mice were counted and measured
(Figure 32B). Representative images of lungs resected from metastasis-bearing mice in control (Figure
32C) and Lunasin (Figure 32D) treatment groups are shown. In addition, macrometastases were present in
the lungs of all control mice (n = 10); however, lungs from 2 mice in the Lunasin group (n = 10) had no
observable macrometastases.
Hematoxylin and eosin (H&E) stained lung sections also showed an observable difference in the
average area of micrometastases between treatment groups. Control mice had an average lesion area of
31.6 mm2 compared to 10.3 mm2 in the Lunasin group (Figure 32B). Micrometastases formed in the lungs
of vehicle treated mice (Figure 32E) were larger and more abundant than in mice treated with Lunasin
(Figure 32F). Cellular morphology was similar between lesions derived from both control and Lunasintreated mice. A subsequent graphic (Figure 33) which includes all pulmonary tissues resected from all
mice in each treatment group (n = 20) is also provided. The total number of observable macrometastases
found on each set of lungs is provided in the bottom left corner of each image (Figure 33).
The decreased size and number of micrometastases present in Lunasin-treated animals led to the
investigation of whether Lunasin has a significant effect on cell cycling in melanoma cell lines. Although
Lunasin has been shown to have an antiproliferative effect in NSCLC, no significant effect on cell cycle or
cell viability (despite a modest increase in the G1 population) was observed when A375 or B16-F10 cell
were treated with 100 μM Lunasin (Figure 34A-B). Vemurafenib was used as a positive control and
significantly reduced the number of cells in S-phase leading to an accumulation of cells in G1 (Figure 34C).
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Figure 32: Lunasin reduced pulmonary metastases in vivo. B16-F10 melanoma cells were injected i.v.
into female C57BL/6 mice. Lunasin-treated mice had less incidence of macrometastases (A) as well as
significantly reduced average lesion area (B) as measured using ImageJ software. Representative images of
pulmonary tissues resected from control (C) and Lunasin (D) treated mice are shown. H&E stained
sections demonstrate the significant difference between average lesion area in vehicle (E) and Lunasin (F)
treated mice. Stained sections were imaged at 10x (left) and 40x (right), scale bar = 1 mm. Graphs
represent data plotted as mean ± s.e.m. Means were determined to be statistically significant by student’s ttest and significance is denoted by an asterisk.

Lunasin antagonizes integrin signaling through FAK/AKT/ERK and inhibits histone acetylation
It was next investigated whether the effects of Lunasin on human and murine melanoma cells is
related to the known effects of Lunasin on integrin signaling. Immunoblot analysis showed that A375 and
B16-F10 melanoma lines treated with Lunasin for 24 h had decreased phosphorylation patterns of FAK,
AKT, and ERK. When compared to ALDHlow cells, A375 ALDHhigh cells exhibited decreased AKT and
ERK phosphorylation in Lunasin-treated cells (Figure 35A); both ALDHlow and ALDHhigh showed
decreased FAK phosphorylation when treated with 100 μM Lunasin. Integrin β1 engagement has been
shown to activate auto-phosphorylation of FAK at Y397 [276, 277], thus, binding of Lunasin to the α-
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subunit (via Lunasin’s RGD motif) and the subsequent inhibition of β1 engagement with downstream signal
transducers may cause the observed decreased in phosphorylation patterns. Because β1 subunits dimerize
with a plethora of α subunits (reviewed in [278]), the baseline phosphorylation may be due to the
expression of various integrin heterodimers (e.g. α1β1) in melanoma cells. Similarly, the β1 integrin subunit
has been shown to phosphorylate AKT at S473 [279], suggesting a analogous mechanism to FAK
activation.
In order to validate the effects of Lunasin on integrin signaling in CICs, PLA assays were used to
investigate the interactions between integrin β subunits and the intracellular signal transducers ILK and
pFAK (Y397). Firstly, it was observed that Lunasin interacts with the integrin αV subunit of A375
ALDHhigh cells (Figure 35B). This interaction suppressed downstream interactions between β1 and β3
integrin subunits with ILK and pFAK by approximately 40- 50% (Figure 35B and 35C). These results are
consistent with those seen in NSCLC models [10], and further confirm that the effects of Lunasin on
melanoma CICs are, in part, due to altered integrin signaling pathways.
Immunoblot analysis for several phosphorylation sites corresponding to activation of FAK and
AKT were conducted on A375 and B16-F10 ALDHhigh cells. Phosphorylation of FAK at tyrosine residues
Y397 and Y925 was inhibited when ALDHhigh cells were treated with Lunasin for 24 h (Figure 36A). It
was also observed that PI3K/AKT signaling was reduced in Lunasin-treated cells. Lunasin treatment
decreased phosphorylation of AKT at S473 and T308 as well as phosphorylated ERK1/2 at T202/Y204
(Figure 36B).
Because Lunasin has been reported to have activity as a HAT inhibitor, it was also investigated if
any histone acetylation marks may have been changed in Lunasin-treated cells. Histones were isolated by
acid extraction, and acetylation marks in H3 and H4 histone were assessed by immunoblot analysis. It was
previously reported that several acetylation marks were altered when NSCLC cells were incubated with
Lunasin [10]. Interestingly, an observable change in a different set of acetylation marks in melanoma cells
treated with Lunasin. Lunasin treatment reduced histone acetylation at H3K9 and H4K12, while no
difference was seen in acetylation of H4K8 and H3K14 (Figure 37). The present data suggest that Lunasin
modulates histone acetylation in melanoma cells resulting in decreased acetylation marks, which may lend
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itself to the anticancer effects of Lunasin. These results are consistent with previously published reports
supporting a mechanism in which Lunasin disrupts histone acetylation at H3 and H4 histone tails [9, 10].

Figure 33: Lungs resected from experimental metastasis in vivo model. Lungs were resected from
mice receiving vehicle (A) or Lunasin (B) treatment after implantation of B16-F10 cells. Lunasin-treated
mice displayed significantly less tumor burden in pulmonary tissues when compared to vehicle-treated
mice. The number of macrometastatic lesions observed for each set of lungs is shown in the bottom left of
each image.

Interestingly, ALDHhigh and ALDHlow A375 cells had somewhat contrasting integrin expression
profiles; ALDHhigh cells expressed integrin subunits αV and β3 more abundantly than ALDHlow cells when
grown in anchorage independent culture, while ALDHlow cells seemed to express higher levels of α5 and β1
integrin subunits (Figure 38). These data may suggest a mechanism for the increased disruption of
integrin-associated signaling in cells derived from ALDHhigh CICs when compared to cells from the nonCIC compartment (i.e. ALDHlow).
The RGD-domain is essential for Lunasin uptake and disrupting oncosphere formation
Immunoblot analyses implicated suppression of integrin signaling and effects on histone
acetylation as being important for Lunasin action. To investigate whether these mechanisms are required
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for Lunasin activity, peptides were synthesized in which the RGD domain or poly-D tail were mutated in
order to disrupt Lunasin’s interaction between integrins or histones, respectively. The generation of
oncospheres was utilized as a surrogate assay to identify the effect of Lunasin on CIC clonogenicity. No
difference in the ability of A375 ALDHhigh cells to form oncospheres between vehicle-treated cells and cells
treated with RAD-mutated peptide was observed. Conversely, cells treated with native Lunasin (p < 0.001)
and the scrambled tail peptide (p = 0.0013) had a significantly reduced ability to form oncospheres in
anchorage-independent culture (Figure 39). These data suggest that the RGD domain, which interacts with
integrins, is necessary for preventing sphere formation by CICs.

Figure 34: Cell cycle was not significantly affected by Lunasin. A375 (A) and B16-F10 (B) ALDHhigh
cells were treated with 100 μM Lunasin, and stained with PI for analysis of cell cycle. No significant
difference in populations in G1, S-phase, or G2/M was observed with Lunasin treatment compared to
control in either cell line. A representative image shows the cell cycle curve for control, Lunasin, and
vemurafenib (positive control) as analyzed using FlowJo cell cycle analysis software. Data were obtained
from three independent experiments and shown as mean ± s.d. Statistical significance was determined by
student’s t-test (p < 0.05), and significant values are denoted by an asterisk (*).
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An endocytic mechanism by which Lunasin is internalized has been reported in human
macrophages [38]. Since the RGD domain appears to be necessary for Lunasin’s disruption of oncosphere
formation, it was next asked whether or not the RGD domain was essential for Lunasin’s internalization.
A375 cells, which express the RGD-recognizing integrin subunits αV and α5, were treated with 100 μM
native Lunasin (Figure 40A) or RAD-Lunasin (Figure 40B) for 5, 10, 30, and 60 min. Cells were fixed and
probed for Lunasin using a rabbit polyclonal antibody which was confirmed to recognize the mutated
peptide sequence. Although Lunasin was detected intracellularly in cells treated with both native and
RAD-mutated peptides, fluorescent intensity was much higher in cells treated with native Lunasin
compared to RAD-Lunasin. Interestingly, RAD-Lunasin never localized in the nucleus, while the native
peptide was observed in the nucleus after 10-30 m. These data support the notion that Lunasin’s
internalization is integrin-dependent, and may explain why the RGD domain is an integral part of Lunasin’s
anticancer activity.

Figure 35: Lunasin suppressed integrin signal transduction. ALDHhigh and ALDHlow cells derived from
the A375 melanoma cell line were treated with 100 μM Lunasin in low adherent culture for 24 h, and the
resulting lysates were probed for integrin-associated signaling proteins (A). Reductions in phosphorylation
patterns of FAK, AKT, and ERK in ALDHhigh cells were observed in Lunasin-treated ALDHhigh cells, while
only a modest effect was observed on FAK phosphorylation in ALDHlow cells (A). Actin was used as a
reference protein. Relative protein expression (normalized to control) is shown above corresponding
bands. Additionally, PLA assays were utilized to validate that Lunasin was targeting integrin signal
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transduction (B). A significant decrease (~40 – 50%) in fluorescence signals per cell were observed when
interactions between integrins and ILK/pFAK were detected in vehicle and Lunasin-treated cells (C).
These results suggest Lunasin decreased the interactions between integrin β subunits and the intracellular
kinases FAK and ILK.

Figure 36: Lunasin inhibited phosphorylation of FAK, AKT, and ERK. ALDHhigh cells derived from
human A375 and murine B16-F10 melanomas were treated with Lunasin for 24 h, and the resulting cell
lysates were subjected to SDS-PAGE and probed for integrin-associated signaling pathways. Lunasin
inhibited activating phosphorylations of FAK (A), AKT (B), and ERK (B) at several amino acid residues.
Immunoblot analysis of integrin-associated pathways were performed in two independent experiments.
Densitometry analysis was performed, normalized to control, and is denoted above each representative
band.
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Figure 37: Lunasin modulates histone acetylation. It was observed that Lunasin treatment caused a
decrease in histone acetylation at H3K9 and H4K12, which suggests epigenetic modification may play a
role in Lunasin’s effects on melanoma CICs. Histone acetylation was assessed by immunoblot and relative
protein expression (shown above corresponding bands) was taken from analysis of two independent
experiments.

Figure 38: Differential expression of integrin subunits by melanoma CICs. A375 ALDHlow and
ALDHhigh cells were isolated by FACS, and lysates were subjected to SDS-PAGE. Integrin expression
profiles show that ALDHhigh cells express higher levels of αV and β3 subunits when compared to ALDHlow
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cells. ALDHlow cells showed higher abundance of integrin α5 and β1 subunits when compared to samples
from ALDHhigh cells.

Figure 39: Lunasin’s RGD motif is essential for disrupting oncosphere formation. Mutated peptides
based on Lunasin’s activity domains were synthesized and used to treat A375 ALDHhigh cells in low
adherent culture. Vehicle-treated cells readily formed oncospheres, but native Lunasin disrupted
oncosphere formation (A). When the RGD sequence was mutated to RAD, Lunasin lost its ability to
inhibit oncosphere formation, while a peptide containing a scrambled tail retained the ability to inhibit
oncosphere generation (A). Representative images taken at 10x (left) and 20x (right) demonstrate the
ability of the peptide to inhibit oncosphere formation (B). Averages from three independent experiments
were plotted at mean ± s.d. Statistical significance was determined by student’s t-test and denoted by an
asterisk.
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Figure 40: Lunasin uptake is an integrin-dependent process. RGD (A) and RAD (B) Lunasin peptides
were incubated with A375 cells for various time points up to 1 h. While some RAD-Lunasin was detected,
cells treated with RGD-Lunasin (native) showed significantly more abundant intracellular Lunasin as
illustrated by a significantly increased fluorescent signal (C). Additionally, it was observed that native
Lunasin with an intact RGD motif was localized in the nucleus of A375 cells after just 10 min, while RADLunasin was only detected in the cytoplasm at up to 1 h after treatment. Images represent data obtained
from two independent experiments, and is plotted as average fluorescence per cell ± s.d. Statistical
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significance was determined by student’s t-test (p < 0.05). An asterisk (*) denotes significance between
RGD and RAD peptides at the respective time points.

4.4 DISCUSSION
The findings that Lunasin reduced metastatic dissemination in vivo and invasion through Matrigel
in vitro, support the unique hypothesis that RGD peptides may help alleviate patient relapse in malignant
melanomas. Chapter 4 shows that mechanisms previously described for Lunasin’s anticancer effects
persist in melanoma models, and perhaps most importantly, are exacerbated in isolated CIC populations.
Uptake and internalization of Lunasin in A375 cells was shown to be integrin-dependent and correlated
with the expression of the integrin αV subunit. Colocalization of Lunasin with integrin subunits was
observed at several time points varying from 4 h to 24 h, and localization of Lunasin in both the cytoplasm
and nucleus was observed for all time points. These data are in agreement with previously reported studies
on Lunasin’s interaction and uptake with specific integrin subunits [12, 38]. Interestingly, a morphological
difference between A375 cells treated with Lunasin and vehicle was observed. Intracellular localization of
integrin αV in Lunasin-treated cells was observed, while integrin αV was found only on the periphery of
vehicle-treated cells. These data indicate that Lunasin was readily internalized in A375 cells, and support
the previously described endocytic mechanism reported in human macrophages [38].
The Davis lab has previously published results using human melanoma cell lines showing that
Lunasin efficiently reduced pools of CICs based on the ALDH biomarker, and resulted in disrupted
oncosphere formation when ALDHhigh cells were plated in stem cell media in anchorage-independent
culture conditions [228] (described in Chapter 3, page 43). Additionally, it was found that Lunasin induced
expression of melanocyte-associated differentiation markers MITF and Tyrosinase (described in Chapter 3,
page 46). Low-MITF expressing populations in melanomas have been described to harbor a slow cycling
stem-like population with intrinsic chemoresistant and tumorigenic properties [200]. It was recently
reported that MITF regulates melanoma invasion through Rac/Rho GTPases [280], which supports
previous evidence showing MITF is explicitly involved in melanoma progression [281, 282]. This is a
particularly interesting discovery given the regulation of Rac1 by integrins [283].
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In the present study, a significant decrease in B16-F10 oncosphere generation was observed when
cells were treated with 100 μM Lunasin concomitant with a significant decrease in the ALDH-positive
population of cells, which has been reported to bear the CIC fraction responsible for tumor formation and
metastasis [103]. When the in vitro invasive potential of A375 and B16-F10 ALDHhigh cells was measured,
Lunasin-treated cells were significantly less capable of invading through the basement membrane when
compared to vehicle-treated cells). These data are in agreement with Lunasin’s effect on depleting
ALDHhigh populations [228], which may be responsible for metastatic dissemination [103, 106, 228].
When C57Bl/6 mice were subjected to an experimental metastasis model of melanoma using B16F10 cells, Lunasin treatment significantly suppressed the ability of these cells to invade and proliferate in
the lungs. Two mice in the Lunasin-treated group displayed no sign of macrometastases suggesting that
Lunasin was an effective treatment for reducing or abolishing metastatic burden altogether. It was
demonstrated that Lunasin inhibited subcutaneous tumor growth of murine models of melanoma and
NSCLC [275]. Utilizing immunocompetent preclinical models of cancer allows researchers to explore the
complex relationship between host immunity and tumor microenvironment; this especially holds true given
the immunogenic nature of melanomas [136, 284]. It has been found that Lunasin has robust immune
boosting effects, and may improve vaccine efficacy by promoting dendritic cell maturation [41, 42].
Furthermore, Lunasin synergistically enhanced the cytotoxic effect of NK cells when combined with
cytokine therapy [13]. The exciting possibility that Lunasin not only directly affects cells by reducing
integrin signaling or histone acetylation, but can also “prime” the innate immune system to repress cancer
cell proliferation illustrates the extremely promising benefits of the peptide that deserve further study.
As described in Chapter 3 [228], Lunasin has a selective effect on melanoma CICs compared to
bulk tumor cells. It was questioned whether these selective effects would persist when integrin signal
transduction was evaluated. Phosphorylations of FAK, AKT, and ERK, intracellular kinases downstream
of integrins, were significantly reduced when A375 and B16-F10 cells were treated with Lunasin; A more
robust effect was observed in the ALDHhigh cells when compared to the ALDHlow cells. These mechanisms
have been described in several cancer models including breast [227], colon [36], and lung cancer [10];
however, the Davis lab is the first to report that CICs are more sensitive to Lunasin’s integrin antagonism in
melanoma. Given the explicit involvement of FAK and AKT in carcinogenesis, progression, and
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metastasis [195, 234], these results are promising especially taken in conjunction with the finding that
Lunasin decreased CIC pools.
Lunasin sensitivity of A375 ALDHhigh and ALDHlow cells correlates with differential expression of
specific integrin subunits when cultured as spheres in low-adherent conditions. ALDHhigh cells expressed
relatively higher amounts of αV and β3 integrin subunits, while ALDHlow cells expressed comparatively
higher levels of α5 and β1 integrin subunits. The complexities of integrin signal transduction mechanisms
remain somewhat of a mystery; however, new research has revealed disparities in signaling coordinated
though αvβ3 integrins and α5β1 [285, 286]. In fact, expression of specific integrins in stem cell-like cancer
cells has been reported in other cancer models including prostate [196] and breast [198], which may reveal
a potential weakness of CICs that provides a potential therapeutic target to specifically inhibit CIC
expansion.
Histone acetylation by HATs (Reviewed in [287]) results in chromatin remodeling to allow for the
initiation of transcription; efficient histone acetylation is necessary for replicative machinery to initiate
transcription of target genes. Thus, targeting HATs appears an attractive means to reduce cancer cell
proliferation. Lunasin’s activity as a HAT inhibitor has been described [20]. Histone acetylation in A375
and B16F10 ALDHhigh cells was affected with Lunasin treatment; however, Lunasin induced different
acetylation patterns in melanoma when compared to previously reported results in NSCLC [10]. Recently,
it was shown that HAT inhibition preferentially induced apoptosis and inhibited stem-associated markers in
a NSCLC model [288]. While an induction of apoptosis in melanoma was not observed, many of the
results described in Chapters 3 and 4 parallel those obtained in this study, suggesting a potential link
between suppression of CIC invasion and Lunasin’s epigenetic mechanisms.
The present study suggests that inhibition of integrin signaling is the primary mechanism
mediating Lunasin’s effects in melanoma stem cells. When the RGD domain of Lunasin was mutated,
Lunasin lost its ability to disrupt oncosphere formation, a surrogate assay for stem cell identification and
propagation. Mutating the poly-aspartic acid tail seemingly had no effect on oncosphere formation. This
result implies that the poly aspartic acid tail is not required for inhibiting CIC clonogenicity; however,
functional assays utilizing siRNA-mediated knockdown of both integrins and histone acetylation would
provide a more suitable system to test this hypothesis. Though supporting evidence shows that stem cells
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can be maintained through integrin signaling [289], further research must be conducted to unequivocally
determine that integrin antagonism is the sole mechanism for Lunasin’s reduction of the CIC compartment,
especially given that CICs may also be maintained by histone acetylation [290]. This is particularly
interesting considering that when p300, a HAT whose activity is antagonized by Lunasin [33], was knocked
out in embryonic stem (ES) cells, Nanog expression was markedly reduced yet, self-renewal capacity (a
function measured by oncosphere formation) was not significantly affected [291]. These results
corroborate findings from a previous study [228] (described in Chapter 3, page 47) showing Lunasin
treatment resulted in a significant reduction in Nanog levels; however, Lunasin treatment also robustly
inhibited sphere formation, suggesting oncosphere formation may be integrin-dependent and independent
of histone acetylation. Crosstalk between integrin signaling and histone acetylation is relatively
unexplored; though, evidence that integrin β1 engagement with ECM proteins may regulate H3 acetylation
patterns has been described [292]. The complex signaling circuits between extracellular cues transduced
through integrins, and intracellular events leading to changes in histone acetylation patterns is slowly
unraveling; however, several key pieces of the puzzle remain. Lunasin may serve as a key tool to bridge
the gap between these two interesting and highly complex signaling pathways.
In summary, the present study found that Lunasin has robust antimetastatic properties in vitro and
in vivo. CICs, characterized by elevated ALDH activity, showed a greater disruption in integrin signaling
induced by Lunasin treatment when compared to non-CICs as assessed by downstream activating
phosphorylations of FAK and AKT. In agreement with the studies described in Chapter 3, it was shown
that B16-F10 cells exhibited Lunasin-dependent depletion of ALDHhigh populations, and disruption of
oncosphere formation. While Lunasin also altered histone acetylation patterns, Lunasin’s effects in
melanoma appear to be largely an integrin-dependent process. The present study extends upon the novel
therapeutic approach that using Lunasin to reduce pools of CICs will ultimately lead to decreased invasion
and subsequent metastatic outgrowths. By modulating integrin signaling through FAK and PI3K/AKT
pathways as well as altering histone acetylation patterns, Lunasin’s complex and multifaceted anticancer
activities suggest a potential therapeutic utility against malignant diseases in which recurrence due to CICs
is likely. Given the results presented in this dissertation as well as those from others, a sufficient body of
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evidence has been presented to examine the clinical utility of Lunasin as an antimetastatic agent in patients
with late stage cancers that are at risk of further metastatic dissemination.

104

CHAPTER 5: DISCUSSION AND CONCLUSIONS
5.1 Restatement of Specific Aims
Specific Aim 1: Identify the mechanisms in which Lunasin targets CICs
Sub Aim A. Assess the ability of Lunasin to reduce populations expressing CIC and stemassociated markers
Sub Aim B. Characterize the effects of Lunasin on CICs through analysis of proliferative,
apoptotic, and differentiation markers
Specific Aim 2: Evaluate the interaction between Lunasin and integrin subunits
Sub Aim A. Specify the explicit integrin subunits interacting with Lunasin and identify the
downstream mediators of integrin signal transduction
Sub Aim B. Mutate the Lunasin peptide to discriminate the effects caused by histone
acetyltransferase inhibition and integrin antagonism
Sub Aim C. Genome-wide microarray analysis to discover Lunasin associated gene targets
Specific Aim 3: Investigate the antimetastatic effects of Lunasin
5.2 Summary of Findings and Impact of the Work
The overall aim of this dissertation was to investigate the therapeutic benefit that Lunasin may
achieve in malignant melanomas, and identify the potential mechanisms driving its anticancer properties.
Initially, it was demonstrated that Lunasin suppressed melanoma cell growth in 3D in vitro assays as well
as in vivo. In Chapter 3, these studies were expanded to describe the selective effects of Lunasin on CICs,
identified by elevated ALDH activity. It was shown that Lunasin efficiently reduced ALDH-high
populations, a subset of cells that harbor the stem cell-like population, and consequently inhibited the
functional characteristics and self-renewal capabilities of these cells. Mechanistically, Lunasin drastically
decreased integrin signaling through FAK, AKT, and ERK while also inducing a differentiated phenotype
with reduced expression of stem-associated markers. Data presented in Chapter 4, investigated the
antimetastatic effects of Lunasin on melanoma CICs, and elucidated the potential mechanisms underlying
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Lunasin’s antimetastatic activity. Given the significant involvement of CICs and integrin signaling in
metastatic dissemination, this work aims to explain how Lunasin may be useful clinically in patients with
malignant diseases. This dissertation advances the potential utility of the novel therapeutic Lunasin which
is largely unexplored and additionally, provides a compelling argument for the development of Lunasin,
not only in melanoma, but malignant diseases in which CICs can produce refractory tumors.
The first aim of this work was to define the selective effects of Lunasin on CICs by assessing
proliferation, apoptosis, and differentiation markers, and additionally, show that Lunasin induced a
movement of cells out of the CIC compartment (defined by elevated ALDH activity) and into the non-stem
compartment (i.e. ALDHlow). The human melanoma cell lines A375 and SKMEL-28 had subpopulations of
cells with both ALDHhigh and ALDHlow activity. In both cell lines, Lunasin induced a shift of cells from the
ALDHhigh compartment to the ALDHlow compartment without decreasing cell viability or cell cycling. This
phenotype switch was concomitant with an induction of melanocyte-associated differentiation markers
MITF and its downstream target Tyrosinase. A significant decrease in the stem-associated transcription
factor NANOG was observed when melanoma cell lines were treated with Lunasin. NANOG has been
shown to control stemness and self-renewal properties of physiological stem cells as well as CICs [293].
Perhaps the most interesting discovery from these initial studies is the fact that CICs were more sensitive to
Lunasin when compared to parental cells in vitro. This exacerbated effect on melanoma CICs persisted in
vivo when nude mice were subcutaneously injected with parental and ALDHhigh A375 cells. Lunasin’s
safety profile was also quite promising; no cytotoxicity was observed in mice receiving i.p. injections of
Lunasin at 30 mg/kg. Liver and kidney functions were not significantly impaired, nor was a significant
difference in CBC counts observed between mice receiving vehicle and Lunasin-treated mice.
To follow up the studies presented in Chapter 3, Chapter 4 questioned whether Lunasin’s effects
on CICs were driven by the inhibition of integrin signaling; thus, the second aim of this dissertation was to
describe the downstream effectors of integrin signal transduction which may be affected by Lunasin.
Additionally, the work in Chapter 4 investigated the effects elicited by Lunasin on integrin antagonism and
alterations in histone acetylation patterns. It was revealed that Lunasin’s effects in melanoma cells was
primarily integrin-driven, and integrin signal transduction through FAK, PI3K-AKT, and ERK was
significantly suppressed when melanoma cells were treated with Lunasin. The final sub-aim was to utilize
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a genome-wide microarray screen in order to help reveal selective targets of Lunasin in CICs, but also to
define a unique gene signatures between ALDHhigh melanoma cells and parental cells. The datasets
generated from the microarray analysis revealed the upregulation of EMT-associated genes in ALDHhigh
populations along with several genes linked to invasion and metastasis. Although Lunasin had a modest
effect on both parental and ALDHhigh cells treated for 72 h, ALDH-sorted cells had nearly twice as many
genes up- or down-regulated when compared to parental cells, which may indicate why isolated CIC were
more sensitive to Lunasin. Furthermore, this study validated the use of ALDH as a viable biomarkers for
stem-like cells in melanoma models; ALDHhigh cells had increased expression of several genes associated
with EMT and melanoma invasion.
Given the results presented in Chapter 3 and Chapter 4 describing the robust effects of Lunasin on
depleting CIC pools and suppression of integrin signaling, it was hypothesized that Lunasin would have
significant antimetastatic effects. Therefore, the final aim of this dissertation was to investigate the
proposed antimetastatic effects using an experimental metastasis model. Boyden chamber assays using
Matrigel coated inserts provided evidence that in vitro invasion was repressed when A375 and B16-F10
ALDHhigh melanoma cells were pretreated with Lunasin. Subsequently, a syngeneic murine model of
metastasis was utilized to demonstrate that Lunasin’s antimetastatic effects were enduring in vivo. A
significant decrease in pulmonary colonization of B16-F10 cells was observed in Lunasin-treated mice
when compared to mice receiving vehicle treatment.
Completion of these studies contributed significantly to the field of Lunasin research in several
ways. The Davis laboratory is the first to report on the anticancer effects of Lunasin in a melanoma model,
and additionally, the first to report that CICs may be more sensitive to Lunasin’s inhibition of integrin
signaling. The present study also showed that functionally, the RGD domain of the Lunasin peptide is
essential for Lunasin uptake as well as its disruption of oncospheres generated from isolated CICs. This
dissertation provides substantial evidence supporting that Lunasin has robust antiproliferative effects in
subcutaneous xenograft models of melanoma as well as considerable antimetastatic effects in a syngeneic
mouse model of experimental metastasis; studies which are largely lacking in the field of Lunasin research.
Moreover, this work has created a foundation upon which future studies of Lunasin can draw from in
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addition to provided concepts which could be further expanded upon. These studies support the already
solid body of evidence supporting the development of the Lunasin peptide as an anticancer therapeutic.
5.3: Strengths and Weaknesses of the Dissertation
This dissertation has several strengths that have contributed significantly to understanding the
mechanisms involved in the anticancer activities of Lunasin. Using Lunasin to treat isolated CICs based on
the ALDH biomarker is a novel strategy for the treatment of malignant disease in which CICs have been
described. Furthermore, the present study compared ALDHhigh samples to parental samples in order to
differentiate the specific signaling pathways mediating Lunasin-sensitivity. Evidence was provided which
supports previous studies involving Lunasin’s interactions and uptake with specific integrin subunits, as
well as expands upon the idea that Lunasin drives alterations in intracellular signaling cascades involving
FAK, AKT, and ERK. Not only do these studies define specific mechanisms implicated in Lunasin’s
activity as a chemotherapeutic, but also support the concept that targeting CICs may provide an innovative
intervention strategy for malignant diseases.
Another strength of the dissertation is the use of several preclinical in vivo murine models of
cancer to demonstrate the ability of Lunasin to inhibit cancer progression in a living system.
Immunocompromised mice were utilized to show that Lunasin robustly inhibits human melanoma
proliferation in subcutaneous xenograft models of melanoma. An immunocompetent syngeneic mouse
model was also utilized to demonstrate that Lunasin significantly suppressed metastatic dissemination to
pulmonary tissues of mice injected with the highly metastatic B16-F10 cell line. Both
immunocompromised and immunocompetent mouse models have distinct advantages and disadvantages.
By using both types of murine models, this dissertation demonstrates that Lunasin has robust anticancer
effects regardless of host immune status, or species from which the cancer cells are derived.
Although preclinical murine models can mimic human diseases, there are several distinct
differences between model organisms and humans. Firstly, subcutaneous xenografts do not recapitulate the
correct microenvironment from which a human tumor will arise. Although the human condition cannot be
exactly recapitulated in murine models, certain cellular processes such as angiogenesis or proliferation can
somewhat be observed within the tumor microenvironment; however, these model are lacking the
interactions typically reserved between tumor stroma and surrounding tissues. Additionally, these studies

108

cannot accurately mimic the de novo formation of tumor cells; nor do subcutaneous tumors readily progress
to malignant disease, therefore, limiting subcutaneous models to essentially measuring in vivo tumor
proliferation, but not progression.
Experimental metastasis models have the advantage of being quick, easy, and reproducible. Yet,
injecting tumor cells intravenously does not account for the early cellular changes involved in metastatic
dissemination. Because these cells are already in systemic circulation, this model avoids important
processes involved in metastasis including invasion of surrounding tissues and extravasation. While
melanomas commonly metastasize to the lungs, experimental metastasis models are generally confined to
producing pulmonary lesions and do not allow for colonization of other common metastatic sites such as
the brain, bone, or lymph nodes.
The lack of positive controls for several in vitro assays is another source of potential error. In
order to determine if the assay(s) is working correctly, positive controls must be included in the analysis of
apoptosis, proliferation, and invasion. For Annexin V binding assays and immunoblot analysis of
apoptosis-associated proteins, a positive control (e.g. staurosporin) should have been included.
Additionally, the inclusion of an agent known to inhibit proliferation of melanoma cells (e.g. vemurafenib)
should have been included in the tetrazolium-based proliferation assays. Many of these controls were used
in prior experiments to demonstrate that the assays were performing as expected; however, were not
included in the representative experiments shown in this dissertation. The absence of such controls lowers
the potential impact of such studies, and should be included in any future studies. Furthermore, many
assays utilizing PB (the vehicle in which Lunasin is dissolved) as a control would benefit from the addition
of an RGD tripeptide control. The simple addition of this tripeptide as a control would potentially explain
if perhaps Lunasin’s activity is significantly higher due to mechanisms other than those associated with its
RGD domain. Several experiments in which immunoblot analysis revealed a significant impact on
integrin-associated signal transduction would have benefitted from the inclusion of several concentrations
of Lunasin; the addition of multiple treatment groups would demonstrate whether or not the observed
effects were dose-dependent. Furthermore, several techniques could have been used to definitively
demonstrate that mutated peptides were interacting with integrin subunits including knockdown of integrins
and subsequent Lunasin internalization, saturation binding assays, or competition binding assays. The
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addition of such an assay would strengthen the discussion on whether or not the RGD motif is necessary to
Lunasin’s activity in melanoma cells.
Perhaps the most glaring weakness of this dissertation is the use of cell lines without employing
any primary melanoma cultures. Several disadvantages to using cell lines include: 1) the continual passage
in culture can alter cellular phenotypes, 2) without genotyping the status of several critical genes involved
in specific models of cancer (e.g. B-Raf) can be ambiguous, 3) cross-contamination and mycoplasma, and
4) they do not accurately mimic primary cultures. Although many of these problems can be avoided
through simple testing procedures, purchasing from approved vendors, and using proper controls in
experiments, using cell lines can be especially problematic when studying CIC populations.
While the experimental system used to identify changes in gene expression in the genome-wide
microarray analysis was robust and technically sound, it is necessary to validate these results by qRT-PCR
as well as determine the subsequent changes in protein levels. Conversely, the inclusion of several
technical replicates, sample integrity, and stringent analysis minimized any artifacts or false discoveries
resulting from the array.
It was observed that ALDHlow cells derived from A375 and SKMEL-28 cell lines tended to
“dedifferentiate” into ALDHhigh cells when grown in culture (described in Chapter 3). This is counter to
some studies in which ALDH-sorted cells were isolated from primary melanomas; ALDHhigh cells could
differentiate into ALDHlow cells, but ALDHlow cells did not generate ALDHhigh populations. Whether this is
a condition of using cells that have been propagated in culture, plasticity in ALDHlow melanoma cells, or a
“rebound” effect initiated by cells trying to recapitulate the balance of heterogeneous populations in
parental cell lines remains unclear.
5.4: Future Studies
The questions answered in this work, while significant to the field of Lunasin, created several new
questions that will need to be investigated to obtain a more thorough understanding of the novel
mechanisms described in CICs as well as the role they play in tumorigenesis and metastasis. Listed below
are several of these questions:
1.

What is the connection (if any) between integrin signaling and histone acetylation?
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While this study linked several of Lunasin’s effects in melanoma to integrin signaling, a
significant change in histone acetylation patterns was also observed. Without functional studies which
manipulate integrin signaling and measure the resulting histone acetylation patterns (or vice versa), it is
impossible to determine unequivocally that these effects are only driven by integrin signaling networks.
Using peptides with mutated activity domains, it was shown that uptake and localization of Lunasin
intracellularly was associated with the interaction between the RGD domain and integrins. In RADLunasin-treated samples, a minimal fluorescent signal was observed when probing for Lunasin. However,
some Lunasin in the cytoplasm was observed, which may suggest an alternative mechanism for Lunasin
internalization.
2.

What are the pharmacokinetic properties of Lunasin?
Lunasin has been shown to be bioavailable in men consuming applicable amounts of soy protein;

however, kinetic profiling of Lunasin in vivo has been a rather unexplored field. Obtaining metabolomics
data in a relevant system is paramount to developing any therapeutic. Because this study used
comparatively high concentrations of Lunasin in vitro, many questions arise to the practicality and
correlation to achievable concentrations in vivo. While the authors digress that Lunasin’s kinetic properties
are unknown, several biologics including peptide therapeutics and monoclonal antibodies are dosed at
similar ranges to the in vivo studies in this work which utilized Lunasin at a concentration of 30 mg/kg.
More importantly, robust anticancer effects were achieved using this dosing regimen while also observing
minimal dose-limiting toxicity.
3.

What therapeutics could be used in conjunction with Lunasin to achieve a synergistic
response?
Novel, first-line therapeutics to battle cancer are essential to the development and evolution of

chemotherapy; however, several institutions are focusing on combination therapies to combat diseases
traditionally treated with single agents; malignant melanomas are often treated with temozolomide as the
only agent of the chemotherapeutic arm. While these strategies may alleviate some primary and secondary
tumor growth, they simply are not effective in the long-term treatment of recurrent malignant diseases.
Combination therapy allows for several advantages over traditional single agent approaches including less
dose-associated toxicity, minimizing chemoresistance, and modulation of several oncogenic pathways.
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Initial studies in the Davis laboratory have focused on utilizing molecules which affected histone
acetylation in combination with Lunasin in order to induce a synergistic response in cancer cells. While
little positive data were obtained from these studies, they seem to support the hypothesis that Lunasin’s
anticancer effects are primarily integrin-driven. Indeed, combinations of vemurafenib and Lunasin resulted
in an additive/ slightly synergistic interaction. Because Lunasin does not induce apoptosis or inhibit
proliferation in vitro, the authors do not foresee using the peptide as a stand-alone therapeutic; a real-world
application of Lunasin as an adjuvant therapy seems much more likely.
4.

Does Lunasin target EMT-associated genes?
It was demonstrated that Lunasin repressed the invasive phenotype of melanoma CICs; however

proteins associated with EMT were not explored in this study. Since the experimental metastasis model
used in this dissertation does not accurately mimic EMT and extravasation, it would be interesting to
explore the modulation of EMT-associated genes that are potentially targeted by Lunasin. For example,
assessing the effect of Lunasin on Notch, TGF-β, Wnt/β-Catenin, and BMP signaling may provide a critical
perspective in further describing mechanisms associated with Lunasin’s antimetastatic properties.
5.

How does Lunasin modulate the expression of differentiation-associated biomarkers?
A novel component of this study was revealing the activity of Lunasin on the induction of

melanocyte-associated differentiation markers. Several proteins can regulate MITF expression including
AKT yet, a major unanswered question to this dissertation is how Lunasin induced MITF. What upstream
pathway(s) was associated with the observed effects on MITF protein expression? Answering these
questions would unravel the mechanisms behind Lunasin’s function as a differentiation-inducing agent, and
perhaps the mechanisms behind the suppression of self-renewal capacity of CICs. While it was shown that
Lunasin treatment suppressed Nanog levels, it was not conclusively answered how Lunasin was inhibiting
Nanog expression, and whether this effect was a result of altered integrin signaling, histone acetylation, or
some other mechanism.
6.

Can Lunasin prevent UV-mediated melanomagenesis?
As several studies have shown, Lunasin has significant chemopreventive activity in chemical and

viral oncogene-induced carcinogenesis [27]. In the case of melanoma, the greatest risk factor is ultraviolet
(UV) exposure. Examining the literature on Lunasin revealed that there have been no studies investigating
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whether Lunasin’s chemopreventive activity would apply to a UV-induced model of carcinogenesis. The
data presented in this dissertation would indicate that Lunasin has significant antimelanoma effects, yet,
this work did not test human melanocytes for any functional effects stemming from Lunasin treatment. It
would be interesting to see if the protective effects of Lunasin exist in melanocytes, or if the results
observed in this work are due to dysregulated oncogenic signaling in melanoma cells. Although several
studies in NSCLC parallel these results, it would be interesting to assess whether these effects are tissuespecific especially when considering the induction of melanocyte-specific transcription factors such as
MITF.
5.5: Final Summary and Conclusions
The overall aim of this work was to examine the mechanisms involved in the anticancer effects of
the Lunasin peptide. The work in Chapter 3 uncovered a novel function of Lunasin in that it can selectively
target CICs based on the ALDH biomarker. Additionally, it was demonstrated that Lunasin depleted pools
of cells displaying elevated ALDH activity, a subpopulation which has been reported to harbor the stem
cell-like population occurring in several malignant diseases. These studies were extended upon by using in
vivo xenograft studies to demonstrate that Lunasin has robust antiproliferative effects in preclinical
melanoma models, and exhibited an excellent safety profile with no significant cytotoxicity. Work
completed in Chapter 4 confirmed that CICs were more sensitive to the antagonism of integrin signaling by
Lunasin; however, Lunasin treatment also resulted in alterations of histone acetylation patterns.
Mechanistically, the work presented in this dissertation showed that the RGD domain is necessary for rapid
uptake of Lunasin as well as for inhibiting the self-renewal capacity of CICs. Combining the concepts that
Lunasin depleted pools of CICs and antagonizes integrin signaling, this study investigated the
antimetastatic effects of Lunasin in vitro and in vivo. Lunasin significantly reduced invasive potential of
ALDHhigh CICs in vitro, and suppressed colonization of the lungs by B16-F10 cells in an experimental
metastasis model. Taken together, this dissertation highlights several mechanisms associated with
Lunasin’s effects, and examines its potential clinical utility as an adjuvant therapy to minimize patient
relapse due to the presence of highly invasive and tumorigenic subpopulations of CICs.
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AA

Amino acid

ABCB5

ATP-binding cassette sub-family B member 5

AEBSF

4-(2-aminoethyl)benzenesulfonyl fluoride hydrochloride

AKT

V-akt murine thymoma viral oncogene homolog 1

ALDH

Aldehyde dehydrogenase

ALKP

Alkaline phosphatase

ALT

Alanine transaminase

AST

Aspartate aminotransferase

ATCC

American Type Culture Collection

BBI

Bowman-Birk inhibitor

BCA

Bicinchoninic acid assay

BCL-2

B-cell lymphoma 2

BMP2

Bone morphogenetic protein 4

BMP4

Bone morphogenetic protein 4

BRAF

V-Raf murine sarcoma viral oncogene homolog B

BSA

Bovine serum albumin

BUN

Blood urea nitrogen

C

Cysteine

CBC

Complete blood count

CD133

Cluster of differentiation 133 (prominin-1)

CD147

Cluster of differentiation 147 (Basigin)

CD20

Cluster of differentiation 20 (B-lymphocyte antigen 20)

CD271

Cluster of differentiation 271 (low-affinity nerve growth factor receptor)

CDK

Cyclin-dependent kinase
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CIC

Cancer initiating cell

CO2

Carbon dioxide

CREA

Creatinine

cRGD

cyclic-RGD

D

Aspartic acid

DAPI

4',6-diamidino-2-phenylindole

DEAB

N,N-diethylaminobenzaldehyde

DI

Drewinko index

DMEM

Dulbecco’s modified eagle medium

DMSO

Dimethyl sulfoxide

DTT

Dithiothreitol

E

Glutamic acid

ECL

Electrochemiluminescent

ECM

Extracellular matrix

EDTA

Ethylenediaminetetraacetic acid

EGFR

Epidermal growth factor receptor

EMT

Epithelial to mesenchymal transition

ERBB2

Erb-b2 receptor tyrosine kinase 2

ERK

Extracellular signal–regulated kinases

ES

Embryonic stem

ETS1

ETS proto-oncogene 1

FACS

Fluorescence-assisted cell sorting

FAK

Focal adhesion kinase

FBS

Fetal bovine serum

FITC

Fluorescein isothiocyanate

FN1

Fibronectin 1

FOS

FBJ osteosarcoma oncogene

FOSB

FBJ osteosarcoma oncogene B
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FOXP1

Forkhead box P1

G

Glycine

GFP

Green fluorescent protein

GI

Gastrointestinal

H

Histidine

H&E

Hematoxylin and eosin

H2SO4

Sulfuric acid

H3

Histone H3

H4

Histone H4

HAT

Histone acetyltransferase

HBSS

Hank’s balanced salt solution

HDAC

Histone deacetylase

HPLC

High-performance liquid chromatography

HRP

Horseradish peroxidase

I

Isoleucine

i.p.

Intraperitoneal

i.v

Intravenous

IGFR1

Insulin-like growth factor receptor-1

IL

Interleukin

ILK

Integrin-linked kinase

JAG1

Jagged 1

JUN

Jun proto-oncogene

K

Lysine

KAT2B

Lysine acetyltransferase 2B

KBP

Kentucky BioProcessing

KCl

Potassium chloride

L

Leucine

M

Methionine
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MAP2K11

Mitogen-activated protein kinase kinase 11

MAP2K7

Mitogen-activated protein kinase kinase 7

MAPK

Mitogen-activated protein kinase

MgCl2

Magnesium chloride

MITF

Microphthalmia-associated transcription factor

MMP1

Matrix metallopeptidase 1

MMP13

Matrix metallopeptidase 13

MS

Mass Spectrometry

MTS

[3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4sulfophenyl)-2H-tetrazolium

N

Asparagine

NANOG

Nanog homeobox

NaOH

Sodium hydroxide

NCI

National Cancer Institute

NF-ĸB

Nuclear factor kappa-light-chain-enhancer of activated B cells

NIH

National Institutes of Health

NK

Natural killer

NOD/SCID

Nonobese diabetic/severe combined immunodeficiency

NSAID

Non-steroidal anti-inflammatory drug

NSCLC

Non-small cell lung cancer

OCT4

Octamer-binding transcription factor 4

P

Proline

PARP

Poly ADP ribose polymerase

PB

Phosphate buffer

PBS

Phosphate-buffered saline

PCR

Polymerase chain reaction

PE

Phycoerythrin

PFA

Paraformaldehyde
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PI

Propidium iodide

PI3K

Phosphatidylinositol-4,5-bisphosphate 3-kinase

PLA

Proximity ligation assay

PTEN

Phosphatase and tensin homolog

PVDF

Polyvinylidene fluoride

Q

Glutamine

R

Arginine

RAC1

Ras-related C3 botulinum toxin substrate 1

RAR

Retinoic acid receptor

RAS

Rat sarcoma

RIN

RNA integrity number

RIPA

Radioimmunoprecipitation assay

RPC

Reverse-phase chromatography

RXR

Retinoid X receptor

S

Serine

s.c.

Subcutaneous

SA

Senescence-associated

SDS-PAGE

Sodium dodecyl sulfate polyacrylamide gel electrophoresis

SEER

Surveillance, Epidemiology, and End Results

SF

Surviving fraction

SKI

SKI proto-oncogene

SMAD5

SMAD family member 5

SMAD6

SMAD family member 6

SMAD7

SMAD family member 7

SNAI1

Snail family transcriptional repressor 1

SNAI2

Snail family transcriptional repressor 2

T

Threonine

TBS

Tris-buffered saline
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TCA

Trichloroacetic acid

TGF-β

Transforming growth factor beta

TGF-β3

Transforming growth factor beta 3

TME

Tumor microenvironment

TNF

Tumor necrosis factor

TP73

Tumor protein p73

TTBS

Tris-buffered saline with Tween

UV

Ultraviolet

V

Valine

VCAM-1

Vascular cell adhesion protein 1

W

Tryptophan

WNT5a

Wnt (wingless) oncogene analog 5a
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